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Abstract 
 
This thesis is concerned with the synthesis and characterisation of a series of 
functionalised bis-picolinamide ruthenium and rhodium dihalide complexes that have 
the potential to be developed as anti-cancer agents and catalysts. Their structural 
characterisations and, anti-cancer and catalytic activities were explored and 
investigated. 
 
There are more than thirty novel bis-picolinamide ruthenium dihalide complexes 
[RuX2L2] and six bis-picolinamide rhodium dihalide complexes [RhX2L2] (where X is 
chloride or iodide, and L is the functionalised bidentate picolinamide ligand) 
synthesised and fully characterised. X-ray crystallography showed the picolinamide 
ligands are bonded in N,N- and N,O- coordination modes to the metal centre. Three 
different geometries were seen for the dichloride complexes which were cis-cis-cis, 
cis-trans-cis and trans-trans-trans, whereas only the trans geometry was seen for the 
diiodide complexes. UV-Vis solution studies of the Ru complexes have shown no 
visible changes in the spectra over a range of days and temperature. Powder diffraction 
of Ru dichloride gave inconclusive data, however Ru diiodide complexes showed 
evidence of trans structural stability. As Ru(III) complexes are not amendable to study 
by NMR, Rh analogues were prepared to analyse their structural characterisation. The 
results have shown that there is a possible mixture of three different isomers within the 
Rh dichloride complexes, whereas the Rh diiodide only showed trans isomer, 
confirming that the diiodide complexes both for Ru and Rh are stable in structure 
conformations. 
 
There has been much interest in developing new metal-based anti-cancer complexes 
since the successful discovery of cisplatin. Ru-based complexes have become one of 
the most promising groups of complexes, having cytotoxic properties but not 
significantly affecting normal healthy cells. Bis-picolinamide Ru dihalide complexes 
were tested against a variety of cancer cell lines to determine the cytotoxicity.  It was 
found that the cytotoxicity increases when changing the halide ligands from dichloride 
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to diiodide, and when the substituents on the phenyl ring of the ligands are meta or 
para chloro or bromo substituents. Complexes 4.8 and 4.13 are the two most 
promising anti-cancer complexes, which are potent both under normoxic and hypoxic 
conditions. Following the cytotoxicity studies, selected complexes were examined for 
hydrolysis and hydrophobicity. The most cytotoxic Ru dichloride complex hydrolyses 
more and undergoes the fastest hydrolysis, which is in contrast with Ru diiodide 
complexes, by which the most cytotoxic complex undergoes the least hydrolysis. 
There are very few correlations observed between the cytotoxicity and log P values of 
the Ru dichloride complexes, suggesting that the cell uptake mechanism may not relate 
to their cytotoxic anti-cancer activities. 
 
The ongoing research on catalytic transfer hydrogenation reaction is targeted towards 
metal catalysts that can favour high activity under mild operating conditions. Several 
bis-picolinamide Ru and Rh dihalide complexes were studied as catalysts in the 
reduction of benzaldehyde. The complexes that were selected for the studies have 
several components that can be used to investigate their structural-activity 
relationships. In general, the diiodide analogues of the catalysts are more active than 
the dichloride analogues. In combination of the dihalide ligands with the appropriate 
functionalised picolinamide ligands can improve their catalytic activities. There is a 
contrasting activity seen between Ru and Rh catalysts, whereby their catalytic 
activities are affected by different components of the catalysts. Ru catalyst may be 
largely affected by the different functionalised picolinamide ligands, whereas Rh 
catalysts have showed difference in activities when changing the X ligands. 
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CHAPTER 1 
 
Introduction 
 
Introduction  Chapter 1 
1 
1 Introduction 
 
This chapter introduces various metal complexes as anti-cancer agents, including 
platinum, titanium, ruthenium and rhodium that have been found to be active 
against cancer cells. Cisplatin is the most successful anti-cancer drug, however 
there were several side effects found and modification of these complexes are 
required with the aim to have better anti-cancer activity and fewer side effects. 
Budotitane has successfully entered Phase I clinical trials, but has shown to 
undergo rapid dissociation and failed to progress to Phase II. NAMI-A and KP1019 
are the two most promising ruthenium-based anti-cancer complexes with very low 
toxicities which are currently in the Phase II clinical trials. Previous works reported 
by Tocher et al, Sheldrick et al, Sadler et al and McGowan et al, on organometallic 
ruthenium anti-cancer complexes having bioactive ligands, and the coordination 
chemistry of ruthenium complexes and their ligands reported by Mestroni et al, 
Alessio et al, Keppler et al, Bhattachrya et al, Reedijk et al and McGowan et al are 
also discussed in this chapter. 
 
1.1 Cancer 
Cancer remains the main cause of mortality worldwide, according to the statistics 
of the World Health Organisation reported in February 2008.
1, 2
 It is defined as a 
class of diseases in which cells undergo uncontrollable growth, leading to their 
ability to invade the surrounding normal healthy tissues. It develops mainly due to 
the growing adoption of unhealthy lifestyles.
3
 Initiation and progression of cancer 
depends on both external factors in the environment (biological, physical and 
chemical carcinogens) and factors within the cell (hormones, immune conditions 
and genetic mutations).
4 
 
Cancer mortality can be decreased dramatically by early diagnosis and providing 
effective treatments. These cells are less likely to spread to other normal tissue 
regions if detected at an earlier stage, and so the more favourable the diagnosis for 
the individual. Surgical removal of the original cancer cell may not always be a 
successful treatment as microscopic spread can occur.
5
 If these cancer cells are left 
untreated, these will result in localised recurrence of the cancer and eventually 
spread to the healthy living cells in the body (metastasis). Research is constantly 
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ongoing in order to develop treatments against different types of cancer of different 
stages. 
 
1.2 Metal complexes as Anti-Cancer Agents 
For years, metals have had a very important role in medicine. They are classified 
into two forms, which can either be a nutrient that is essential for maintaining a 
healthy life, or simply toxic. Even though metals can appear to be toxic at minimal 
dosage levels, they may not be equally dangerous for all organisms at all levels.
6
 
They can be used as invaluable diagnostic tools in the medical profession, which 
uses a variety of radioactive element techniques to discover the inner structures of 
the human body without the need for invasive procedures. It has also been proven 
that toxic metal complexes can kill tumours at certain body locations. 
 
Cisplatin, which contains platinum, is one of the many exciting and valuable drugs 
found from research into metals for therapeutic agents.
7-10
 Other metal-based 
medicines include silvadene, a silver-based drug that has antimicrobial 
properties,
11-13
 and the iron complex sodium nitroprusside which is used as a 
cardiovascular drug (Figure 1.1).
14
 These metal-based drugs have been 
successfully developed and more studies are performed to design new metal-based 
drugs from different complexes that could lead to a wide range of therapeutic 
applications.  
 
 
Cisplatin Sodium nitroprusside 
 
 
Silvadene 
 
Figure 1.1 Examples of successfully developed metal-based medicines 
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The search of metal-based complexes which are active towards cancer cells with 
mild toxicity and fewer side-effects, are still developing. Cisplatin has been used 
for the treatment of various cancers. The ruthenium-based complex, NAMI-A, has 
successfully finished Phase I clinical trial and is currently in Phase II clinical 
trial.
15
 The titanium-based complex, budotitane, failed to progress further due to its 
rapid dissociation upon interaction with water molecules. These complexes are 
discussed further in detail. 
 
1.3 Platinum-based anti-cancer complexes 
Cisplatin or cis-diamminedichloroplatinum(II) is a platinum-based anti-cancer 
complex which continues to be the most successful drug used for the treatment of 
several cancers, including testicular, ovarian, bladder, cervical, head and neck and 
small-cell lung cancers, either as a first-line treatment or in combination with other 
anti-cancer drugs. The anti-cancer activity of cisplatin was discovered in 1965 by 
Rosenberg when it was found to inhibit bacterial cell division from the effect of an 
electromagnetic field.
16
 It was the first metal-based drug to enter clinical trials in 
1971 after its anti-cancer activity was demonstrated in a mouse model, and was 
approved by the Food and Drug Administration for use as an anti-cancer drug in 
1978. 
 
Cisplatin is a neutral complex which has square planar coordination geometry. The 
cis configuration is responsible for its anti-cancer activity. It has two amine ligands 
which are inert to substitution under biological conditions, and two labile cis 
chloride groups which undergo hydrolysis in the cells resulting in a positively 
charged complex. Scheme 1.1 shows the chemical structure of cisplatin and its 
hydrolysis.
17-23
 
 
 
 
Scheme 1.1 Structure of cisplatin and its mechanism of hydrolysis in the cell 
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Blood plasma, having a high chloride concentration (~100mM), prevents the 
hydrolysis of cisplatin until it enters the cell by either passive diffusion
24
 or a 
copper transporter CTR1.
25, 26
 The  very low chloride concentration in the cells 
(~3mM) facilitates the hydrolysis of cisplatin, making it an active electrophile 
which then reacts with the nucleophilic sites in the cell, where DNA is the most 
preferential and cytotoxic target.
10
 Electrostatic attraction and covalent bonding of 
the positively charged complex to DNA, specifically the N7 atoms of the imidazole 
rings of guanine and adenine bases (Figure 1.2) are believed to be its mechanism 
of action.
27
 
 
 
 
 
Figure 1.2 Cisplatin coordinates to the N7 atoms of the imidazole rings of guanine 
and adenine DNA bases 
28 
 
 
 
Adenine Thymine 
Guanine Cytosine 
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There are three different types of aquated cisplatin crosslinking to DNA (Figure 
1.3).
29
 DNA monoadducts are formed when one molecule of water is lost from the 
aquated cisplatin, which then tends to react and form crosslinks. Intrastrand 
crosslinks are formed when two chloride ligands of the aquated cisplatin are  
replaced by purine nitrogen atoms on adjacent bases of the same DNA strand. 
These crosslinks are referred to as 1,2-d(GpG) crosslinks and almost all cisplatin 
DNA crosslinks are of this type.
30-33
 Additional DNA crosslinks include the 
interstrand crosslinks.
 
All cisplatin crosslinks to DNA lead to the disruption of its 
helical structure that cannot be identified by repair enzymes, hence trigger a series 
of events leading to the inhibition of DNA replication
34, 35
 which is responsible for 
the anti-cancer activity of cisplatin.  
 
Figure 1.3 Cisplatin-DNA crosslinking. (a) DNA monoadducts; (b) Intrastrand 
crosslinks; (c) Interstrand crosslinks 
29
 
 
Since only a small fraction, approximately 1% of intracellular cisplatin is bound to 
DNA,
36, 37
 much research has been carried out, and is still ongoing, into the 
mechanism of action of cisplatin in killing cancer cells. Another study has revealed 
that cisplatin prevents tubulin to form microtubules, leading to the blocking of cell 
division in living cells and eventually, cell apoptosis.
38
 Despite the success of 
cisplatin towards the death of cancer cells, cancer treatment with cisplatin is 
associated with toxicities ranging from mild to severe adverse effects such as 
nephrotoxicity and ototoxicity. It has also been shown that cancer cells are able to 
develop resistance towards cisplatin through changes in the cell environment.
39-42
  
 
 
 
 
 
 
 
 
 
  
(a) (b) (c) 
G 
G 
G 
G 
A 
G 
G 
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These include drug transport that leads to a decrease of intracellular cisplatin 
accumulation, an increase in drug detoxification systems, an increase in DNA 
repair system, changes in tolerance mechanisms from damage of DNA and changes 
in cell death pathways to apoptosis. 
 
Due to the drawbacks, a second generation of platinum-based anti-cancer agents 
was introduced (Figure 1.4). Carboplatin [cis-diammine-1,1-cyclobutane 
dicarboxylate platinum(ll)] was first introduced into the clinic in 1989 
43, 44
 and 
used for the treatment of advanced ovarian cancer in combination with other 
approved chemotherapeutic agents.
45-47
 The two chloride leaving groups of 
cisplatin are replaced by a bidentate dicarboxylate ligand, which leads to less side 
effects and less toxicity, being more lipophilic when compared with cisplatin. 
 
 
(a) (b) 
Figure 1.4 Second generation platinum-based anti-cancer agents (a) carboplatin 
(b) oxaliplatin 
 
Carboplatin reacts with DNA in a similar way to cisplatin. It undergoes hydrolysis 
and forms adducts with DNA.
48
 The difference between the activity of the drugs is 
the variation in their aquation rates to release the active Pt(II) that contributes to 
cancer cell death.
49
 A study has also been presented that carbonate may play an 
important role in the activation of carboplatin to produce platinum-carbonato and –
hydroxo complexes.
50
 Scheme 1.2 shows the reaction of carboplatin with 
carbonate.  
 
Scheme 1.2 Reaction of carboplatin with carbonate ions 
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Oxaliplatin was first synthesised in the late 1970s and is the third successful 
derivative of platinum based anti-cancer drugs and entered the clinic in 1994.
51, 52
 It 
has an oxalate ligand which hydrolyses, and diaminocyclohexane (DACH) as the 
inert ligand. The mechanism of action is similar to cisplatin and carboplatin, by 
undergoing hydrolysis and forming crosslinks with guanine or adenine bases of 
DNA. Oxaliplatin has the potential to treat cisplatin-resistant cancer cells and is 
also active against colorectal cancer cells for which it is now used for treatment in 
combination with 5-fluorouracil.
53
 It has been tested against ovarian cancer cell 
lines, and was found to be more potent than cisplatin, in which the fewer DNA 
adducts by oxaliplatin induce early secondary DNA strand breaks and huge 
apoptosis of cancer cells.
54
 The difference that occurs with oxalipatin when 
compared to cisplatin and carboplatin is rather the effect that the drug gives rather 
than the mechanism of action. Oxaliplatin gives lower toxicity and has shown the 
absence of nephrotoxicity and a decrease in ototoxicity, which were present in 
treatments with cisplatin and carboplatin against cancer cells. 
 
1.4 Titanium-based anti-cancer complexes 
The titanium (IV) complex, cis-[(CH3CH2O)2(bzac)2Ti(IV)] (Budotitane), as shown 
in Figure 1.5, was the first non-platinum complex that entered clinical trials after it 
has shown promising anti-cancer activity in vivo on three different transplantable 
tumour systems, which are the transplantable murine ascitic-colorectal MAC 15A, 
the TD-osteosarcoma of the rat, and the intramuscularly transplanted murine 
sarcoma 180.
55-57
 
 
Figure 1.5 Budotitane 
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Budotitane undergoes hydrolysis in a similar manner to cisplatin. However, there 
were problems with the complex displaying low solubility and stability in aqueous 
solution. It hydrolyses greatly in water at pH > 5 to form oligomeric [Ti(bzac)2O]2 
which is insoluble, leading to toxicities affecting the liver and kidneys.
58 
 
The interest in non-platinum complexes was limited and was not explored in detail 
until 1979, when titanocene dichloride, (Cp2TiCl2) was discovered to have anti-
cancer activity with no evidence of nephrotoxicity.
59
 This has stimulated the 
interest in investigating various non-platinum complexes that have different 
mechanisms of action against cancer cells. Metallocenes of the general formula, 
Cp2MX2, where Cp = cyclopentadienyl anion, M = Ti, V, Nb, Mo, and X = halides 
and pseudo-halides, have been synthesised and investigated to determine their anti-
cancer activities. Figure 1.6 shows the structure of titanocene dichloride. This 
complex has shown lower toxicity than cisplatin, and was the most active 
metallocene complex to enter Phase I and Phase II clinical trials.
60, 61
 
 
 
Figure 1.6 Titanocene dichloride 
 
Studies to understand the mechanism of action of titanocene dichloride are still 
ongoing, with initial studies showing that it undergoes hydrolysis
62
 and binds with 
DNA to form adducts. Scheme 1.3 shows the three-step reaction for hydrolysis of 
titanocene dichloride, and studies have shown that the rate of the first hydrolysis is 
faster than that of the second hydrolysis.
63
 Hydrolysis is the activation process 
before it interacts with DNA, where the chloride ligands dissociate rapidly and are 
replaced by water molecules forming aqua and hydroxy-titanocene complexes. 
These complexes are then able to develop titanium-rich compounds during further 
reaction steps.
63
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Scheme 1.3 Hydrolysis of Titanocene Dichloride 
  
More recent investigations of titanocene dichloride with DNA have indicated that 
hydrogen-bond donors of aquated titanocene complexes play an important role in 
forming stable complexes by interacting with hydrogen-bond acceptors of purine 
N7 bases or O6 phosphate group, with the latter being the preferred binding site.
64 
These interactions are shown in Figure 1.7. Titanocene dichloride has anti-
proliferative activity against various cell lines in vitro, and has shown anti-cancer 
activity against ovarian cancer cells which are resistant to cisplatin. However, after 
spending many years in clinical trials, titanocene dichloride was dismissed and its 
trials were not pursued. It failed to show enough promising results against renal 
and breast cancer in Phase II clinical trials.
65, 66
 There was no response detected for 
anti-cancer activity with the given dose, and since its mechanistic details are poorly 
understood, this also impedes its use as an anti-cancer agent. 
 
 
 
Figure 1.7 The interaction of aquated titanocene complexes with purine N7 and O6 
phosphate group of DNA 
 
 
N7 
O6 
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Despite the failure of titanocene dichloride in the clinical trials, many papers are 
still published on the mechanism of action and have given a lot of interest to the 
scientific community. Various modifications of the complex have been synthesised 
and characterised, in order to improve future novel anti-cancer complexes. Careful 
selection of groups to functionalise Cp ligands and replacing chloride with 
hydrophilic ligands are very important for the stability and solubility of these 
complexes. Figure 1.8 shows examples of titanium derivatives with functionalised 
ligands.  
 
 
 
 R = o,p-F, o,p-Cl, o,p-Br, p-NO2 
(a) (b) 
 
Figure 1.8 Examples of titanium derivatives (a) Titanocene Y; (b) salan-Ti(IV) 
 
Ansa-titanocene dichloride complexes were first synthesised in 1970 as catalysts 
for olefin polymerisation.
67
 It is thought that the C2 bridge between the two Cp 
groups increase the hydrolytic stability of the complex, and the introduction of two 
dimethylamino substituents increase the water solubility when compared to 
titanocene dichloride itself. These complexes were tested on Ehrlich ascites 
tumours (EAT) in mice and results have shown that they have restored natural 
killer cell function in mice that prevents the cancer cells from growing thus 
extending life.
68, 69
 
 
New titanium derivatives have been introduced recently, having [ONNO]-type 
diamine bis(phenolato) salan ligands, where salan = N,N’-bis(o-hydroxybenzyl)-
1,2-diaminoethane.  Salan-Ti(IV) complexes have demonstrated higher hydrolytic 
stability having hydrolytic half lives in the range of hours,
70, 71
 and higher anti-
cancer activity towards breast and colon cancer cells in vitro and in vivo.
69, 72
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Salan-Ti(IV) complexes with halogens on the aromatic rings have been found to be 
the most promising subgroup, having low IC50 values.
73
 However, the mechanism 
of action and cell uptake of these salan-Ti(IV) complexes are not yet well known. 
Within the McGowan group, much research has focused on functionalised 
cyclopentadienyl complexes. The Cp rings in these complexes are functionalised 
with an amino pendant arm that could make the complex become more water 
soluble and more stable. Figure 1.9 shows the structure of a functionalised-Cp 
titanocene dibromide that has been synthesised and characterised. Their cytotoxic 
properties have shown that they have significantly better activity and stability than 
non-functionalised counterparts, and have exhibited anti-cancer properties against 
cisplatin-resistant ovarian cancer cell lines.
74
 
 
Figure 1.9 Example of a titanocene derivative functionalised-Cp titanocene 
dibromide 
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1.5 Ruthenium-based anti-cancer complexes 
Various metal complexes have been synthesised and tested for cytotoxicity in the 
search for new metal-based anti-cancer agents with high cytotoxic properties. 
Among all complexes, ruthenium-based complexes have become one of the most 
promising groups of complexes, having cytotoxic properties but not significantly 
affecting normal healthy cells. As illustrated in Figure 1.10, ruthenium-based 
agents appear especially attractive because they exhibit three important properties 
suitable to biological applications: (1) Ligand exchange, (2) Accessible oxidation 
states and (3) Iron mimicking.
75
 
 
 
Figure 1.10 “Activation by reduction” hypothesis of Ru(II)/Ru(III) complexes, 
adapted from “Ruthenium in Medicine: Current Clinical  
Uses and Future Prospects” 75 
 
(1) Ligand Exchange 
Ligand exchange is important to determine the biological activity of a drug. Most 
metal-based drugs are able to reach their biological target after being modified. 
Ru(II)/Ru(III) complexes have similar rate of ligand exchange as those Pt(II) 
complexes, which takes hours at ambient temperature.  Ligand exchange rate is 
dependent on the concentration of the ligand exchange in surrounding solution. 
Due to this, the drug’s activity can be affected as diseases are able to change the 
concentrations in cells. 
Albumin 
Binding 
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(2) Accessible oxidation states 
Ru(Il), Ru(III) and Ru(IV) are all accessible under physiological conditions. 
Ru(III) complexes are biologically inert compared to Ru(II) and (IV) complexes. 
By varying the ligands in the complexes, the redox potential of a complex is 
modifiable. Prodrugs which are relatively inert Ru(III) complexes may be 
administered and then reduced, hence activated, in diseased tissues. Cancer cells 
are known to have higher metabolic rate, higher levels of glutathione and a lower 
pH than healthy normal tissues, creating a strongly reducing environment in which 
Ru(II) is favoured over Ru(III). Ru(II) is more available for binding to cellular 
components than Ru(III), which gives the advantage of potential drugs to be 
administered in a +3 oxidation state and reduced in vivo to a +2 oxidation state. 
When the biologically active Ru(II) complexes leave an oxygen poor environment, 
they can be converted back by biological oxidants to inert Ru(III) complexes. This 
is called the “activation by reduction” hypothesis, where Ru(III) complexes are 
basically prodrugs that are activated by reduction when entering cancer cells. 
 
(3) Iron mimicking 
Ruthenium has the ability to mimic iron in binding to albumin and transferrin, 
which are the two iron-carriers that reduce toxicity of ruthenium.
76
 Cancer cells are 
rapidly dividing cells having an increase number in transferrin receptors, and 
therefore a high requirement for iron molecules. This allows the ruthenium 
complexes to mimic iron and target cancer cells specifically, which explains the 
reason of its low toxicity, as the drug targets cancer cells rather than healthy 
cells.
77, 78
 Also, the ability of the cells to release the excess ruthenium is thought to 
be another reason for their lower toxicity when compared to platinum-based 
complexes.
78, 79
 
 
Complexation of ruthenium with different ligands has been of much interest in 
recent years. This is due to its properties of being able to reduce and oxidise, as 
well as its photophysical and photochemical properties. These properties are 
directed by the different coordination environment around the central metal ion.
80
 
In general, ruthenium complexes are well suited for pharmaceutical applications.
81-
83
 Ruthenium complexes with varying oxidation states have recently displayed 
good anti-cancer activity and have exhibited remarkably low toxicity compared to 
cisplatin and its derivatives.  
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1.5.1 NAMI-A 
[Na]trans-[RuCl4(Im)(dmso-S)] (NAMI) was first synthesised and found to be 
active against solid metastasising tumours in mice.
84
 At a later stage in pre-clinical 
experiments, its Na salt was replaced with imidazolium salt, to avoid co-
precipitation of DMSO with Na
+ 
during the last phase of complexation.
85 
 
 
Figure 1.11 NAMI-A 
 
[ImH]trans-[RuCl4(Im)(dmso-S)] (NAMI-A) (Figure 1.11) has an increased 
stability towards air oxidation compared to NAMI. It is the most promising 
ruthenium-based anti-cancer complex and was the first to successfully finish Phase 
1 clinical trials. It was found to be inactive against primary cancer cell lines, 
however, it has the same anti-metastatic properties as NAMI and is more stable 
towards air oxidation. It has shown a reduction in the formation of lung metastasis 
of malignant tumours,
86
 however, this did not show a relation with the cytotoxicity 
against tumour cells, which has been suggested that extracellular activity might be 
involved. 
 
The mechanism of action for NAMI-A is thought to be unique compared to that of 
platinum-based complexes. It shows several features that might be related for its 
activity in inhibiting in vivo metastases. These include the involvement of 
biological activities that influence cell functions in cancer cells. NAMI-A interacts 
rapidly with targets at cell membrane and triggers integrin activation, actin 
nucleation and microfilament elongation, which relate to adhesion in cancer cells.
87
 
An important contribution is also caused by the decrease in angiogenic activity, 
which is an important process involved in metastasis. This has been shown in an 
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experiment with CAM (Chorio Allantoic Membrane) model that inhibits a number 
of in vitro endothelial cell functions.
88
 
 
In NAMI-A the DMSO ligand, bound through sulfur, is a reasonable π-acceptor 
and stabilises Ru(II). It also influences its chemical behaviour in aqueous solution, 
where it undergoes two well-separated steps of hydrolysis, as shown in Scheme 
1.4. Inert NAMI-A is administered by infusion, which gives a reactive aqua 
complex in slightly acidic environment by suppressing the hydrolysis of Cl
-
 and 
slowly dissociating DMSO.
89
 At physiological pH, biological reducing agents such 
as glutathione, reduce NAMI-A to dianionic Ru(II) species (NAMI-AR), which 
then undergoes a two-step chloride hydrolysis. However, the “activation by 
reduction” hypothesis is not necessary for NAMI-A. Instead, the anti-metastatic 
activity of NAMI-A is strictly related to the presence of the DMSO ligand.
90
 
  
Scheme 1.4 Chemical behaviour of NAMI-A under various conditions 
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The mechanisms of action of NAMI-A are not fully understood yet, but, aquation is 
thought to be an important step for it to function, by forming a reactive aqua 
species in vivo that enables it to bind with biomolecules.  In a very recent study, the 
behaviour of NAMI-A, specifically its ligand-exchange processes with human 
serum albumin (hsA) was investigated using electron paramagnetic resonance 
spectroscopy (EPR).
91
 NAMI-A was found to bind rapidly with the protein side 
chains, possibly the imidazole ring of histidine, via hydrophobic interactions. 
Scheme 1.5 shows the main NAMI-A ligand-exchange processes in hsA, which 
involves the binding of NAMI-A to three distinct proteins following aquated 
NAMI-A complexes. 
 
 
 
Scheme 1.5 Aqua NAMI-A complexes binding with protein Histidine and Cysteine 
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As DNA is thought to be the primary target for cisplatin, a study on NAMI-A and 
its interaction with DNA has been carried out.
10
 DNA was found not to be the only 
target for its anti-metastatic activity, but it is likely to interact with DNA once it 
enters the cancer cells. This has been proven in vitro when at equal concentrations 
of both NAMI-A and cisplatin, the number of Ru-GG and –AG DNA adducts is 
much lower than cisplatin.
15
 The reactive aqua complex formed from hydrolysis of 
NAMI-A in lower pH subsequently binds to DNA.
92
 However, other targets such 
as plasma proteins and glutathione are thought to be more important than DNA for 
their anti-cancer activities.  
 
NAMI-A metabolites are released rapidly from cells which is responsible for its 
low and reversible side effects on kidneys, where high concentration of ruthenium 
was found, suggesting the main pathway of ruthenium excretion.
93
 NAMI-A 
complexes have been shown to exhibit low cytotoxicity and has efficacy against 
metastatic tumours and is potentially a very promising drug for clinic use. 
 
1.5.2 KP1019 and ICR 
KP1019, indazolium[trans-tetrachlorobis(indazole)-ruthenate(III)] is a heterocyclic 
ruthenium (III) complex, developed by Keppler et al.,
94
 which contains an 
octahedral ruthenium (III) centre bound to two indazole ligands trans to each other 
and four chlorides completing the coordination sphere. The structure is shown in 
Figure 1.12. It has exhibited anti-cancer activity against a wide range of cancer cell 
lines including colorectal carcinomas, and has been shown to have lower toxicity 
than other ruthenium-based anti-cancer complexes. 
 
Figure 1.12 KP1019 
 
 
Many studies have been performed to investigate its mechanism of action and 
structural-activity relationships. It is thought to have a high binding affinity to 
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plasma protein transferrin, which transports iron into cells. Since cancer cells have 
a high requirement for iron and contain a huge number of transferrin receptors, 
they tend to bind and transport Ru(III) complexes into cells.
76
 This increases their 
concentration in cancer cells giving a higher chance for them to function as anti-
cancer complexes. Once Ru(III) enters the cell, the complexes are activated by 
reduction to Ru(II), due to the hypoxic environment in cancer cells, and then 
undergoes hydrolysis. The kinetic rates for hydrolysis of KP1019 are highly 
dependent on pH and the temperature of solution.
95
 They hydrolyse by dissociating 
a chloride to give reactive aqua complexes which show high affinity binding to N7 
donor atoms present in DNA bases. A study has also demonstrated that the 
cytotoxic effects of KP1019 are induced by oxidative stress forming H2O2 which 
can react with macromolecules including DNA and induce oxidation of bases, 
promutagenic adducts and strand breaks triggering apoptosis.
96
 
 
Initially, KP1019 demonstrated promising anti-cancer activity with limited side 
effects and lower toxicity in Phase I clinical trials. The ruthenium complex did not 
cause any serious side effects but showed disease stabilisation up to 10 weeks.
97
 It 
was given as flat dose to patients starting from 25 mg/patient, however, has stopped 
dose escalation at 600 mg/patient because of drug solubility problems.
98
 Due to 
this, KP1339, the sodium salt of KP1019, with higher water solubility was selected 
as a lead candidate for further development in the clinical trial.
99
 Generally, 
KP1019 is more potent than KP1339, however studies have shown that both 
Ru(III) drugs share similar mode of action.
100
 
 
ICR, imidazolium[trans-tetrachlorobis(imidazole)-ruthenate(III)] is an imidazole 
analogue of KP1019, whose structure is shown in Figure 1.13. It has a similar 
structure to NAMI-A and has shown promising anti-cancer activity against various 
cancer cell lines. Similar to cisplatin, ICR undergo hydrolysis, reacts and binds to 
DNA bases. However, a study of the interaction between ICR and DNA has shown 
that freshly prepared solutions of ICR did not show the binding of ICR with DNA, 
but it did show ICR-DNA binding in aged ICR solutions.
101
 This indicates that the 
Ru(III) complex acts as a prodrug and undergoes intracellular hydrolysis to form 
the active aqua Ru(II) complex for activation. Similar to KP1019, ICR is also 
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thought to enter cancer cells by binding with transferrin. The mechanism of action 
is however still unknown. 
 
Figure 1.13 Structure of ICR 
 
ICR is one of the most active complexes with improved water solubility. The 
aquation rate constant of ICR was found to be slightly lower than that of cisplatin. 
ICR undergoes hydrolysis and loses Cl
-
, giving different hydrolysis products 
depending on the conditions.  The hydrolysis pathway of ICR is shown in Scheme 
1.6. At pH 6-8, the first aquation step involves a rapid deprotonation and hydrolysis 
of a trans Cl
-
 ligand that happens during the transport process in blood. The lower 
concentration of chloride ions in the cell causes the following aquation to occur, 
and will produce reactive aqua complexes that can then bind to DNA. 
 
 
Scheme 1.6 Hydrolytic pathway of ICR 
fast 
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1.5.3 Ru(azpy)2Cl2 Anti-Cancer Complexes 
The synthesis and chemistry of dichlorobis[2-(phenylazo)pyridine]ruthenium(II) 
(Ru(azpy)2Cl2) was first reported by Krause and Krause in 1980.
102
 They have 
reported the five possible isomers that could exist with complexes of the type 
RuCl2L2, and showed the characterisation of three different isomers of 
Ru(azpy)2Cl2 complexes characterised by IR, NMR, visible spectra, and cyclic 
voltammetry. The fourth and fifth isomers were later found and reported by Popov 
et al.
103
 and Reedijk et al.
104
 accordingly. The five different structural isomers are 
as shown in Figure 1.14 defined by the position of the chloride ligands, pyridine 
and azo group of the azopyridine ligands whether they are cis or trans to each other 
when bonded to the ruthenium metal centre, and each isomers are labelled by the 
different Greek symbols. 
 
   
cis-trans-cis (α) cis-cis-cis (β) cis-cis-trans (γ) 
  
trans-cis-cis (δ) trans-trans-trans (ε) 
Figure 1.14 Five possible isomers for Ru(azpy)2Cl2 
 
Reedijk et al. has reported the anti-cancer activities of the Ru(azpy)2Cl2 complexes 
and has shown the differences in their activities due to different structural 
isomers.
105
 The α-isomer is 10 times more cytotoxic against a series of cancer cell 
lines, than β and δ-isomer. DNA binding studies have also shown that the α-isomer 
is sterically less hindered when binding to guanine compared to the β-isomer. 
These findings indicate that the cis geometry is highly important for the anti-cancer 
activity of (Ru(azpy)2Cl2 complexes specifically the cis-trans-cis (α) isomer.  
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1.5.4 Ruthenium Arene Anti-Cancer Complexes 
The ﬁeld in developing ruthenium arene complexes was started after an enhanced 
cytotoxicity was observed by coordinating the anti-cancer agent metronidazole [1-
β-(hydroxyethyl)-2-methyl-5-nitro-imidazole] to a benzene ruthenium dichloro 
fragment (Figure 1.15a).
106
 A typical structure of a half-sandwich ‘‘piano-stool’’ 
[(η6- arene)Ru(X)(Y)(Z)] complex is shown in Figure 1.15b, where the arene 
forms the seat of the piano stool and the ligands resemble the legs. Ligands X and 
Y are linked forming a bidentate chelating ligand, which seems to give an 
advantage for anti-cancer activities. 
 
Ru(II) half-sandwich complexes have a structure that allow variations on the 
monodentate ligand Z, the bidentate ligand XY and the arene, for tuning the 
properties of these complexes. The chelating ligand helps to control stability and 
the kinetics of ligand-exchange. The arene group influences the cell uptake and its 
interactions towards potential targets. The leaving group Z occupies the 
biomolecule binding site on metal centre. The main reason for the structure design 
is the amphiphilic properties of the arene ruthenium unit, where the arene ligand 
being hydrophobic is balanced by the hydrophilic metal centre. Another important 
feature is the ability of the Ru-Z bonds to hydrolyse giving aqua ruthenium 
complex, once it enters the cell with low Cl
-
 concentration. 
 
  
(a) (b) 
 
Figure 1.15 (a) (η6-benzene) Ruthenium dichloro metronidazole; (b) Typical 
structure of organometallic anti-cancer complexes containing metal (M), a η6-
(arene), a bidentate ligand (XY) and a halide (Z) 
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Sheldrick et al. first discovered the biological use of organometallic η6-arene 
ruthenium complexes, which take the form of [(η6-arene)ruthenium(II)(en)X]+ (X = 
halide, en = ethylenediamine) (Figure 1.16).
107
 Different arene substituents of the 
complexes were also shown to exert activity in vitro and in vivo against a range of 
cancer cell lines. 
 
 
R = 
  
p-Cymene (p-cym) Biphenyl (Bip) 
 
 
 
 
5,8,9,10-Tetrahydroanthracene 9,10-Dihydroanthracene (DHA) 
 
Figure 1.16 Structures of organometallic η6-arene ruthenium complexes in the 
form of [(η6-arene)ruthenium(II)(en)X]+ 
 
Sadler et al. have studied organometallic η6-arene ruthenium complexes in the form 
of [(η6-arene)Ru(azpy)I]+ (arene = p-cymene or biphenyl, azpy = N,-
dimethylphenyl- or hydroxyphenyl-azopyridine) (Figure 1.17). These complexes 
were shown to be inert towards ligand substitution in aqueous solution, but are 
highly cytotoxic to A2780 and A549 cancer cells, due to an increase in reactive 
oxygen species (ROS), which was suggested by fluorescence-trapping studies in 
A549 cells.
108
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Figure 1.17 Structures of organometallic η6-arene ruthenium complexes in the 
form of [(η6-arene)Ru(azpy)I]+ 
 
McGowan et al. worked on organometallic η6-arene ruthenium complexes.109 Their 
studies involved developing a range of ruthenium complexes which incorporate 
ligands having high degree of flexibility, both sterically and electronically, for the 
evaluation of cytotoxicity effects (Figure 1.18). To this end, the ruthenium arene 
complexes synthesised involved fragments for H-bonding and aryl groups, which 
allow DNA interaction as well as affecting increased hydrophobic nature of the 
compounds. 
 
  
Figure 1.18 Examples of organometallic η6-arene ruthenium complexes 
 
1.6 Rhodium-based anti-cancer complexes 
 
There have only been few biological investigations on rhodium complexes, until 
very recently that they are considered to have properties that can make them the 
potential as anti-cancer agents.
110
 By coordinating cytotoxic ligands to the rhodium 
metal centre, it can lead to the increase in solubility and cell uptake, hence 
contributing to their anti-cancer activity. Ligand combination and coordination 
geometry are important in the design of drugs in order to improve their 
pharmacokinetics and bioavailability. 
R = NMe2; OH; H 
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A variety of rhodium(III) analogues of ruthenium(III) anti-cancer complexes have 
showed  contrasting activities between ruthenium and their rhodium analogues.
111, 
112
 The ‘activation by reduction’ mechanism of Ru(III) complexes was found to be 
unlikely for the Rh(III) analogues which could explain their low in anti-cancer 
activity. Figure 1.19 shows the structures of previously reported rhodium anti-
cancer complexes. Rh complexes mer,cis-[Cl3(Me2SO)(Im)2Rh(III)], Na[trans-
[Cl4(Me2SO)(Im)Rh(III)] and (Him)trans-[Cl4(Im)2Rh(III)] were found to be 
inactive against A2780 ovarian cancer cells with IC50 values > 200 µM, > 100 µM 
and > 1000 µM respectively. Whereas mer, cis-[Cl3(Me2SO)2LRh(III)], where L is 
either NH3 or imidazole, showed significant cytotoxic activity against A2780 
ovarian cancer cells with IC50 value 1.5 ± 0.4 µM and 15.6 ± 2 µM respectively. 
Both Na[trans-[Cl4(Me2SO)(Im)Rh(III)] and mer, cis-
[Cl3(Me2SO)2(Me2SO)Rh(III)] have shown to inhibit the growth of the primary 
MCa mammary tumor implanted in mice and the latter Rh complex have also 
shown to inhibit metastatic cancer cells in the lungs. 
 
  
 
 
mer, cis-[Cl3(Me2SO)2LRh(III)] 
L = NH3 or Im 
 
mer,cis-[Cl3(Me2SO)(Im)2Rh] 
 
 
  
Na[trans-[Cl4(Me2SO)(Im)Rh(III)] (Him)trans-[Cl4(Im)2Rh(III)] 
 
Figure 1.19 Rhodium(III) anti-cancer complexes 
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Sheldrick et al. prepared a series of trichlorido rhodium(III) complexes, 
RhCl3(DMSO)LL, where LL is either ethylenediamine (en), bipyridine (bpy), 1,10-
phenantroline (phen), 1,2-diaminobenzene (dab) or [6]aneS2 ligand (Figure 
1.20).
113
 These complexes have showed high cytotoxicity values against MCF7 
breast cancer cells and HT-29 colon cancer cells. Their cytotoxicity increases in the 
order of en < dab < [6]aneS2 < bpy, showing the importance of the polypyridyl 
ligands in their anti-cancer activity. They have also reported that the high cell 
uptake of the complexes along the series, as well as, an increase in kinetic stability 
may relate to their cytotoxic activity against the different cancer cells. 
 
 
 
Y = DMSO 
LL = en, bpy, phen,dab, [6]anesS2 
 
Figure 1.20 A general structure of trichlorido rhodium(III) complexes 
 
Dyson et al has reported the rhodium analogues of an antimetastatic agent [(η6-p-
cym)RuCl2(pta)] (RAPTA-C), as shown in Figure 1.21a.
114
 Both the dichlorido, 
[(η5-C5Me5)RhCl2(pta)], and monochlorido, [(η
5
-C5Me5)RhCl(pta)2]
+
 Rh 
complexes did not show any activity against a series of human cancer cell lines, 
with IC50 values > 380 μM and > 400 μM respectively. McGowan et al. reported 
[(η5-C5Me5)RhCl(3-Cl-picolinamide)] (Figure 1.21b) which has showed a 
moderate cytotoxicity with IC50 value of 28.8 ± 0.5 µM against A2780 ovarian 
cancer cells.
115
 This complex was also found to be a potent inhibitor of thioredoxin 
reductase 1 (Trx-R) activity, which may be a potential mechanism of action in its 
cytotoxic activity. 
  
(a) (b) 
Figure 1.21 Structure of (a) [(η5-C5Me5)RhCl2(pta)], and (b) [(η
5
-C5Me5)RhCl(3-
Cl-picolinamide)] 
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1.7 Metal Picolinamide Complexes 
Bhattacharya et al. have selected a group of picolinamide ligands to obtain 
ruthenium complexes of the type [Ru(L-R)3]. These complexes were synthesised 
using RuCl3.3H2O or [RuCl2(DMSO)4] in the presence of triethylamine. Figure 
1.22a shows the complex reported, in which picolinamide ligands are coordinated 
to the metal centre through the nitrogens of pyridine and amide, giving an (N,N) 
bonding to ruthenium and leaving the whole complex as neutral.
116
 Nair et al. have 
reported structural and electrochemical studies of cyclometalated iridium(III) 
picolinamide complexes (Figure 1.22b). Their electrochemical studies have shown 
two oxidation peaks, where one occurs due to the metal center with a substantial 
contribution from the ligands. The second oxidation is due to the ancillary 
picolinamide ligand.
117
 Another Ru(L-R)3 complex that has also been reported in 
the literature contains picolinic acid as the tris-bidentate ligand bonded to 
ruthenium centre through nitrogen of pyridine and oxygen of carboxylated 
group,
118
 as shown in Figure 1.22c. 
 
 
 
(a) (b) 
 
(c) 
 
Figure 1.22 (a) N,N-binding on RuL3 complex (b) Ir(ppy)2L, where L is a 
picolinamide ligand (c) N,O-binding on Ru(III) Picolinic acid complex 
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Several metal picolinamide complexes have also been synthesised within the 
McGowan group as shown in Figure 1.23. Complex 1 was prepared by 
synthesising a solution of [(Ru(p-cymene))2(μ-Br)2Br2)] in ethanol with an excess 
of the ligands in the presence of NH4PF6, to give a tris-picolinamide with (N,O)-
coordination to the ruthenium centre, giving the whole complex a +2 charge, and 
balanced with two PF6
-
 counter ions.
119
 Complex 2 and 3, where M is either 
Ruthenium or Osmium, and arene is either p-cymene or a biphenyl ring, have 
different coordination mode of the picolinamide ligands to show which binding 
mode, either N,N- or N,O-coordination, gives a major effect to their anti-cancer 
activity.
120 
 Their studies have shown that N,N-coordinated complexes are more 
active than the N,O-coordinated complexes in terms of cytotoxicity, hydrolysis and 
DNA binding. Complex 4, where M is either iridium or rhodium, have also been 
reported to have the potential in anti-cancer activity and they were found to be the 
potent inhibitors of Thioredoxin Reductase 1 (Trx-R) enzymes’ activity, which is a 
good target for anti-cancer treatment.
115
  
 
 
2 
 
3 
 
1 4 
Figure 1.23 Metal-picolinamide complexes synthesised within the McGowan group
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III 
1.8 Aims of the research project 
The aims of this project were to: 
- Synthesise and characterise a series of N-functionalised picolinamide 
ligands using IR, NMR, ES-MS, CHN elemental analysis and X-ray 
crystallisation (Chapter 2) 
- Synthesise and characterise a range of novel ruthenium dihalide complexes 
containing bidentate picolinamide ligands using IR, ES-MS, CHN 
elemental analysis and X-ray crystallisation (Chapters 3 and 4) 
- Synthesise and characterise a library of novel rhodium dihalide complexes 
containing bidentate picolinamide ligands using IR, NMR, ES-MS, CHN 
elemental analysis and X-ray crystallisation (Chapter 5) 
- Study on the structural isomers of the ruthenium and rhodium dihalide 
complexes by NMR, UV-Vis and X-ray powder diffraction (Chapters 3-5) 
- Investigate the structural-activity relationship of the ruthenium dihalide 
complexes as anti-cancer agents. The studies include cytotoxicity (IC50), 
hydrophobicity (Log P) and hydrolysis (Chapters 6 and 7) 
- Study the structural-activity relationship of the ruthenium and rhodium 
dihalide complexes as catalysts against transfer hydrogenation reactions 
(Chapter 8) 
 
The ruthenium complexes synthesised contain several fragments, which have 
shown to be important for anti-cancer, as listed below:  
 
 
 
IV 
I 
II 
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I Planar aromatic groups may cause a potential site π-π stacking with nucelobases 
within DNA chain (intercalation) 
 
II The acidic amide proton may interact with guanine or other hydrogen acceptor 
sites on the DNA chain, as a hydrogen bind donor 
 
III The labile halide ligand enables fast hydrolysis at low chloride concentration 
inside cell, making the complex to form covalent bonds with nucleophilic site on a 
DNA chain 
 
IV Various substituents on the aromatic phenyl ring increase the hydrophilicity of 
the complex, also increase the anti-cancer activity of the complex 
 
The rhodium complexes prepared were the analogue of the ruthenium dihalide 
complexes containing several possible moieties that may be involved in transfer 
hydrogenation reactions. 
 
 
 
I The labile halide ligand may undergo substitution to generate alkoxide formation 
 
II The NH moiety may be used to deliver a hydroxyl proton to the substrate 
 
III Modifying the substituents on the phenyl ring may increase the catalytic 
activity of the complex 
I 
II 
III III 
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2 Arene Functionalised Picolinamide Ligands 
 
2.1 Introduction 
The chemistry of amide ligands is of much interest due to their role in biological 
activities where the amide bond [-C=O-NH-] is an essential building unit in forming 
protein structure.
1
 It has a high stability towards hydrolysis,
2
 which is important for 
biological systems, as this allows the construction and maintenance of proteins. It has 
been known for many years that the synthetic routes towards picolinic amide 
derivatives involve the reaction between amines with either picolinic acid,
3
 or 
pyridine-2-carbonyl chloride.
4, 5
 Bhattacharya et al. have developed a preparation for 
high yielding picolinamide ligands adapted from Barnes et al., by a condensation 
reaction of picolinic acid and the respective aniline with the presence of a base.
6, 7
 
These ligands have the ability to chelate to the metal centre in two ways, either as 
neutral N,O-donors or as monoanionic N,N-donors via the loss of amide proton,
8 
as 
shown in Figure 2.1. 
 
 
 
(a) (b) 
 
Figure 2.1 (a) monoanionic N,N-donors (b) neutral N,O-donors 
 
N,N-coordination to the metal centre is known to stabilise metal ions in their high 
oxidation states due to the strong σ-donor effect,9 while N,O-coordination, relatively 
favours lower oxidation states.
10
 Interconversion between these two coordination 
binding modes is able to influence the chemical properties of the metal centre, as well 
as biological properties of the complex. 
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2’-Br     (2.11) 
3’-Br       (2.12) 
4’-Br       (2.13) 
2,4’-Br    (2.14) 
2,5’-Br    (2.15) 
2’-I     (2.16) 
        
  
2.2 Picolinamide ligands 
The picolinamide ligands used in this work are shown in Figure 2.2. Ligands 2.1 - 
2.10 and 2.16 were previously synthesised and have been fully characterised within the 
McGowan group and will not be reported in detail here.
11, 12
 Ligands 2.11 - 2.15 are 
novel and have been fully synthesised and characterised. 
 
 
 
 
 
 
 
 
Figure 2.2 Functionalised picolinamide derivatives 2.1-2.16 
 
These ligands were synthesised according to Scheme 2.1 by a condensation reaction 
between picolinic acid and the relevant aniline in the presence of pyridine and 
triphenyl phosphite. The crude product was isolated via filtration and washed with 
distilled water.  
 
Scheme 2.1 Synthesis of picolinamide ligands 
 
R = H     (2.1) 
       2’-F (2.2) 
       4’-F (2.3) 
       2’,4’-F  (2.4) 
       2’,5’-F      (2.5) 
       2’-Cl (2.6) 
       3’-Cl  (2.7) 
       4’-Cl (2.8) 
       2,4’-Cl (2.9) 
       2,5’-Cl (2.10) 
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2.3 Characterisation of N-Functionalised Picolinamide Ligands 
N-functionalised picolinamide ligands were prepared via Scheme 2.1 to obtain ligands 
2.11 - 2.15 as pure products in yields ranging from 37-69% and characterised using IR, 
1
H NMR, 
13
C{
1
H} NMR, ES-MS, elemental analysis and single crystal X-Ray 
diffraction. The NMR and IR spectra for all the picolinamide ligands have very similar 
patterns. The IR, 
1
H, 
13
C{
1
H},  
1
H-
13
C{
1
H} NMR spectra for ligand 2.11 are shown as 
an example of the comparison, in Section 2.3.1 and 2.3.2. 
 
2.3.1 IR Data for Ligand 2.11 
The IR spectrum for ligand 2.11 is as shown in Figure 2.3. It has several bands of 
different intensities in the 1600-400 cm
-1 
area.  Two NH stretches are observed at 3105 
and 3281 cm
-1
, and a strong stretch for the CO group is seen at 1691 cm
-1
. 
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Figure 2.3 IR spectra of ligand 2.11 
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2.3.2 NMR Data for Ligand 2.11 
A labelled diagram of ligand 2.11 is shown in Figure 2.4. The 
1
H, 
13
C{
1
H} and 
1
H-
13
C{
1
H} NMR spectra are shown in Figure 2.5, Figure 2.6 and Figure 2.7 
respectively, with the chemical shift assignments presented in Table 2.1. A broad NH 
singlet is seen at the downfield region at 10.72 ppm, and signals of doublets and 
triplets between 7.04 - 8.70 ppm which corresponds to the protons on the pyridine and 
phenyl rings of the picolinamide. The 
13
C{
1
H} NMR spectra shows a C=O signal at 
162.28 ppm, and C-Br signal at 113.90 ppm. 
 
 
 
 
 
 
Figure 2.4 Labelled diagram of ligand 2.11 
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Figure 2.5 
1
H NMR spectrum of ligand 2.11 (CDCl3, 300.13 MHz, 300 K) 
NH 
a d h c 
b 
e 
g/f 
g/f 
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Table 2.1 
1
H and 
13
C{
1
H} NMR chemical shift assignments for ligand 2.11 
Chemical Shift 
(δ ppm) 1H 
Splitting 
Pattern 
Assignment 
Chemical Shift 
(δ ppm) 13C{1H} 
Assignment 
10.72 s NH 162.28 C=O 
8.70 d a 149.78 Quaternary 
8.66 dd d 148.33 a 
8.32 d h 137.64 c 
7.94 td c 135.94 Quaternary 
7.62 dd e 132.49 e 
7.53 ddd b 128.37 g 
7.40 m g or f 126.62 b 
7.04 td g or f 125.13 f 
   122.43 h 
   121.41 d 
   113.90 C-Br 
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Figure 2.6 
13
C{
1
H} NMR spectrum of ligand 2.11 (CDCl3, 75.48 MHz, 300K) 
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Figure 2.7 Expanded 
1
H-
13
C{
1
H} NMR spectrum of ligand 2.11 (CDCl3, 300K) 
 
2.3.3 X-ray Crystal Structure for Ligand 2.13 
Colourless prisms suitable for X-ray crystallography were obtained from a 
concentrated methanol solution. Ligand 2.13 crystallised in a triclinic cell and 
structural solution was performed in the space group P1 with the asymmetric unit 
containing one molecule. The molecular structure is shown in Figure 2.8 and selected 
bond lengths and angles are given in Table 2.2. Ligand 2.13 adopts an almost planar 
configuration, in which C(7)-N(2)-C(6)-C(5) shows a torsion angle between the 
pyridyl ring and aniline ring of 178.5(6)°. Intramolecular hydrogen bonding exists 
between N(2)-H and N(1) with bond distance of 2.718(8) Å, and between C(12)-H and 
O(1) with bond distance of 2.946(9) Å.  Ligand 2.13 arranges itself in parallel planes 
along the a axis as shown in  Figure 2.9(a), and in alternating direction by 180° when 
viewed along the c axis as shown in Figure 2.9(b). These planes are held together by 
intermolecular hydrogen bonding between C(8)-H and O(1) with bond distance of 
3.279(9) Å (Figure 2.9(c)). 
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Figure 2.8 Molecular structure of ligand 2.13. Displacement ellipsoids are at the 50% 
probability level. 
 
Table 2.2 Selected bond lengths and angles for ligand 2.13 with s.u.s shown in 
parenthesis 
Bond length (Å) Bond Angle (°) 
C(1)-N(1) 1.378(10) N(1)-C(5)-C(6) 117.8(6) 
N(1)-C(5) 1.375(9) C(5)-C(6)-O(1) 121.3(6) 
C(5)-C(6) 1.513(10) O(1)-C(6)-N(2) 124.6(6) 
C(6)-O(1) 1.257(8) C(6)-N(2)-C(7) 130.3(6) 
C(6)-N(2) 1.378(9) N(2)-C(7)-C(8) 117.9(6) 
N(2)-C(7) 1.427(9) C(9)-C(10)-Br(1) 118.4(5) 
C(7)-C(8) 1.392(10)   
C(10)-Br(1) 1.943(7)   
 
 
 
 
(a) (b) (c) 
 
Figure 2.9 Packing diagram of ligand 2.13 viewed along the (a) a axis, (b) c axis, and 
(c) showing intermolecular hydrogen bond interactions 
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2.3.4 X-ray Crystal Structure for Ligand 2.15 
White needle-like crystals suitable for X-ray crystallography were obtained from a 
concentrated methanol solution. Ligand 2.15 crystallised in a monoclinic cell and 
structural solution was performed in the space group P 21/c with the asymmetric unit 
containing one molecule. The molecular structure is shown in Figure 2.10 and 
selected bond lengths and angles are given in Table 2.3. Similarly as previously 
synthesised picolinamide ligands, ligand 2.15 adopts an almost planar configuration, in 
which the torsion angle between the pyridyl ring and aniline ring N(1)-C(5)-C(6)-N(2) 
is 9.2(16)°. Intramolecular hydrogen bonding exists in ligand 2.15 between N(2)-H 
and N(1), C(12)-H and O(1), and N(2)-H and Br(1) with bond distances of 2.679(14) 
Å, 2.888(14) Å, and 3.080(8) Å respectively. Figure 2.11(a) and (b) show the packing 
diagrams of ligand 2.15. When packed, the molecule stacks in a herringbone motif 
along the a-axis, and in layers along the b-axis with the molecule alternating direction 
by 180°. These planes are held together by intermolecular hydrogen bonding between 
C(4)-H and O(1) with bond distance of 3.323(15) Å (Figure 2.12).  
 
 
 
Figure 2.10 Molecular structure of ligand 2.15. Displacement ellipsoids are at the 
50% probability level. 
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Table 2.3 Selected bond lengths and angles for ligand 2.15 with s.u.s shown in 
parenthesis 
Bond Distance (Å) Bond Angle (°) 
C(1)-N(1) 1.369(16) N(1)-C(5)-C(6) 117.5(10) 
N(1)-C(5) 1.348(13) C(5)-C(6)-O(1) 122.7(11) 
C(5)-C(6) 1.523(16) O(1)-C(6)-N(2) 124.9(11) 
C(6)-O(1) 1.222(13) C(6)-N(2)-C(7) 128.6(9) 
C(6)-N(2) 1.384(14) N(2)-C(7)-C(8) 118.2(10) 
N(2)-C(7) 1.417(15) C(7)-C(8)-Br(1) 120.4(9) 
C(7)-C(8) 1.414(16) C(12)-C(11)-Br(2) 116.0(8) 
C(8)-Br(1) 1.916(10)   
C(11)-Br(2) 1.910(11)   
 
 
 
(a) (b) 
Figure 2.11 Packing diagram of ligand 2.15 viewed along the (a) a axis (b) b axis. 
Hydrogen atoms are omitted for clarity. 
 
 
 
 
 
 
 
Figure 2.12 Intermolecular hydrogen bond interactions in ligand 2.15 
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3 Synthesis of Ruthenium Dichloride Complexes 
3.1 Introduction 
This chapter discusses the synthesis and characterisation of novel bis-picolinamide 
ruthenium (III) dichloride complexes. Ruthenium picolinamide complexes of the type 
ML2X2 have not been reported in the literature previously, nor have been attempted 
within the McGowan group before. The aim is to add a new series of complexes within 
the McGowan group and to study the reaction involving coordination chemistry of 
ruthenium together with the biological properties of the complexes. 
 
3.2 Synthesis of bis-Picolinamide Ruthenium (III) Dichloride (RuCl2L2) 
Complexes 
The design of bis-picolinamide ruthenium (III) dichloride (RuCl2L2) complexes 
involves planar aromatic groups, a carbonyl group and an acidic amide proton on the 
ligands, which may contribute to their interaction with the DNA chain. Also, the halide 
ligands bound to the metal centre and the various substituents on the aromatic phenyl 
rings could contribute to modify the complexes’ hydrolysis, hydrophobicity and anti-
cancer properties. Scheme 3.1 outlines the general synthesis for these complexes, 
where the reaction proceeds via direct addition of two equivalents of ligand to the 
ruthenium precursor in the presence of triethylamine, and induces the binding between 
the ligands and ruthenium. Triethylamine in the reaction acts as a base in order to 
deprotonate the hydrogen atom of NH from one of the picolinamide ligands, forming 
triethylamine hydrochloride salt, to give an (N,N)-coordination of the ligand to the 
ruthenium metal centre. A number of structural isomers are possible for complexes of 
the type RuX2L2 in solution, shown in Figure 3.1.
1-4
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R Complex Yield 
H 3.1 74% 
2’-F 3.2 50% 
4’-F 3.3 52% 
2’,4’-F 3.4 72% 
2’,5’-F 3.5 28% 
2’-Cl 3.6 58% 
3’-Cl 3.7 55% 
4’-Cl 3.8 28% 
2’,4’-Cl 3.9 44% 
2’,5’-Cl 3.10 40% 
2’-Br 3.11 46% 
3’-Br 3.12 62% 
4’-Br 3.13 44% 
2’,4’-Br 3.14 51% 
2’,5’-Br 3.15 54% 
2’-I 3.16 33% 
 
Scheme 3.1 Synthesis of bis-picolinamide ruthenium (III) dichloride complexes 
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Figure 3.1 Possible isomers of bis-picolinamide ruthenium dihalide complexes 
trans-trans-trans 
trans-cis-cis 
cis-cis-trans 
cis-cis-cis 
cis-trans-cis 
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3.3 Characterisation of bis-Picolinamide Ruthenium (III) Dichloride 
Complexes 
Bis-picolinamide ruthenium (III) dichloride complexes were prepared via Scheme 3.1, 
where two equivalents of the substituted picolinamide ligands were added to one 
equivalent of RuCl3.3H2O in ethanol and heated under reflux for 2 hours. Complexes 
3.1 - 3.16 were obtained as pure products in yields ranging from 28-74% and 
characterised using IR, ES-MS, elemental analysis and single crystal X-Ray 
diffraction. These complexes were found to be soluble in polar solvents, including 
acetonitrile, methanol, dichloromethane, chloroform and acetone, producing intense 
red-orange solutions. 
 
The IR spectra of complexes 3.1 to 3.16 are very similar, with several bands of 
different intensities in the 1600-400 cm
-1 
area. A comparison was made between the 
spectra of the uncoordinated ligands and of the complexes. It can be seen that the CO 
and NH stretches were both shifted to lower wavenumber when the ligands were 
bonded to the metal centre. In the IR spectrum of these ruthenium complexes, there are 
two stretches for the NH group within the region 3000-3500 cm
-1
, and one strong 
stretch for the CO group with a weak split in the 1548-1618 cm
-1 
region. The IR 
spectrum for ligand 2.11 and complex 3.11 are shown as an example of the 
comparison in Figure 3.2. Magnetic susceptibility measurements have shown that all 
of the complexes are low-spin d
5
 with unpaired one-electron (µeff = 1.83 - 2.53), which 
corresponds to the +3 state of ruthenium (µeff = 1.73). 
 
Three different types of structural isomers have been shown to exist for these 
complexes, which are the cis-cis-cis, cis-trans-cis and trans-trans-trans structural 
isomers confirmed by their single crystal structures. X-ray crystallography has been 
used to show the geometry of the different structural isomers, as well as to verify the 
coordination mode of the ligands in the complexes. The ligands are bonded in N,N- 
and N,O- coordination modes to the ruthenium metal centre. Single crystal structures 
and data are shown for complexes 3.1, 3.3, 3.5, 3.6, 3.7, 3.9, 3.11, 3.12, 3.13, 3.14 and 
3.16, which were recrystallised by vapour diffusion, either from methanol/hexane or 
methanol/pentane.  
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3.4 IR Data for Ligand 2.11 and Complex 3.11 
The IR spectra, with wavenumbers between 4000-450 cm
-1
, of ligand 2.11 and 
complex 3.11 are shown in Figure 3.2. In the spectrum of the uncoordinated ligand, a 
strong CO stretch is observed at 1691 cm
-1
, and is shifted to 1590 cm
-1
 showing a weak 
split of the stretch into two bands. The aromatic CH stretching is seen at 3105 cm
-1
 for 
the ligand, which is shifted to 3065 cm
-1
, and an NH stretching is at 3281 cm
-1
 seen 
shifted to 3202 cm
-1
 for the complex. This pattern is consistent for all of the bis-
picolinamide ruthenium dichloride complexes reported in this chapter. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 IR spectra of ligand 2.11 and complex 3.11 
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3.5 X-ray Crystallography Data for bis-Picolinamide Ruthenium (III) 
Dichloride Complexes 
Single crystals suitable for x-ray crystallography were obtained by vapour diffusion of 
hexane/pentane into a methanolic solution of the crude product of the complexes. The 
bis-picolinamide ruthenium dichloride complexes have a distorted octahedral centre, 
with bond angles in the range 84.8°-107.7° between the ligands that are cis to each 
other, and bond angles of 170.5°-178.4° between the trans ligands about the ruthenium 
metal centre. 
 
Both picolinamide ligands coordinated to the ruthenium metal centre adopt a non-
planar configuration, in which the phenyl ring is almost perpendicular to the pyridine 
ring when it is coordinated in N,N-fashion, with a torsion angle for C(6)-N(2)-C(7)-
C(12) of 73.2(4)°, and C(18)-N(4)-C(19)-C(20) of 45.3(5)° when it is N,O-coordinated 
(for complexes 3.5 and 3.11). Complex 3.1a has a torsion angle of 92.8(6)° between 
the planes of the phenyl ring and the pyridine ring for its N,N-coordinated ligand and 
of 47.8(9)° for its N,O-coordinated ligand. Complex 3.15 has an angle of 68.6(4)° and 
51.5(5)° between the two planes for N,N- and N,O-coordinated ligands respectively. 
 
The Ru-Cl bond distances for all the bis-picolinamide ruthenium dichloride complexes 
are similar, where one of the Ru-Cl bonds is longer than the other, with an average 
bond distance of 2.34 Å for Ru-Cl(1) and 2.37 Å for Ru-Cl(2). The average bond 
lengths of Ru(1)-N(1), Ru(1)-N(2), Ru(1)-N(3) and Ru(1)-O(2) for all complexes are 
2.04 Å, 2.02 Å, 2.08 Å and 2.09 Å respectively, consistent and comparable with 
previously reported η6-ruthenium arene picolinamide complexes.5, 6 
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3.5.1 X-ray Crystal Structure of Complex 3.1 
Complex 3.1 crystallises as two different shapes of red crystals - red needles (complex 
3.1a) and red blocks (complex 3.1b), both of which were suitable for x-ray 
crystallography. These crystals were obtained by vapour diffusion of pentane into a 
methanolic solution of the complex. Both sets of crystals 3.1a and 3.1b were 
crystallised in a monoclinic cell with the structural arrangement trans-trans-trans and 
cis-cis-cis respectively. Their structural solutions were performed in the space groups 
P21/c, and P21/n respectively with the asymmetric unit containing one complex 
molecule and one methanol molecule for complex 3.1a and two molecules of methanol 
for complex 3.1b. The molecular structure for both complexes 3.1a and 3.1b are 
shown in Figure 3.3 and selected bond lengths and angles are given in Table 3.1. 
 
  
  
(a) (b) 
Figure 3.3 Molecular structure of complex 3.1 showing (a) trans-trans-trans and (b) 
cis-cis-cis structural arrangements. Displacement ellipsoids are at the 50% 
probability level. Hydrogen atoms are omitted for clarity. 
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Table 3.1 Selected bond lengths and angles for complex 3.1a and 3.1b with s.u.s 
shown in parenthesis 
Bond length (Å) / angle (°) 3.1a 3.1b 
Ru(1)-Cl(1) 2.3408(14) 2.3540(9) 
Ru(1)-Cl(2) 2.3498(13) 2.3769(9) 
Ru(1)-N(1) 2.037(4) 2.018(3) 
Ru(1)-N(2) 2.008(4) 1.997(3) 
Ru(1)-N(3) 2.102(4) 2.045(3) 
Ru(1)-O(2) 2.067(3) 2.087(3) 
Cl(1) - Ru(1) - Cl(2) 175.93(5) 96.16(3) 
N(1) - Ru(1) - O(2) 96.51(16) 175.63(10) 
N(2) - Ru(1) - O(2) 175.18(16) 96.34(11) 
N(2) - Ru(1) - N(3) 106.92(16) 86.23(11) 
N(1) - Ru(1) - N(3) 174.22(16) 98.72(11) 
 
Complex 3.1a arranged itself into a diagonal linear distribution when packed along the 
b-axis as shown in Figure 3.4, held by intermolecular hydrogen bond between one 
methanol molecule with three complex molecules involving the amide group of one 
molecule (bond distance N(4)-O(3) of 2.756(6) Å), the carbonyl group of the second 
molecule (bond distance O(3)-O(1) of 2.699(5) Å) and the hydrogen of the phenyl ring 
of the third molecule (bond distance C(11)-O(3) of 3.329(7) Å). There is also an 
intramolecular hydrogen bonding between the carbonyl group and the hydrogen of the 
phenyl ring within a molecule (bond distance C(20)-O(2) of 2.920(9) Å). 
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Figure 3.4 Packing diagram of complex 3.1a viewed along the b-axis showing 
intermolecular hydrogen bond interactions between molecules. Hydrogen atoms are 
omitted for clarity. 
 
Complex 3.1b packed in rows alternately along the b-axis, with the molecules pointing 
in alternate directions, as shown in Figure 3.5a. The molecules are held together by 
intermolecular hydrogen bonding (Figure 3.5b), between the amide group of a 
complex molecule with the oxygen of one methanol molecule (bond distance (N(4)-
O(3) of 2.766(4) Å), between the two methanol molecules (bond distance O(3)-O(4) of 
2.675(4) Å), between the second methanol molecule with the carbonyl of the second 
complex molecule (bond distance O(4)-O(1) of 2.673(4) Å), and between the carbonyl 
of the second complex molecule with the hydrogen of a pyridyl ring of the third 
complex molecule (bond distance O(1)-C(13) of 3.251(5) Å). 
  
(a) (b) 
Figure 3.5 (a) Packing diagram of complex 3.1b viewed along the b-axis; (b) 
Intermolecular hydrogen bond interactions between three complex molecules and two 
methanol molecules. Hydrogen atoms are omitted for clarity. 
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3.5.2 X-ray Crystal Structure of Complex 3.3 
Red prisms of complex 3.3 suitable for X-ray crystallography were obtained via 
vapour diffusion of hexane into a methanolic solution of the complex. Complex 3.3 
crystallised in a monoclinic cell with the arrangement of trans-trans-trans and 
structural solution was performed in the space group P21/n. The asymmetric unit 
contains one complex molecule. The molecular structure is shown in Figure 3.6 and 
selected bond lengths and angles are given in Table 3.2. 
 
 
Figure 3.6 Molecular structure of complex 3.3. Displacement ellipsoids are at the 
50% probability level. Hydrogen atoms are omitted for clarity. 
 
Table 3.2 Selected bond lengths and angles for complex 3.3 with s.u.s shown in 
parenthesis 
Bond length (Å) Bond angle (°) 
Ru(1)-Cl(1) 2.3318(10) Cl(1) - Ru(1) - Cl(2) 176.60(5) 
Ru(1)-Cl(2) 2.3533(10) N(1) - Ru(1) - O(2) 97.82(16) 
Ru(1)-N(1) 1.999(3) N(2) - Ru(1) - O(2) 176.38(16) 
Ru(1)-N(2) 2.036(3) N(2) - Ru(1) - N(3) 105.90(18) 
Ru(1)-N(3) 2.113(3) N(1) - Ru(1) - N(3) 175.45(18) 
Ru(1)-O(2) 2.087(3)   
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Complex 3.3 packed in a linear arrangement along the a-axis as shown in Figure 3.7a. 
Figure 3.7b shows the intermolecular hydrogen bonding interactions, in which one 
complex molecule interacts with three other complex molecules. The chloride ligand 
of the first molecule forms a hydrogen bond with the hydrogen on the pyridyl ring of 
the second molecule (bond distance Cl(1)-C(2) of 3.558(4) Å). The second chloride 
ligand of the first molecule interacts with two other complex molecules, one with the 
amide group of the second molecule (bond distance Cl(2)-N(4) of 3.283(3) Å), and the 
other with the hydrogen on the phenyl ring of the third molecule (bond distance Cl(2)-
C(8) of 3.596(4) Å). 
 
 
(a) (b) 
Figure 3.7 (a) Packing diagram of complex 3.3 viewed along the a-axis; (b) 
Intermolecular hydrogen bond interactions between the complex molecules. Hydrogen 
atoms are omitted for clarity. 
 
3.5.3 X-ray Crystal Structure of Complex 3.5 
Thin red rectangular crystals of complex 3.5 suitable for X-ray crystallography were 
obtained via vapour diffusion of hexane into a methanol solution of the complex. 
Complex 3.5 crystallised in a triclinic cell with the arrangement of trans-trans-trans 
and structural solution was performed in the space group P1. The asymmetric unit 
contains one complex molecule and one methanol molecule. The molecular structure is 
shown in Figure 3.8 and selected bond lengths and angles are given in Table 3.3. 
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Figure 3.8 Molecular structure of complex 3.5. Displacement ellipsoids are at the 
50% probability level. Hydrogen atoms are omitted for clarity 
 
Table 3.3 Selected bond lengths and angles for complex 3.5 with s.u.s shown in 
parenthesis 
Bond length (Å) Bond angle (°) 
Ru(1)-Cl(1) 2.3328(9) Cl(1) - Ru(1) - Cl(2) 176.80(3) 
Ru(1)-Cl(2) 2.3664(9) N(1) - Ru(1) - O(2) 95.46(11) 
Ru(1)-N(1) 2.036(3) N(2) - Ru(1) - O(2) 174.21(10) 
Ru(1)-N(2) 2.027(3) N(2) - Ru(1) - N(3) 107.74(11) 
Ru(1)-N(3) 2.102(3) N(1) - Ru(1) - N(3) 173.36(11) 
Ru(1)-O(2) 2.077(2)   
 
Complex 3.5 is arranged in a diagonal linear distribution when viewed along the a-axis 
as shown in Figure 3.9a. Several intermolecular interactions are seen within the 
packing arrangement. Each molecule interacts with two adjacent molecules, where two 
molecules are held in pairs by hydrogen bonds with a methanol molecule, between the 
amide group of one molecule (bond distance N(4)-O(3) of 2.760(5) Å) and the 
carbonyl group of the second molecule (bond distance O(3)-O(1) of 2.689(4) Å) 
(Figure 3.9b). A second interaction is held by intermolecular hydrogen bonding 
between the fluorine of the phenyl ring and the hydrogen of the pyridyl ring (bond 
distance C(3)-F(3) of 3.241(5) Å), as shown in Figure 3.9c. 
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(b) 
 
(a) (c) 
 
Figure 3.9 (a) Packing diagram of complex 3.5 viewed along the a-axis. Hydrogen 
atoms are omitted for clarity; (b) Intermolecular hydrogen bond interactions with a 
methanol molecule; (c) Intermolecular hydrogen bond interactions with fluorine 
substituent 
 
3.5.4 X-ray Crystal Structure of Complex 3.6 
Red fragments of complex 3.6 suitable for X-ray crystallography were obtained via 
vapour diffusion of hexane into a methanol solution of the complex. Complex 3.6 
crystallised in a monoclinic cell with the arrangement of cis-cis-cis and structural 
solution was performed in the space group P21/c. The asymmetric unit contains two 
molecules of the complex and two molecules of methanol, with one of the complex 
molecule shown to have a positional disorder with an extra phenyl ring attached on the 
N atom of the (N,O)-coordinated ligand. The molecular structure of complex 3.6 is 
shown in Figure 3.10 and selected bond lengths and angles are given in Table 3.4. 
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Figure 3.10 Molecular structure of complex 3.6. Displacement ellipsoids are at the 
50% probability level. Hydrogen atoms are omitted for clarity 
 
Table 3.4 Selected bond lengths and angles for complex 3.6 with s.u.s shown in 
parenthesis 
Bond length (Å) Bond angle (°) 
Ru(1)-Cl(1) 2.345 (2)  Cl(1) - Ru(1) - Cl(2) 95.39(9) 
Ru(1)-Cl(2) 2.381(3) N(1) - Ru(1) - O(2) 176.8(3) 
Ru(1)-N(1) 2.030(8) N(2) - Ru(1) - O(2) 97.1(3) 
Ru(1)-N(2) 2.013(8) N(2) - Ru(1) - N(3) 87.7(3) 
Ru(1)-N(3) 2.071(8) N(1) - Ru(1) - N(3) 100.8(3) 
Ru(1)-O(2) 2.091(7)   
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3.5.5 X-ray Crystal Structure of Complex 3.7 
Complex 3.7 crystallises as two different shapes of red crystals - red needles (complex 
3.7a) and red prisms (complex 3.7b), both of which are suitable for x-ray 
crystallography. These crystals are obtained by vapour diffusion of pentane into a 
methanolic solution of the complex. The red needles crystallised in a triclinic cell with 
the structural arrangement trans-trans-trans, while the red prisms crystallised in a 
monoclinic cell with the structural arrangement cis-cis-cis. Their structural solutions 
were performed in the space group P1 and P21/n respectively, with the asymmetric 
unit containing one complex molecule for both complexes 3.7a and 3.7b, along with 
one methanol molecule for complex 3.7a. The molecular structure for both complexes 
3.7a and 3.7b are shown in Figure 3.11 and selected bond lengths and angles are 
given in Table 3.5. 
  
  
(a) (b) 
Figure 3.11 Molecular structure of complex 3.7 showing (a) trans-trans-trans and (b) 
cis-cis-cis structural arrangements. Displacement ellipsoids are at the 50% 
probability level. Hydrogen atoms are omitted for clarity 
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Table 3.5 Selected bond lengths and angles for complexes 3.7a and 3.7b with s.u.s 
shown in parenthesis 
Bond length (Å) / angle (°) 3.7a 3.7b 
Ru(1)-Cl(1) 2.3355(9) 2.3594(6) 
Ru(1)-Cl(2) 2.3362(9) 2.3848(5) 
Ru(1)-N(1) 2.033(3) 2.0510(15) 
Ru(1)-N(2) 2.006(3) 2.0270(14) 
Ru(1)-N(3) 2.106(3) 2.0741(16) 
Ru(1)-O(2) 2.061(2) 2.1089(12) 
Cl(1) - Ru(1) - Cl(2) 174.66(3) 95.033(19) 
N(1) - Ru(1) - O(2) 96.70(10) 177.80(6) 
N(2) - Ru(1) - O(2) 175.10(10) 98.13(5) 
N(2) - Ru(1) - N(3) 107.74(11) 88.07(6) 
N(1) - Ru(1) - N(3) 173.84(10) 100.49(6) 
 
Complex 3.7a packed in a diagonal linear arrangement along the a-axis, as shown in 
Figure 3.12a, held together by intermolecular hydrogen bonding between two 
complex molecules and a methanol molecule with bond distance N(4)-O(3) of 
2.831(4) Å and O(3)-O(1) of 2.782(3) Å to form a plane of complex molecules. 
Intermolecular hydrogen bonding interactions exists between three complex molecules 
with bond distance C(15)-Cl(1) of 3.409(4) Å, and  Cl(2)-C(23) of 3.324(4) Å forming 
a second plane of complex molecules. These interactions are shown in Figure 3.12b. 
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(a) (b) 
Figure 3.12 (a) Packing diagram of complex 3.7a along the a-axis; (b) Intermolecular 
hydrogen bonding interactions between molecules. Hydrogen atoms are omitted for 
clarity. 
 
Complex 3.7b packed in rows with a zig-zag pattern along the a-axis, as shown in 
Figure 3.13. Each molecule interacts with neighbouring molecules of the same row, 
via hydrogen bonds between the amide group of one molecule and the carbonyl group 
of the other molecule (bond distance N(4)-O(1) of 2.855(2) Å), as shown in Figure 
3.14a. The row of complexes is held by intermolecular hydrogen bonding between 
C(2)-Cl(1) with a bond distance of 3.680(2) which can be seen in Figure 3.14b. The 
ligands also exhibit intramolecular hydrogen bonding with bond distances C(1)-Cl(2) 
of 3.347(4) and C(20)-O(2) of 2.866(2). 
 
Figure 3.13 Packing diagram of complex 3.7b viewed along the a-axis. Hydrogen 
atoms are omitted for clarity. 
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Figure 3.14 Intermolecular hydrogen bond interactions of complex 3.7b (a) along the 
rows and (b) between the rows 
 
3.5.6 X-ray Crystal Structure of Complex 3.9 
Red cubic crystals of complex 3.9 suitable for X-ray crystallography were obtained via 
vapour diffusion of hexane into a methanol solution of the complex. Complex 3.9 
crystallised in a triclinic cell with the arrangement of trans-trans-trans and structural 
solution was performed in the space group P1. The asymmetric unit contains one 
complex molecule and one methanol molecule. The molecular structure is shown in 
Figure 3.15 and selected bond lengths and angles are given in Table 3.6. 
  
 
Figure 3.15 Molecular structure of complex 3.9. Displacement ellipsoids are at the 
50% probability level. Hydrogen atoms are omitted for clarity 
(a) (b) 
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Table 3.6 Selected bond lengths and angles for complex 3.9 with s.u.s shown in 
parenthesis 
Bond length (Å) Bond angle (°) 
Ru(1)-Cl(1) 2.3543(6) Cl(1) - Ru(1) - Cl(2) 173.54(18) 
Ru(1)-Cl(2) 2.3767(5) N(1) - Ru(1) - O(2) 96.08(6) 
Ru(1)-N(1) 2.0514(15) N(2) - Ru(1) - O(2) 175.25(6) 
Ru(1)-N(2) 2.0273(15) N(2) - Ru(1) - N(3) 106.95(6) 
Ru(1)-N(3) 2.1219(15) N(1) - Ru(1) - N(3) 173.80(6) 
Ru(1)-O(2) 2.1056(13)   
 
Complex 3.9 packed in a diagonal linear distribution with a zig-zag pattern along the 
a-axis as shown in Figure 3.16a. Several intermolecular interactions are seen within 
the packing arrangement, as shown in Figure 3.16b. Two complex molecules are held 
in pairs by hydrogen bonds with a methanol molecule, between the amide group of one 
molecule (bond distance N(4)-O(3) of 2.899(3) Å) and the carbonyl group of the 
second complex molecule (bond distance O(3)-O(1) of 2.733(3) Å). A second 
interaction is held by intermolecular hydrogen bonding between the chlorine ligand 
and the hydrogen of the pyridyl ring of the third complex molecule (bond distance 
C(3)-Cl(2) of 3.593(4) Å). Another interaction is between one of the chloride 
substituent on the phenyl ring of the picolinamide ligand with the hydrogen of the 
pyridyl ring on another complex molecule forming a hydrogen bond (bond distance 
C(14)-Cl(6) of 3.652(3) Å). 
  
(a) (b) 
Figure 3.16 (a) Packing diagram viewed along the a-axis of complex 3.9 (b) 
Intermolecular hydrogen bonding between molecules. Hydrogen atoms are omitted for 
clarity. 
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3.5.7 X-ray Crystal Structure of Complex 3.11 
Red plates of complex 3.11 suitable for X-ray crystallography were obtained via 
vapour diffusion of pentane into a methanol solution of the complex. Complex 3.11 
crystallised in a monoclinic cell with the arrangement of trans-trans-trans and 
structural solution was performed in the space group P21/c. The asymmetric unit 
contains one complex molecule and one methanol molecule. The molecular structure is 
shown in Figure 3.17 and selected bond lengths and angles are given in Table 3.7. 
 
 
Figure 3.17 Molecular structure of complex 3.11. Displacement ellipsoids are at the 
50% probability level. Hydrogen atoms are omitted for clarity. 
 
Table 3.7 Selected bond lengths and angles for complex 3.11 with s.u.s shown in 
parenthesis 
Bond length (Å) Bond angle (°) 
Ru(1)-Cl(1) 2.3452(9) Cl(1) - Ru(1) - Cl(2) 174.27(3) 
Ru(1)-Cl(2) 2.3914(8) N(1) - Ru(1) - O(2) 96.76(10) 
Ru(1)-N(1) 2.056(3) N(2) - Ru(1) - O(2) 174.07(10) 
Ru(1)-N(2) 2.036(3) N(2) - Ru(1) - N(3) 106.13(11) 
Ru(1)-N(3) 2.106(3) N(1) - Ru(1) - N(3) 174.43(11) 
Ru(1)-O(2) 2.095(2)   
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Complex 3.11 packed in a herringbone motif along the a-axis as shown in Figure 3.18. 
Each molecule interacts with two adjacent complex molecules, held in pairs by 
hydrogen bonds with a methanol molecule, between the amide group of one complex 
molecule (bond distance N(4)-O(5) of 2.797(5) Å) and the carbonyl group of the 
second complex molecule (bond distance O(5)-O(1) of 2.672(5) Å). 
 
 
 
Figure 3.18 Packing diagram viewed along the a-axis of complex 3.11, showing the 
intermolecular hydrogen bonding between molecules. Hydrogen atoms are omitted for 
clarity.
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3.5.8 X-ray Crystal Structure of Complex 3.12 
Red cubic crystals of complex 3.12 suitable for X-ray crystallography were obtained 
via vapour diffusion of pentane into a methanol solution of the complex. Complex 3.12 
crystallised in a monoclinic cell with the arrangement of cis-cis-cis and structural 
solution was performed in the space group P21/n. The asymmetric unit contains one 
complex molecule. The molecular structure is shown in Figure 3.19 and selected bond 
lengths and angles are given in Table 3.8. 
 
 
Figure 3.19 Molecular structure of complex 3.12. Displacement ellipsoids are at the 
50% probability level. Hydrogen atoms are omitted for clarity 
 
Table 3.8 Selected bond lengths and angles for complex 3.12 with s.u.s shown in 
parenthesis 
Bond length (Å) Bond angle (°) 
Ru(1)-Cl(1) 2.3505(7) Cl(1) - Ru(1) - Cl(2) 95.57(2) 
Ru(1)-Cl(2) 2.3833(7) N(1) - Ru(1) - O(2) 178.36(8) 
Ru(1)-N(1) 2.053(2) N(2) - Ru(1) - O(2) 98.69(8) 
Ru(1)-N(2) 2.029(2) N(2) - Ru(1) - N(3) 87.81(8) 
Ru(1)-N(3) 2.080(2) N(1) - Ru(1) - N(3) 102.07(8) 
Ru(1)-O(2) 2.1043(17)   
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Complex 3.12 packed in rows with a zig-zag pattern along the a-axis, as shown in 
Figure 3.20a. A pair of molecules interacts via hydrogen bonds between the amide 
group of one molecule and the carbonyl group of the other molecule (bond distance 
N(4)-O(1) of 2.857(3) Å), which again interacts with another molecule between a 
chloride ligand and the hydrogen of a pyridyl ring (bond distance C(14)-Cl(2) of 
3.670(3) Å) (Figure 3.20b). 
 
 
 
(a) (b) 
 
Figure 3.20 (a) Packing diagram viewed along the a-axis of complex 3.12 (b) 
Intermolecular hydrogen bonding between molecules. Hydrogen atoms are omitted for 
clarity. 
 
3.5.9 X-ray Crystal Structure of Complex 3.13 
Orange needles of complex 3.13 suitable for X-ray crystallography were obtained via 
vapour diffusion of pentane into a methanol solution of the complex. Complex 3.13 
crystallised in a triclinic cell with the arrangement of trans-trans-trans and structural 
solution was performed in the space group P1. The asymmetric unit contains one 
complex molecule and one methanol molecule. The molecular structure is shown in 
Figure 3.21 and selected bond lengths and angles are given in Table 3.9. 
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Figure 3.21 Molecular structure of complex 3.13. Displacement ellipsoids are at the 
50% probability level. Hydrogen atoms are omitted for clarity. 
 
Table 3.9 Selected bond lengths and angles for complex 3.13 with s.u.s shown in 
parenthesis 
Bond length (Å) Bond angle (°) 
Ru(1)-Cl(1) 2.3397(13) Cl(1) - Ru(1) - Cl(2) 176.59(5) 
Ru(1)-Cl(2) 2.3425(14) N(1) - Ru(1) - O(2) 97.83(16) 
Ru(1)-N(1) 2.039(4) N(2) - Ru(1) - O(2) 176.41(16) 
Ru(1)-N(2) 1.996(4) N(2) - Ru(1) - N(3) 105.86(18) 
Ru(1)-N(3) 2.089(4) N(1) - Ru(1) - N(3) 175.47(18) 
Ru(1)-O(2) 2.100(4)   
 
Complex 3.13 packed in a linear arrangement along the b-axis, as shown in Figure 
3.22. The complex molecules are held by intermolecular hydrogen bond between one 
methanol molecule with two complex molecules involving the amide group of one 
complex molecule (bond distance N(4)-O(3) of 2.850(6) Å) and the carbonyl group of 
the second molecule (bond distance O(3)-O(1) of 2.754(5) Å). Another intermolecular 
interaction is the hydrogen bonding between the bromine substituent of one molecule 
and the hydrogen of the pyridyl ring on another molecule (bond distance C(15)-Br(1) 
of 3.633(6) Å). 
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Figure 3.22 Packing diagram viewed along the b-axis of complex 3.21, showing the 
intermolecular hydrogen bonding between molecules. Hydrogen atoms are omitted for 
clarity. 
 
3.5.10 X-ray Crystal Structure of Complex 3.15 
Red plates of complex 3.15 suitable for X-ray crystallography were obtained by 
vapour diffusion of pentane into a methanol solution of the complex. Complex 3.15 
crystallised in a monoclinic cell with the arrangement cis-trans-cis, and structural 
solution was performed in the space group P21/c. The asymmetric unit contains one 
complex molecule and two methanol molecules. The molecular structure is shown in 
Figure 3.23 and selected bond lengths and angles are given in Table 3.10. 
 
 
Figure 3.23 Molecular structure of complex 3.15. Displacement ellipsoids are at the 
50% probability level. Hydrogen atoms are omitted for clarity. 
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Table 3.10 Selected bond lengths and angles for complex 3.15 with s.u.s shown in 
parenthesis 
Bond Distance (Å) Bond Angle (°) 
Ru(1)-Cl(1) 2.3462(10) Cl(1)-Ru(1)-Cl(2) 94.71(4) 
Ru(1)-Cl(2) 2.3943(10) N(1) - Ru(1) - O(2) 98.88(10) 
Ru(1)-N(1) 2.089(3) N(2) - Ru(1) - O(2) 85.17(10) 
Ru(1)-N(2) 2.052(3) N(2) - Ru(1) - N(3) 97.05(11) 
Ru(1)-N(3) 2.096(3) N(1) - Ru(1) - N(3) 175.62(11) 
Ru(1)-O(2) 2.113(2) 
  
 
Complex 3.15 packed in a herringbone motif along the c-axis (Figure 3.24a). A pair of 
molecules are held together by intermolecular hydrogen bonds between the amide 
group of one complex molecule and the oxygen of the carbonyl group of the second 
complex molecule (bond distance N(4)-O(1) of 2.776(4) Å). Another interaction 
between two complex molecules is via hydrogen bonding between one of the chloride 
ligands of one molecule with the hydrogen of the phenyl ring of another molecule 
(bond distance C(10)-Cl(2) of 3.574(4) Å). These interactions are as shown in Figure 
3.24b. There is also a hydrogen bonding between two methanol molecules, however 
they do not interact within the packing of the complex molecules 
 
 
(a) (b) 
Figure 3.24 (a) Herringbone packing of complex 3.15 viewed along the c-axis;  
(b) Intermolecular hydrogen bonding between a pair of complex molecules. Hydrogen 
atoms are omitted for clarity. 
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3.5.11 X-ray Crystal Structure of Complex 3.16 
Complex 3.16 crystallises as two different types of crystals - orange needles (complex 
3.16a) and red blocks (complex 3.16b), which were suitable for x-ray crystallography. 
These crystals were obtained by vapour diffusion of pentane into a methanolic solution 
of the complex. The orange needles crystallised in an orthorhombic cell with the 
structural arrangement trans-trans-trans, while the red blocks crystallised in a 
monoclinic cell with the structural arrangement cis-trans-cis. Their structural solution 
was performed in the space group P212121 and P21/n respectively, with the asymmetric 
unit containing one complex molecule for both complexes 3.16a and 3.16b, along with 
one methanol molecule for complex 3.16a. Complex 3.16b has shown a positional 
disorder with an extra phenyl ring attached on the N2 atom of the (N,N)-coordinated 
ligand. The molecular structure for both complexes 3.16a and 3.16b are shown in 
Figure 3.25 and selected bond lengths and angles are given in Table 3.11. 
  
  
(a) (b) 
Figure 3.25 Molecular structure of complex 3.16 showing (a) trans-trans-trans and 
(b) cis-trans-cis structural geometry. Displacement ellipsoids are at the 50% 
probability level. Hydrogen atoms are omitted for clarity. 
Synthesis of Ruthenium Dichloride Complexes  Chapter 3 
72 
 
Table 3.11 Selected bond lengths and angles for complex 3.16a and 3.16b with s.u.s 
shown in parenthesis 
Bond length (Å) / angle (°) 3.16a 3.16b 
Ru(1)-Cl(1) 2.330(4) 2.3241(13) 
Ru(1)-Cl(2) 2.352(3) 2.3600(13) 
Ru(1)-N(1) 2.023(13) 2.045(4) 
Ru(1)-N(2) 2.016(10) 2.030(4) 
Ru(1)-N(3) 2.067(12) 2.060(4) 
Ru(1)-O(2) 2.116(9) 2.056(3) 
Cl(1) - Ru(1) - Cl(2) 173.82(13) 92.54(5) 
N(1) - Ru(1) - O(2) 98.3(4) 93.55(14) 
N(2) - Ru(1) - O(2) 176.3(5) 91.98(14) 
N(2) - Ru(1) - N(3) 104.6(5) 94.94(15) 
N(1) - Ru(1) - N(3) 175.8(5) 171.69(15) 
 
Complex 3.16a packed in a vertical linear arrangement along the b-axis as shown in 
Figure 3.26a. Intermolecular hydrogen bonds are held between one methanol 
molecule with three complex molecules involving the amide group of one molecule 
(bond distance N(4)-O(3) of 2.757(17) Å), the carbonyl group of the second molecule 
(bond distance O(3)-O(1) of 2.757(16) Å) and the iodide substituent on the phenyl ring 
of the third molecule (bond distance C(25)-I(1) of 3.561(16) Å). A pair of complex 
molecules are also held together via hydrogen bond between the carbonyl group of one 
molecule and the hydrogen of the phenyl ring on another molecule (bond distance 
C(10)-O(1) of 3.268(17) Å) (Figure 3.26b). 
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(a) (b) 
Figure 3.26 (a) Packing diagram viewed along the b-axis of complex 3.16a (b) 
Intermolecular hydrogen bonding between molecules. Hydrogen atoms are omitted for 
clarity. 
 
Complex 3.16b packed in a zig-zag pattern when packed along the c-axis as shown in 
Figure 3.27a. The complex molecules are packed together by intermolecular hydrogen 
bonding between the amide group of one molecule and the carbonyl group of the 
second molecule (bond distance N(4)-O(1) of 2.751(5) Å), and between oxygen atom 
of the (N,O)-coordinated ligand and the hydrogen of the pyridyl ring of the third 
molecule (bond distance C(3)-O(2) of 3.161(6) Å) (Figure 3.27b). 
 
  
(a) (b) 
Figure 3.27 (a) Packing diagram viewed along the c-axis of complex 3.16b (b) 
Intermolecular hydrogen bonding between molecules. Hydrogen atoms are omitted for 
clarity. 
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3.6 Isomerisation studies on bis-Picolinamide Ruthenium (III) 
Dichloride (RuCl2L2) Complexes 
There have been many attempts to separate the isomers of bis-picolinamide ruthenium 
dichloride complexes from their main product, including fractional sublimation, 
column chromatography using a mixture of different good and poor solvents, washing 
off with a wide range of different solvents (assuming the different isomers have 
different solubility), and using different procedures to synthesise the respective 
isomers following the previously reported synthesis of complexes with different 
structural isomers.
 1, 4, 7
 However, no successful results have been obtained. Fractional 
recrystallisation has separated the isomers of the ruthenium dichloride complexes into 
different shapes and colours of crystals as described previously, but the different 
crystals were close to each other in the solution that collecting them separately for 
further studies was not possible. Comparison of IR spectra between each complex was 
used to observe the differences in their NH and CO group stretches as to whether the 
main product of the complex contains one single isomer or a mixture of isomers. 
However, all IR spectra have been shown to be similar, where the differences of shift 
or intensity of the bands between the spectra of each complex was insignificant. 
 
Complex 3.7 has been shown to have two different structural isomers and was 
therefore analysed by uv-vis spectrophotometry as a function of time and temperature. 
Complex 3.7 was dissolved in dry methanol and was analysed to observe the effective 
changes in spectra that could result from an isomerisation process. Figure 3.28(a) 
shows a time-dependant spectra of complex 3.7 in dry methanol taken at 0 h, 24 h and 
48 h. A slight change is seen for peak centred at about 298 nm, which has decreased in 
intensity after 48 h. A temperature-dependent spectra of complex 3.7 in dry methanol 
observed every decrease of 5°C from 58°C to 10°C, is as shown in Figure 3.28(b).  
An increase in intensity of peak with maxima at 298 nm can be seen as the temperature 
decreases. These changes observed are very insignificant and no new peaks appeared 
over time and temperature to indicate that there are changes in their structural isomers 
in solution.  
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(a) (b) 
  
Figure 3.28 (a) Time-dependant, and (b) Temperature-dependant uv-vis solution 
studies in dry MeOH for complex 3.7 (30 µM) 
 
The powder diffraction (PXRD) pattern of complex 3.7 was also recorded. The 
diffraction patterns were compared between the bulk powder sample and its single 
trans and cis crystal structures for complexes 3.7a and 3.7b respectively, as shown in 
Figure 3.29. The patterns are very different between the diffractograms. The positions 
of the peaks in the simulated patterns do not match those of the recorded pattern of 
complex 3.7 hence it was not possible to obtain a ratio of trans:cis ratio. Furthermore, 
since the dried powder sample was used for the study, the presence of solvent in the 
trans crystal structure may also affect the pattern. Thus, separation of the mixtures to 
obtain pure isomers is useful for further characterisation studies. 
 
Figure 3.29 PXRD diffractogram of complex 3.7 for simulated trans and cis, and 
experimental with scan rate at 30 secs/scan 
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Synthesis and Characterisation of Functionalised Bis-
Picolinamide Ruthenium Diiodide Complexes 
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4 Synthesis of Ruthenium Diiodide Complexes 
4.1 Introduction 
This chapter discusses previously reported trans-platinum diiodide anti-cancer 
complexes, followed by the synthesis of a series of novel bis-picolinamide ruthenium 
(III) diiodide complexes, and their characterisation. The aim for this synthesis is to 
extend the library of bis-picolinamide ruthenium (III) dihalide complexes, by 
coordinating monodentate iodide ligands to the ruthenium metal centre, as well as, the 
interest in investigating the effect of changing the ancillary halide ligands towards 
their biological activity. 
 
4.2 Trans-platinum diiodide anti-cancer complexes 
Monodentate iodide ligands have been used in the design of anti-cancer drugs for 
many years,
1
 after numerous chemical studies on cisplatin clearly demonstrated that 
the chlorides are the reactive ligands.
2, 3
 This led to the interest in observing the effects 
towards biological activity when varying the leaving groups on cisplatin.  
 
The structural-activity rules for metal complexes as anti-cancer drugs were developed 
in the initial studies by Rosenberg,
4
 and Cleare and Hoeschele.
1, 5
 Their studies 
specifically focused on platinum (II) complexes based on the structure of cisplatin, 
observing the effects of varying the complexes’ structural geometries, monodentate 
ligands and charge, on their anti-cancer activities in vivo. The platinum complex with 
trans dichloride ligands was shown to be inactive, revealing that cis geometry is 
important in anti-cancer activity. 
1, 5
 This could be due to two main factors. Trans 
geometry complexes are highly reactive due to kinetic instability, leading to an 
increase in toxicity. In addition, the complexes with cis geometry have the potential for 
biological interaction within the cells through chelate formation, which is 
stereochemically inaccessible for trans complexes. When the ancillary chloride ligands 
of cisplatin were changed to iodide, the complex has showed a decrease in potency. A 
very high dose was required for the platinum diiodide complex to create a maximum 
effect for its anti-cancer activity. 
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Despite these studies, several trans-platinum complexes have shown, in recent years, 
to be potent anti-cancer complexes when compared to their cis analogues, breaking the 
structural-activity rules for metal anti-cancer complexes.
6, 7
 Based on the general 
structure of cisplatin, the cytotoxicity of trans-platinum complexes increase 
significantly both in vitro and in vivo when substituting the inert ammine ligands with 
more bulky ligands, as shown in Figure 4.1. Mechanistic studies suggest that these 
bulky ligands can hinder the substitution of the trans dichloride ligands, decreasing the 
kinetic instability of the trans-platinum complexes, hence leading to lower toxicity. 
Farrell et al. proposed TPA complexes, in which trans dichloride platinum complexes 
that contain at least one aromatic N-donor ligand (L = L’ = Pyridine; Thiazole, or L = 
Quinoline, L’ = RR'SO (R= Me, R' = Me, Bz, or Ph)), and have shown a 100-fold 
higher cytotoxicity than transplatin and comparable with cisplatin.
8
 A recent platinum 
complex reported is the platinum (IV) diazido complex, trans-trans-trans-
Pt(N3)3(OH)2(Py)2 that is photoactivated by visible light at 420 nm, and is more potent 
upon irradiation at 365 nm.
9
 
 
 
L = L’ = Pyridine; Thiazole, or L = 
Quinoline, L’ = RR'SO (R= Me, R' = Me, Bz, 
or Ph 
TPA complexes trans-trans-trans-Pt(N3)3(OH)2(Py)2 
 
Figure 4.1 Recently reported active trans-platinum anti-cancer complexes 
 
There is also a variety of platinum anti-cancer drugs with monodentate diiodide 
ligands as shown in Figure 4.2. Complex 1 has ethylenediamine as the neutral ligand, 
X = Cl or I as the anionic ligands, and various axial ligands, where Y is Cl, OH, 
OCOCH3, OCOCF3 or OSO2CH3. These complexes were studied to investigate the 
influence of anionic ligands on reduction rates and potentials, DNA binding ability, 
and cell growth inhibitory activity.
10
 Carbohydrate 2,3-diamino-2,3-dideoxy-D-
glucopyranose was chosen as a ligand for complex 2 to resemble the structure of the 
third generation platinum-based anticancer drug, oxalipatin, and diiodide ligands as the 
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leaving groups. These complexes were evaluated for their affinity toward dGMP by 
capillary electrophoresis (CE) and for their in vitro cytotoxicity by MTT assay.
11
 In a 
more recent report, complexes 3 and 4 analogues of each other, having diiodide 
ligands either in cis or trans configuration, and diamine ligands, where Y is 
isopropylamine, dimethylamine or methylamine have been studied. They have shown 
a higher cytotoxicity is seen for complexes with trans diiodide ligands compared to 
their corresponding cis analogue, which brought them to further investigation on the 
possible molecular mechanisms of action, by analysing the reactivity of these 
complexes with a few representative biomolecules using various physicochemical 
techniques.
12
 
 
 
  
X= Cl or I 
Y = Cl, OH, 
OCOCH3, OCOCF3 
or OSO2CH3 
Y = CH3NH2, (CH3)2NH2 or 
(CH3)2CHNH2  
 (1) (2)  (3)  (4) 
Figure 4.2 Previously reported platinum-diiodide as potential anti-cancer complexes 
 
Sadler et al. have reported metal (Ru or Os) p-cymene complexes with a chloride or 
iodide as the monodentate ligand, and either azopyridine or iminopyridine as the 
chelating ligand. They have shown dramatic differences in biological activities, when 
substituting the coordinating chloride ligands to iodide, with remarkable advantages 
towards having the iodide ligand bonded to the metal centre.
13, 14
 The IC50 values of 
[Ru(η6-p-cym)(p-Azpy-NMe2)Cl]PF6 and [Ru(η
6
-p-cym)(p-Azpy-NMe2)I]PF6 against 
A549 lung cancer cell lines were reported to be 15 ± 1 µM and 1.27 ± 0.01 µM 
respectively, which is about 15-fold difference. There are, however, only limited 
known ruthenium based anti-cancer complexes containing iodide monodentate ligands, 
furthermore, with two iodide ligands, encouraging the exploration of structural-activity 
relationships on trans-metal based anti-cancer complexes. 
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4.3 Synthesis of bis-Picolinamide Ruthenium (III) Diiodide (RuI2L2) 
Complexes 
Bis-picolinamide ruthenium (III) diiodide (RuI2L2) complexes contain two bidentate 
ligands with planar aromatic rings, an amide group and a carbonyl group that are able 
to form interactions with biological molecules, and two monodentate iodide ligands 
coordinating to the metal centre, which may influence the biological properties of the 
whole complex. The general synthesis for these complexes is as shown in Scheme 4.1.  
 
 
 
R = H (Complex 4.1, Yield 
58%) 
 2’,4’-Cl (Complex 4.9, Yield 
44%)  2’-F    (Complex 4.2, Yield 
59%) 
 2’,5’-Cl (Complex 4.10, Yield 
44%)  4’-F (Complex 4.3, Yield 
58%) 
 2’-Br (Complex 4.11, Yield 
52%)  2’,4’-F (Complex 4.4, Yield 
36%) 
 3’-Br (Complex 4.12, Yield 
50%)  2’,5’-F (Complex 4.5, Yield 
31%) 
 4’-Br (Complex 4.13, Yield 
52%)  2’-Cl (Complex 4.6, Yield 
34%) 
 2’,4’,-Br (Complex 4.14, Yield 
74%)  3’-Cl (Complex 4.7, Yield 
62%) 
 2’,5’-Br  (Complex 4.15¸Yield 
33%)  4’-Cl (Complex 4.8, Yield 
60%) 
   
 
Scheme 4.1 Synthesis of bis-picolinamide ruthenium (III) diiodide complexes 
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The reaction starts by synthesising the ruthenium dichloride analogue, and the addition 
of an excess of solid potassium iodide in situ during reflux favours halide-exchange 
reaction.
15, 16
 The dichloride ligands of RuCl2L2 complex undergo substitution with 
iodide from solid KI, giving the ruthenium diiodide complex and forming a salt, 
potassium chloride, which was dissociated as white precipitate and filtered over celite 
after the 18 h reaction. Several filtration and washing were involved in order to fully 
discard the white precipitate of KCl, resulting in different percentage yield obtained in 
the series of bis-picolinamide ruthenium diiodide complexes. 
 
4.4 Characterisation of bis-Picolinamide Ruthenium (III) Diiodide 
Complexes 
Bis-picolinamide ruthenium (III) diiodide complexes were prepared by a halide-
exchange reaction via Scheme 4.1, where an excess of potassium iodide was added 
directly to the functionalised bis-picolinamide ruthenium (III) dichloride complex and 
heated under reflux for 18 hours. Complexes 4.1 - 4.15 were obtained as pure products 
in yields ranging from 31-74% and characterised using IR, ES-MS, elemental analysis 
and single crystal X-Ray diffraction. These complexes are found to be soluble in 
dimethylformamide, tetrahydrofuran and nitromethane to give dark green-brown 
solutions. 
 
Complexes 4.1 to 4.15 have similar IR spectra to their dichloride analogues, showing 
several bands with different intensities in the 1600-400 cm
-1 
area. There are two NH 
stretches with different intensities - medium and weak, within the region 3000-3500 
cm
-1
, and one strong stretch with a weak split for the CO group around the 1500-1600 
cm
-1 
region. A shift of the stretches towards lower wavenumber is seen on the IR 
spectra of ruthenium diiodide when compared with the IR spectra of its dichloride 
analogue. Figure 4.3 shows the IR spectra of ligand 2.11, complex 3.11 and complex 
4.11 as an example of the comparison. Magnetic susceptibility measurements have 
shown that all of the complexes are low-spin d
5
 with unpaired one-electron (µeff = 1.60 
- 1.92 µB), which corresponds to the +3 state of ruthenium (µeff = 1.73 µB). 
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Two different types of structural isomers have been shown to exist for these 
complexes, which are the trans-trans-trans and trans-cis-cis structural isomers 
confirmed by their single crystal structures. X-ray crystallography has been used to 
show the geometry of the different structural isomers, as well as to verify the 
coordination mode of the ligands in the complexes. The ligands are bonded in N,N- 
and N,O- coordination modes to the ruthenium metal centre. Single crystal structures 
and data are shown for complexes 4.2, 4.3, 4.12 and 4.13, which were recrystallised by 
vapour diffusion of dimethylformamide/ether. 
 
4.5 IR Data for Ligand 2.11, Complex 3.11 and Complex 4.11 
The IR spectra of ligand 2.11, complex 3.11 and complex 4.11 are shown in Figure 
4.3. In the spectrum of the uncoordinated ligand, the strong CO stretch is observed at 
1691 cm
-1
, shifted to 1590 cm
-1
 in complex 3.11 and to 1563 cm
-1
 in complex 4.11 that 
splits into two bands. Two NH stretches seen in the region 3000-3300 cm
-1
 are shifted 
from 3290 cm
-1 
and 3108 cm
-1
 in ligand 2.11, to 3209 cm
-1
 and 3062 cm
-1
 in complex 
3.11 and to 3172 cm
-1 
and 3054 cm
-1
 in complex 4.11. 
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Figure 4.3 IR Spectra of ligand 2.11, complex 3.11 and complex 4.11 
Ligand 2.11 
Complex 3.11 
Complex 4.11 
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4.6 X-ray Crystallography Data for bis-Picolinamide Ruthenium (III) 
Diiodide Complexes 
Single crystals of complexes 4.2, 4.3, 4.12 and 4.13 which were suitable for X-ray 
crystallography were obtained by vapour diffusion of ether into a solution of the 
complex in dimethylformamide. The bis-picolinamide ruthenium diiodide complexes 
have a distorted octahedral centre, with bond angles in the range 96.2°-108.0° between 
the ligands that are cis to each other, and bond angles of 171.6°-177.9° between the 
trans ligands about the ruthenium metal centre. 
 
The bond angle between the two N atoms of the (N,N)-coordinate ligand, and the N and O 
atom of the (N,O)-coordinated ligand, is less than 90° with the range between 76.9 - 78.8°, 
due to the rigidity of the picolinamide ligands. The angle between the two trans iodine 
atoms around the ruthenium centre is between 174.1 - 177.9°. The torsion angle for the 
(N,N)- and (N,O)-coordinated ligand is between 49.3 - 92.5°, and 17.6 - 39.5° respectively, 
adopting non-planar configurations between the picolinamide rings. 
 
The Ru-I bond distances for all of the bis-picolinamide ruthenium diiodide complexes 
are similar, where one of the Ru-I bonds is longer than the other, with an average bond 
distance of 2.67 Å for Ru-I(1) and 2.69 Å for Ru-I(2). The average bond lengths of 
Ru(1)-N(1), Ru(1)-N(2), Ru(1)-N(3) and Ru(1)-O(2) for all the complexes are 2.05 Å, 
2.02 Å, 2.12 Å and 2.09 Å respectively, consistent and comparable with bis-
picolinamide ruthenium (III) dichloride complexes as discussed in Chapter 3. 
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4.6.1 X-ray Crystal Structure for Complex 4.2 
Complex 4.2 crystallises to black block crystals that are suitable for X-ray 
crystallography. The complex crystallised in an orthorhombic cell with the 
arrangement of trans-trans-trans and structural solution was performed in the space 
group Pna21. The asymmetric unit contains one complex molecule. The molecular 
structure of complex 4.2 is shown in Figure 4.4 and selected bond lengths and angles 
are given in Table 4.1. 
 
 
Figure 4.4 Molecular structure of complex 4.2. Displacement ellipsoids are at the 
50% probability level. Hydrogen atoms are omitted for clarity. 
 
Table 4.1 Selected bond lengths and angles for complex 4.2 with s.u.s shown in 
parenthesis 
Bond length (Å) Bond angle (°) 
Ru(1)-I(1) 2.6507(17) I(1) - Ru(1) - I(2) 174.89(6) 
Ru(1)-I(2) 2.6670(18) N(1) - Ru(1) - O(2) 97.1(4) 
Ru(1)-N(1) 2.031(13) N(2) - Ru(1) - O(2) 175.4(5) 
Ru(1)-N(2) 2.009(11) N(2) - Ru(1) - N(3) 107.2(5) 
Ru(1)-N(3) 2.123(12) N(1) - Ru(1) - N(3) 173.7(5) 
Ru(1)-O(2) 2.106(10)   
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The crystal packing of complex 4.2 consists of wave-like layers when viewed along 
the c-axis, as shown in Figure 4.5. The molecules are held together by hydrogen bond 
interactions between the amide group of one molecule and the carbonyl group of the 
other molecule (bond distance N(4)-O(1) of 2.746(16) Å). Another interaction is 
between an oxygen atom of the (N,O)-coordinated ligand of one molecule and the 
hydrogen of a pyridyl ring of the second molecule (bond distance C(11)-O(2) of 
3.383(14) Å). 
 
 
 
Figure 4.5 Packing diagram of complex 4.2 viewed along the c-axis showing 
intermolecular hydrogen bond interactions between molecules. Hydrogen atoms are 
omitted for clarity. 
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4.6.2 X-ray Crystal Structure for Complex 4.3 
Green fragments of complex 4.3 suitable for X-ray crystallography crystallised in an 
orthorhombic cell with the arrangement of trans-trans-trans. The structural solution 
was performed in the space group Pna21, and the asymmetric unit contains one 
complex molecule. The molecular structure is shown in Figure 4.6 and selected bond 
lengths and angles are given in Table 4.2. The molecules of complex 4.3 pack in 
layers when viewed along the c-axis, forming hydrogen bonds between molecules, 
similarly as complex 4.2. 
 
 
Figure 4.6 Molecular structure of complex 4.3. Displacement ellipsoids are at the 
50% probability level. Hydrogen atoms are omitted for clarity. 
 
Table 4.2 Selected bond lengths and angles for complex 4.3 with s.u.s shown in 
parenthesis 
Bond length (Å) Bond angle (°) 
Ru(1)-I(1) 2.6589(8) I(1) - Ru(1) - I(2) 177.93(3) 
Ru(1)-I(2) 2.7149(8) N(1) - Ru(1) - O(2) 96.6(2) 
Ru(1)-N(1) 2.051(6) N(2) - Ru(1) - O(2) 174.3(2) 
Ru(1)-N(2) 2.021(6) N(2) - Ru(1) - N(3) 107.4(2) 
Ru(1)-N(3) 2.119(6) N(1) - Ru(1) - N(3) 173.7(2) 
Ru(1)-O(2) 2.089(5)   
Synthesis of Ruthenium Diiodide Complexes  Chapter 4 
87 
4.6.3 X-ray Crystal Structure for Complex 4.12 
Complex 4.12 crystallised as black prism crystals in a monoclinic unit cell with the 
arrangement of trans-trans-trans. Structural solution was performed in the space group 
Cc. The asymmetric unit contains one complex molecule and one dimethylformamide 
molecule. The molecular structure is shown in Figure 4.7, and the selected bond 
lengths and angles are given in Table 4.3. 
 
 
Figure 4.7 Molecular structure of complex 4.12. Displacement ellipsoids are at the 
50% probability level. Hydrogen atoms are omitted for clarity. 
 
Table 4.3 Selected bond lengths and angles for complex 4.12 with s.u.s shown in 
parenthesis 
Bond length (Å) Bond angle (°) 
Ru(1)-I(1) 2.701(4) I(1) - Ru(1) - I(2) 174.3 (14) 
Ru(1)-I(2) 2.703(4) N(1) - Ru(1) - O(2) 96.85(12) 
Ru(1)-N(1) 2.065(3) N(2) - Ru(1) - O(2) 175.56(13) 
Ru(1)-N(2) 2.023(3) N(2) - Ru(1) - N(3) 107.41(12) 
Ru(1)-N(3) 2.122(3) N(1) - Ru(1) - N(3) 173.65(13) 
Ru(1)-O(2) 2.092(3)   
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When viewed along the b-axis, complex 3.9 can be seen packed in a diagonal linear 
arrangement as shown in Figure 4.8(a). Several intermolecular interactions are seen 
within the packing arrangement, as shown in Figure 4.8(b). Three complex molecules 
are held together by hydrogen bond interactions with a dimethylformamide molecule. 
These interactions are between the amide group of one complex molecule and the 
oxygen atom of dimethylformamide molecule (bond distance N(4)-O(3) of 2.779(5) 
Å). Another interaction is between the carbonyl group of the second complex molecule 
and one of the carbon atoms of the dimethylformamide molecule (bond distance 
C(1A)-O(1) of 3.223(5) Å), and also, an interaction between the bromine substituent of 
another complex molecule and the carbon atom of the dimethylformamide molecule 
(bond distance C(1A)-Br(1) of 3.710(4) Å).  
 
 
 
(a) (b) 
 
Figure 4.8 (a) Packing diagram viewed along the b-axis of complex 4.12; (b) 
Intermolecular hydrogen bonding between molecules. Hydrogen atoms are omitted for 
clarity. 
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4.6.4 X-ray Crystal Structure for Complex 4.13 
Black crystals of complex 4.13 suitable for X-ray crystallography crystallised in a 
monoclinic cell with the arrangement of trans-cis-cis. The structural solution was 
performed in the space group P21/n, and the asymmetric unit contains one complex 
molecule and one dimethylformamide molecule. The molecular structure of complex 
4.13 is shown in Figure 4.9 and the selected bond lengths and angles are given in 
Table 4.4. 
 
 
 
Figure 4.9 Molecular structure of complex 4.13. Displacement ellipsoids are at the 
50% probability level. Hydrogen atoms are omitted for clarity. 
 
Table 4.4 Selected bond lengths and angles for complex 4.13 with s.u.s shown in 
parenthesis 
Bond length (Å) Bond angle (°) 
Ru(1)-I(1) 2.664(11) I(1) - Ru(1) - I(2) 174.1(4) 
Ru(1)-I(2) 2.685(11) N(1) - Ru(1) - O(2) 174.9(3) 
Ru(1)-N(1) 2.039(7) N(2) - Ru(1) - O(2) 96.2(3) 
Ru(1)-N(2) 2.023(7) N(2) - Ru(1) - N(3) 171.6(3) 
Ru(1)-N(3) 2.118(7) N(1) - Ru(1) - N(3) 108.0(3) 
Ru(1)-O(2) 2.066(6)   
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Complex 4.13 packs in a diagonal linear arrangement along the b-axis as shown in 
Figure 4.10. Each molecule interacts with the adjacent complex molecule via two 
hydrogen bond interactions from the carbonyl group of the (N,N)-coordinated ligand 
with the amide group of one molecule (bond distance N(4)-O(1) of 2.809(10) Å), and 
with the carbon atom of another molecule (bond distance C(16)-O(1) of 3.092(11) Å). 
Two intramolecular hydrogen bond interactions can also be found, where one is within 
the (N,O)-coordinated ligand of a complex molecule (bond distance C(24)-O(2) of 
2.790(11) Å), and the other intramolecular interaction is within a dimethylformamide 
molecule (bond distance C(26)-O(3) of 2.803(15) Å). 
 
Figure 4.10 Packing diagram of complex 4.13 viewed along the b-axis showing 
intermolecular hydrogen bond interactions between molecules. Hydrogen atoms are 
omitted for clarity. 
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4.7 Isomerisation studies on bis-Picolinamide Ruthenium (III) Diiodide 
(RuI2L2) Complexes 
The ruthenium diiodide complex 4.13 was studied for isomerisation in DMF solution 
by uv-vis spectrophotometry. Figure 4.11(a) and (b) show the uv-vis spectra of 
complex 4.13 at Day 0 and Day 5, and from 0°C - 100°C, in DMF solution 
respectively. Only one structural trans isomer is observed for ruthenium diiodide 
complexes from its crystal structure, and with no change observed in their uv-vis 
spectra it can be suggested that the trans structural geometry is also stable in solution 
over a period of time and also, over a wide temperature range. Following this, powder 
diffraction (PXRD) patterns were also recorded for complexes 4.2, 4.3 and 4.13. This 
was to further determine the stability of structural geometry in the bulk powder 
samples. The diffractogram simulated from the single crystal structure of complex 4.2 
was compared with the diffractograms recorded from its powder sample at scan rate of 
5secs/scan and 30secs/scan, and are shown in Figure 4.12. The PXRD patterns show 
similarities on the peaks between their diffractograms. Data analysis on the unit cell of 
the powder sample using DiffracEva
17
 and ChekCell
18
 software has shown that it is 
comparable and very well matches with the unit cell data obtained from the single 
crystal structure of the complex, suggesting the stability and purity of the ruthenium 
diiodide complex. 
 
(a) (b) 
  
Figure 4.11(a) Time-dependant and (b) Temperature-dependant uv-vis solution 
studies in DMF for complex 4.13 (30µM) 
Synthesis of Ruthenium Diiodide Complexes  Chapter 4 
92 
 
Figure 4.12 PXRD data of complex 4.2 showing the simulated and experimental 
diffractograms recorded at scan rate of 5secs/scan and 30 secs/scan 
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Synthesis and Characterisation of Functionalised Bis-
Picolinamide Rhodium Dihalide Complexes 
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5 Synthesis of Rhodium Dihalide Complexes 
5.1 Introduction 
Five bis-picolinamide rhodium (III) chloride complexes were recently reported. 
1
 The 
structural characterisation and spectroscopic analysis of Bhattacharya et al synthesised 
rhodium complexes of the type RhX2L2, to give bis-picolinamide rhodium dichloride 
complexes as shown in Figure 5.1.
1
 The complexes consist of trans dichloride ligands 
and two picolinamide ligands coordinating (N,N) and (N,O) to the rhodium metal 
centre, with the two pyridine rings trans  to each other. The picolinamide ligands are 
functionalised by a substituent specifically on the para position in this series of 
complexes. 
 
R = OCH3, CH3, H, Cl, NO2 
Figure 5.1 General structure of bis-picolinamide rhodium (III) dichloride complexes 
developed by Bhattacharya et al
1
 
 
This chapter includes the synthesis and structural characterisation of a series of novel 
bis-picolinamide rhodium (III) dihalide complexes, functionalised with halide 
substituents on the meta position of the phenyl ring. The aim of this work was to create 
rhodium analogues of the bis-picolinamide ruthenium (III) dihalide complexes 
described in Chapters 3 and 4. The rhodium complexes were expected to have similar 
structural characteristics to their Ru analogues, in having five possible isomers (Fig. 
3.1). The Ru(III) complexes were not suitable to study by NMR spectroscopy, Rh 
analogues were prepared to analyse their structural characterisation both in solid state 
using powder diffraction, and in solution by NMR techniques, as well as, their 
application as catalysts.
2
 
Synthesis of Rhodium Dihalide Complexes       Chapter 5 
 
95 
5.2 Synthesis of Bis-picolinamide Rhodium (III) Dihalide Complexes 
Bis-picolinamide rhodium (III) dihalide (RhX2L2) complexes were prepared following 
the general scheme shown in Scheme 5.1, where two equivalents of picolinamide 
ligands were heated under reflux for two hours with rhodium trichloride in ethanol in 
the presence of a base, triethylamine, to afford complexes 5.1 - 5.4. A halide-exchange 
reaction of complexes 5.2 and 5.3 afforded the rhodium diiodide analogues, complexes 
5.5 and 5.6 respectively after the addition of an excess of potassium iodide in situ and 
heating under reflux in ethanol for a further 18 h. 
 
 
 
Complex X R Yield 
5.1 Cl 3’-F 49% 
5.2 Cl 3’-Cl 62% 
5.3 Cl 3’-Br 51% 
5.4 Cl 3’-I 72% 
5.5 I 3’-Cl 45% 
5.6 I 3’-Br 36% 
 
Scheme 5.1 Synthesis of bis-picolinamide rhodium (III) dichloride complexes 
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5.3 Characterisation of bis-picolinamide Rhodium Dihalide Complexes 
Bis-picolinamide rhodium (III) dihalide complexes 5.1 - 5.6 were obtained with yields 
in a range from 36-72%. These complexes were characterised using IR, NMR, ES-MS, 
elemental analysis and single crystal X-Ray diffraction. Complexes 5.1 - 5.4 were 
soluble in polar solvents, including acetonitrile, methanol, dichloromethane, 
chloroform and acetone, giving orange/yellow solutions, whereas complexes 5.5 and 
5.6 were soluble in more polar solvents such as dimethylformamide, tetrahydrofuran 
and nitromethane to give dark red-brown solutions. The IR spectra for complexes 5.1 - 
5.6 show similar characteristics to their ruthenium analogues, with a shift to lower 
wavelength for both the CO and NH stretches between their respective uncoordinated 
ligands and the complexes. The IR spectrum for ligand 2.7, complex 5.2 and complex 
5.5 are shown in Figure 5.2 to show the comparison. 
 
The structural data of complexes 5.1, 5.3, 5.4 and 5.5 were collected by x-ray 
crystallography and show their structural geometry and the N,N- and N,O- 
coordination modes of the ligands to the rhodium metal. Interestingly, the rhodium 
dichloride complexes have shown a different structural geometry from the one 
reported by Bhattacharya et al of trans-trans-trans geometry. The single crystals of 
complexes 5.1, 5.3 and 5.4, were obtained from vapour diffusion of methanol/pentane 
and exhibit the cis-trans-cis structure, and trans-trans-trans geometry for complex 5.5 
which were recrystallised from a dimethylformamide/ether solvent system, described 
in Section 5.9. 
 
The NMR spectra of the complexes show signals between 6.0 - 10.0 ppm, which are 
thought to be due to the mixture of possible structural isomers, indicated by the two 
doublets at downfield region, between 8.91 - 9.85 ppm, which are assigned for the 
proton adjacent to the N atom of the pyridine ring from each picolinamide ligands (
3
J 
(
1
H-
1
H) ~ 5 Hz).
3, 4
 Upon fractional recrystallisation, these complexes crystallise in 
two or three different forms of shapes and colours, as seen with the ruthenium 
analogues. Complex 5.3 crystallises as red, orange and yellow crystals, and their 
characterisation data are described in Sections 5.5 and 5.6. 
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5.4 IR Data for Ligand 2.7, Complex 5.2 and Complex 5.5 
The IR spectra of ligand 2.7, complexes 5.2 and 5.5 are shown in Figure 5.2. In the 
spectrum of the uncoordinated ligand, a strong CO stretch observed at 1678 cm
-1
, is 
shifted to 1558 cm
-1
 in both complexes 5.2 and 5.5. Broad and weak NH stretches are 
also seen, in the region 3000-3500 cm
-1
, shifted from 3328 cm
-1
 of ligand 2.7 to 3064 
cm
-1
 and 3046 cm
-1 
for complexes 5.2 and 5.5 respectively. This pattern is consistent 
for all of the bis-picolinamide rhodium dichloride complexes reported in this chapter. 
 
  
Ligand 2.7 Complex 5.2 Complex 5.5 
4000 3000 2000 1000 0
Wavenumber cm
-1
1678
1558
3328
3064
1558
3046
 
Figure 5.2 IR spectra of ligand 2.7, complex 5.2 and 5.5 
Ligand 2.7 
Complex 5.2 
Complex 5.5 
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5.5 IR Data of Complex 5.3 
Complex 5.3 crystallised in three different fractions - red needles (complex 5.3a), 
orange blocks (complex 5.3b) and yellow microcrystals (complex 5.3c). The different 
fractions were well-separated and collected for further characterisation. The IR spectra 
of complexes 5.3a, 5.3b and 5.3c are shown in Figure 5.3. The weak NH stretch is 
observed at 3033, 3057 and 3065 cm
-1 
for complexes 5.3a, 5.3b and 5.3c respectively. 
A strong CO stretch splits into two bands, within the 1543 - 1613 cm
-1
 region, which is 
clearly seen for complexes 5.3b and 5.3c. A difference in intensities can be seen 
between the C-Br stretches in the region 744 - 783 cm
-1
. The two medium C-Br 
stretches for complex 5.3a and 5.3b appeared at 744 and 783 cm
-1
, and 775 and 760 
cm
-1 
respectively, whereas, the intensity of C-Br stretch for complex 5.3c showed a 
strong intensity at 779 and 752 cm
-1
. 
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Figure 5.3 IR spectra of complexes 5.3a, 5.3b and 5.3c 
 
Complex 5.3a 
Complex 5.3b 
Complex 5.3c 
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5.6 NMR Data of Complex 5.3 
The 
1
H NMR spectra of complex 5.3a and complex 5.3c are shown in Figure 5.5. The 
1
H NMR spectrum for complex 5.3b showed very weak signals due to an insufficient 
amount obtained, therefore is not included in the figure. One molecule is expected to 
integrate to a total number of 17 protons. The spectra, however, did not show the 
presence of an NH peak and integrated to 16 protons. This was also the case with the 
rhodium complexes developed by Bhattacharya et al. 
1
 The reason for this it is as yet 
uncertain as it is known that the ligands are coordinated in (N,N) and (N,O) mode as 
determined from their crystal structures (shown in Section 5.9). 
 
Both spectra showed similar peaks with strong and weak signals at certain chemical 
shifts. The weak signals are thought to be the presence of a different structural isomer 
as they integrate to a total number of 16 protons. Complex 5.3c showed additional 
weak signals (highlighted), where some peaks can be seen overlapping with each 
other. These additional signals similarly gave a total of 16 protons, suggesting yet 
another isomer is present. The ratio of the possible isomers determined from the 
1
H 
NMR peak integrals is 1:0.2 for complex 5.3a and 1:0.2:0.1 for complex 5.3c. The red 
crystals, complex 5.3a, could be the pure and main structural isomer of complex 5.3, 
but with a minor isomer molecule still present. 
 
Based on the x-ray crystal structure obtained for complex 5.3a (discussed in detailed in 
Section 5.9.2), it is known that this complex has a cis-trans-cis structure. In order to 
assign the NMR spectra, the x-ray structure was used as the general structure for 
complex 5.3 (Figure 5.4). The doublets at 8.91 - 9.85 ppm were assigned based on the 
account of the typical 
3
J coupling ~ 5 Hz, for protons adjacent to the N atom of a 
pyridine ring.
3, 4
 The peaks labelled (*) and (#) are assigned for the two unknown 
structural isomers, where peaks are not overlapping. These assignments are presented 
in Table 5.1 based on the 
1
H-
1
H COSY spectra of complex 5.3c, as shown in Figure 
5.6 and Figure 5.7. 
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e’, g’ 
 
 
Figure 5.4 General structure of complex 5.3a 
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Figure 5.5 
1
H NMR spectra of complexes 5.3a (shown in red), and 5.3c (shown in 
yellow) (d6-acetone, 300.13 MHz, 300 K) 
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Table 5.1 
1
H chemical shift assignments for complex 5.3 
Chemical Shift 
(δ ppm) 1H 
Splitting 
Pattern 
Assignment 
9.85, 9.7, 9.5, 9.46, 9.39, 8.91 d 
a, a
*
, a
’*
, a
#
, 
a’, a’# 
7.95, 7.90 ddd b, b’ 
8.29, 8.29 ,8.39 dtd c, c’, c* 
8.57,  8.14, 8.72 d d, d’, d* 
7.64, 7.01, 7.55 ddd e, e’, e* 
7.34, 6.86, 7.51 t f, f’, f* 
7.45, 7.01 ddd g, g’ 
7.83, 7.18, 7.62 t h, h’, h* 
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Figure 5.6 
1
H-
1
H COSY NMR spectrum of complex 5.3c (d6-acetone, 300.13 MHz, 
300K) 
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Figure 5.7 
1
H-
1
H COSY NMR spectrum of complex 5.3c with higher intensity showing 
the correlation of isomeric compounds (d6-acetone, 300.13 MHz, 300K) 
 
5.7 1H- NMR Variable-Temperature Studies of Complex 5.3 
Previously within the McGowan group, a titanium ethoxide complex was synthesised 
and studied to investigate fluxional processes between several isomers in solution.
5
 A 
similar observation was also noted in the budotitane series of complexes developed by 
Keppler et al.
6
 Figure 5.8 shows the structure of the complex with the three isomers 
identified from the 
1
H NMR spectra taken between 233 K and 333 K. As the 
temperature decreases, the timescale of the exchange process between the isomers also 
decreases that leads to the signal broadening and the appearance of more peaks. These 
signals are identified as the three cis isomers of the complex: cis-cis-cis, cis-trans-cis 
and cis-cis-trans. The two diketonate ligands in the cis-cis-cis isomer gives two signals 
each as they are not in identical environments, whereas the two other cis isomers show 
one signal each for the diketonate ligand and methyl protons.  
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Figure 5.8 The three cis isomers of titanium ethoxide complex observed at 233 K, and 
the variable temperature 
1
H NMR study (CDCl3, 300.13 MHz)
5
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The bis-picolinamide rhodium dichloride complex 5.3 was studied for the possibility 
of fluxional processes between the structural isomers present in the solution. This 
study was carried out over a range of days and at variable temperature. The 
1
H NMR 
spectra of complex 5.3a and 5.3c was taken at Day 1, Day 3 and Day 7 at room 
temperature. The spectra showed similar peak splitting and integration of 16 protons 
for each possible major and minor isomers present. This suggests that the complexes 
do not interchange between the different structural isomers present within the solution 
over time at room temperature. 
 
The 
1
H NMR spectra of complex 5.3 at lowest temperature, 213 K and at the highest 
temperature, 323 K, are as shown in Figure 5.9.  These observations are different as 
previously seen with the budotitane series of complexes, whereby instead of having 
three different isomers with the same ratio at the lowest temperature, complex 5.3 
showed a high ratio for one isomer, which is the cis-trans-cis structure. This is 
determined by the peak integrals that correspond to a total number of 16 protons for 
one complex, not including the NH peak. The presence of signals for isomeric 
compounds at 213 K is seen as very broad and weak signals. 
 
Figure 5.10 shows the temperature-dependant 
1
H NMR spectra of complex 5.3c in 
increasing temperature at every 10 K from 213 K up to 323 K. Broadening of the 
peaks is observed at the lowest temperature, 213 K. In increasing the temperature, 
there is a slight shift for the protons on the pyridine rings, whereby the H(a) and H(a’) 
protons are shifted downfield, and upfield shifts for the H(b), H(b’), H(c), H(c’), H(d) 
and H(d’) protons. All the broad signals at 213 K sharpen as the temperature increases. 
These are particularly seen in the coupling of the pyridine H(b) and H(b’) protons, and 
the phenyl H(e’) – H(h’) protons of the (N,O)-coordinated ligand. The signals become 
separated into doublets and triplets, including the weak signals of the isomeric 
compounds which become more resolved. The broad signals at low temperature are 
due to the molecules stacking together as they interact very close between each other.
7
 
The molecules are separated as the temperature increases, hence the appearance of the 
sharp resolved peaks.  
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When decreasing the temperature from 323 K, the signals show similar patterns as 
increasing the temperature. This indicates that the changes are reversible and that the 
molecules may not change in structure and are stable, even when at room temperature. 
 
amb209temp.INO.323.001.1r.esp
10.0 9.5 9.0 8.5 8.0 7.5 7.0
Chemical Shift (ppm)
0
0.0005
0.0010
0.0015
0.0020
0.0025
0.0030
0.0035
0.0040
0.0045
0.0050
0.0055
N
o
rm
a
li
z
e
d
 I
n
te
n
s
it
y
1.192.410.991.251.011.121.151.061.191.002.140.990.981.00
M12(m)M10(m)M08(m)
M07(m) M09(m)
M05(m)M02(m)
M13(m)M11(m)
M14(m)
M06(m)
M01(m) M03(m)
M04(m)
9
.9
9
.9 9
.4
9
.4 8
.5 8
.5
8
.3
8
.3 8
.3
8
.3
8
.2
8
.1
7
.9 7
.9
7
.9
7
.8
7
.6
7
.6
7
.5 7
.5
7
.4
7
.3
7
.3
7
.2
7
.0 7
.0
6
.9
6
.9
6
.9
 
 
amb209temp.INO.213.001.1r.esp
9.5 9.0 8.5 8.0 7.5 7.0
Chemical Shift (ppm)
0.0005
0.0010
0.0015
0.0020
0.0025
0.0030
0.0035
0.0040
0.0045
0.0050
0.0055
0.0060
N
o
rm
a
li
z
e
d
 I
n
te
n
s
it
y
2.182.331.151.221.191.072.231.032.240.990.991.00
M07(m)M05(m) M10(m)M03(m)
M09(m)
M01(m)
M06(m)
M02(m) M12(m)
M11(m)
M04(m)
9
.8 9
.8
9
.3 9
.3
8
.6 8
.6
8
.4
8
.4
8
.4
8
.4 8
.3
8
.2
8
.2
8
.0 8
.0 7
.8
7
.7 7
.6
7
.5
7
.5
7
.4
7
.4
7
.4
7
.1 7
.1
6
.9 6
.9
 
 
Figure 5.9 
1
H NMR spectra of complex 5.3 at 213 K and 323 K 
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Figure 5.10 Temperature-dependant 
1
H NMR spectra of complex 5.3 (d6-acetone, 300 MHz)
213 K 
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5.8 NMR Data of Complex 5.5 
The 
1
H NMR characterisation of bis-picolinamide rhodium diidodide complex 5.5 has 
showed a different observation as compared to its dichloride analogue. The 
1
H NMR 
spectrum and a general structure of complex 5.5 with the assigned protons are as 
shown in Figure 5.11. The signals integrate to a total number of 16 protons, and there 
is no presence of minor isomers seen, indicating that the complex only has one 
structural isomer present. This observation agrees well with the ruthenium diiodide 
analogue, whereby the complex has a stable trans-trans-trans structure both in solid 
state and in solution (Section 4.7). The proton adjacent to the N atom of the pyridine 
ring from each picolinamide ligands appear as two doublets at 8.45 and 9.62 ppm (
3
J 
(
1
H-
1
H) ~ 5 Hz). 
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Figure 5.11 
1
H NMR spectrum of complex 5.5 (d4-MeOD, 500 MHz)
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5.9 X-ray Crystallography Data for bis-Picolinamide Rhodium (III) 
Dihalide Complexes 
Single crystals of complexes 5.1, 5.3 and 5.4 suitable for X-ray crystallography were 
obtained by vapour diffusion of pentane into a solution of the complex in methanol, 
while complex 5.5 which was crystallised by vapour diffusion of ether into a solution 
of dimethylformamide. The bis-picolinamide rhodium dihalide complexes have a 
distorted octahedral centre, with bond angles in the range 88.9°-97.1° between the 
ligands that are cis to each other, and bond angles of 171.5°-173.3° between the trans 
ligands about the rhodium metal centre. 
 
Due to the rigidity of the picolinamide ligands, the bond angles between the two N atoms 
of the (N,N)-coordinate ligand, and the N and O atom of the (N,O)-coordinated ligand, are 
found to be less than 90°. The angle between the two cis chlorine atoms around the 
rhodium centre is between 90.9° - 93.0°, and between the two trans iodine atoms for 
complex 5.5 is 177.35(5)°. The (N,N)-coordinated picolinamide ligands adopt non-planar 
configurations, with the torsion angle between the picolinamide rings ranging from 83.4 to 
111.7°. The (N,O)-coordinated ligands functionalised with a 3’-F and 3’-Br substituents on 
the phenyl ring for the cis complexes adopt an almost planar configurations with torsion 
angle of 171.6° and 177° respectively. The torsion angle for the 3’-I functionalised (N,O)-
picolinamide ligand is 94.9°. This less planar configuration may be due to the extra steric 
bulk of the iodine atom pointing away from the chloride ligands. 
 
The Rh-Cl bond distances for all the bis-picolinamide rhodium dichloride complexes 
are similar, where one of the Rh-Cl bonds is longer than the other, with an average 
bond distance of 2.31 Å for Rh-Cl(1) and 2.36 Å for Rh-Cl(2). The Rh-I bond 
distances for complex 5.5 are longer than its dichloride analogue with an average bond 
distance of 2.66 Å for Rh-I(1) and Rh-I(2). The average bond lengths of Rh(1)-N(1), 
Rh(1)-N(2), Rh(1)-N(3) and Rh(1)-O(2) for all complexes are 2.01 Å, 2.02 Å, 2.04 Å 
and 2.07 Å respectively, which are found to be quite normal.
8
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5.9.1 X-ray Crystal Structure of Complex 5.1 
Complex 5.1 crystallised as orange blocks and yellow microcrystals, which were 
obtained by vapour diffusion of pentane into a methanolic solution of the complex. 
Only the orange blocks of complex 5.1 were found to be suitable for structure 
determination by X-ray crystallography. The complex crystallised in an orthorhombic 
cell and structural solution was performed in the space group P212121. The asymmetric 
unit contains one molecule of the complex and one molecule of methanol. The 
molecular structure of complex 5.1 is shown in Figure 5.12 with a cis-trans-cis 
arrangement, and selected bond lengths and angles are given in Table 5.2. 
 
 
Figure 5.12 Molecular structure of complex 5.1. Displacement ellipsoids are at the 
50% probability level. Hydrogen atoms are omitted for clarity. 
 
Table 5.2 Selected bond lengths and angles for complex 5.1 with s.u.s shown in 
parenthesis 
Bond length (Å) Bond angle (°) 
Rh(1)-Cl(1) 2.3166(15) Cl(1) - Rh(1) - Cl(2) 92.34(5) 
Rh(1)-Cl(2) 2.3569(13) N(1) - Rh(1) - O(2) 93.29(16) 
Rh(1)-N(1) 2.018(4) N(2) - Rh(1) - O(2) 88.92(17) 
Rh(1)-N(2) 2.023(4) N(2) - Rh(1) - N(3) 94.17(19) 
Rh(1)-N(3) 2.030(5) N(1) - Rh(1) - N(3) 171.51(19) 
Rh(1)-O(2) 2.043(4)   
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Complex 5.1 is arranged in a herringbone motif along the a-axis, and in alternate 
layers along the b-axis, as shown in Figure 5.13. Two complex molecules are held 
together by a methanol molecule via hydrogen bond interactions between one of the 
chloride ligands (bond distance O(3)-Cl(1) 3.1877 Å) and the hydrogen on the pyridyl 
ring of the (N,O)-coordinated picolinamide ligand (bond distance C(14)-O(3) 3.470(8) 
Å) (Figure 5.14a). The other interactions are between an amide group of one molecule 
with a carbonyl group of another molecule (bond distance (N(4)-O(1) of 2.794(6) Å), 
and between a fluorine substituent on the phenyl ring with a hydrogen on the pyridyl 
ring (bond distance C(15)-F(1) of 3.221(8) Å). Intramolecular interactions can also be 
seen within a complex molecule, one with the chloride ligand (bond distance C(1)-
Cl(2) of 3.348(6) Å), and the other interaction is within the (N,O)-coordinated ligand 
(C(20)-O(2) of 2.811(7) Å) (Figure 5.14b). 
 
 
(a) (b) 
Figure 5.13 Packing diagrams of complex 5.1 viewed along the (a) a-axis and (b) b-
axis. Hydrogen atoms are omitted for clarity. 
 
 
(a) (b) 
Figure 5.14 (a) Intermolecular and (b) intramolecular hydrogen bond interactions of 
complex 5.1. Hydrogen atoms are omitted for clarity. 
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5.9.2 X-ray Crystal Structure of Complex 5.3 
Complex 5.3 crystallised as red plates, orange blocks and yellow microcrystals, 
however only the red plates were found suitable for x-ray crystallography. These 
crystals were obtained by vapour diffusion of pentane into a methanolic solution of the 
complex. Red plates of complex 5.3 crystallised in a monoclinic cell and structural 
solution was performed in the space group Cc. The asymmetric unit contains one 
complex molecule. The molecular structure is shown in Figure 5.15 with the structural 
arrangement of cis-trans-cis and selected bond lengths and angles are given in Table 
5.3. 
 
 
Figure 5.15 Molecular structure of complex 5.3. Displacement ellipsoids are at the 
50% probability level. Hydrogen atoms are omitted for clarity. 
 
Table 5.3 Selected bond lengths and angles for complex 5.3 with s.u.s shown in 
parenthesis 
Bond length (Å) Bond angle (°) 
Rh(1)-Cl(1) 2.3130(15) Cl(1) - Rh(1) - Cl(2) 92.92(6) 
Rh(1)-Cl(2) 2.3643(14) N(1) - Rh(1) - O(2) 92.92(18) 
Rh(1)-N(1) 2.027(5) N(2) - Rh(1) - O(2) 91.04(19) 
Rh(1)-N(2) 2.018(5) N(2) - Rh(1) - N(3) 97.1(2) 
Rh(1)-N(3) 2.020(5) N(1) - Rh(1) - N(3) 172.4(2) 
Rh(1)-O(2) 2.044(4)   
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Complex 5.3 packed in a zig-zag pattern along the a-axis, and alternate layers along 
the c-axis, as shown in Figure 5.16. The molecules are held together by several 
interactions of intermolecular hydrogen bonding, which are between the amide group 
of a complex molecule with the carbonyl group of the second complex molecule (bond 
distance (N(4)-O(1) of 2.680(6) Å), and between the oxygen atom of the second 
complex molecule with the bromine substituent of the third complex molecule (bond 
distance O(2)-Br(1) of 3.228 Å). 
 
 
 
(a) (b) 
 
Figure 5.16 Packing diagrams of complex 5.3 viewed along the (a) a-axis and (b) c-
axis, showing intermolecular hydrogen bond interactions between the complex 
molecules. Hydrogen atoms are omitted for clarity. 
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5.9.3 X-ray Crystal Structure for Complex 5.4 
Red plates of complex 5.4 suitable for X-ray crystallography were obtained by vapour 
diffusion of pentane into a methanolic solution of the complex. Complex 5.4 
crystallised in an orthorhombic cell and structural solution was performed in the space 
group P21/c. The asymmetric unit contains one molecule of the complex and two 
molecules of methanol solvent. The molecular structure is shown in Figure 5.17 with 
the arrangement of cis-trans-cis and selected bond lengths and angles are given in 
Table 5.4. 
 
 
Figure 5.17 Molecular structure of complex 5.4. Displacement ellipsoids are at the 
50% probability level. Hydrogen atoms are omitted for clarity. 
 
Table 5.4 Selected bond lengths and angles for complex 5.4 with s.u.s shown in 
parenthesis 
Bond length (Å) Bond angle (°) 
Rh(1)-Cl(1) 2.3134(13) Cl(1) - Rh(1) - Cl(2) 90.86(5) 
Rh(1)-Cl(2) 2.3558(14) N(1) - Rh(1) - O(2) 93.76(15) 
Rh(1)-N(1) 2.030(4) N(2) - Rh(1) - O(2) 88.77(16) 
Rh(1)-N(2) 2.018(4) N(2) - Rh(1) - N(3) 96.21(17) 
Rh(1)-N(3) 2.031(4) N(1) - Rh(1) - N(3) 173.27(17) 
Rh(1)-O(2) 2.050(3)   
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Complex 5.4 packed in a horizontal linear distribution along the b-axis, as shown in 
Figure 5.18. Figure 5.19a shows the intermolecular hydrogen bonding between the 
hydrogen on the pyridyl ring of the (N,N)-coordinated picolinamide ligand of one 
complex molecule and the oxygen atom of the (N,O)-coordinated picolinamide ligand 
of another complex molecule (bond distance of C(3)-O(2) of 3.419(7) Å). Another 
interaction involves the hydrogen bonding of two complexes with a methanol 
molecule, between a chloride ligand of one complex molecule (bond distance C(13)-
Cl(1) of 3.336(5) Å) and a carbonyl group of another complex molecule (bond 
distance of O(3)-O(1) of 2.804(7) Å) (Figure 5.19b). 
 
Figure 5.18 Packing diagram viewed along the b-axis of complex 5.4. Hydrogen 
atoms are omitted for clarity.  
 
Figure 5.19 Intermolecular hydrogen bond interactions of (a) carbonyl group, and (b) 
chloride ligand with a methanol molecule
(a) 
(b) 
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5.9.4 X-ray Crystal Structure for Complex 5.5 
Complex 5.5 crystallised as red plates suitable for X-ray crystallography, which were 
obtained by vapour diffusion of diethyl ether into a dimethylformamide solution of the 
complex. The complex crystallised in a monoclinic cell and structural solution was 
performed in the space group Cc. The asymmetric unit contains one complex molecule 
and one dimethylformamide molecule. The molecular structure is shown in Figure 
5.20 with a trans-trans-trans structural geometry and selected bond lengths and angles 
are given in Table 5.5. 
 
  
  
Figure 5.20 Molecular structure of complex 5.5. Displacement ellipsoids are at the 
50% probability level. Hydrogen atoms are omitted for clarity. 
 
Table 5.5 Selected bond lengths and angles for complex 5.5 with s.u.s shown in 
parenthesis 
Bond length (Å) Bond angle (°) 
Rh(1)-I(1) 2.6620(13) I(1) - Rh(1) - I(2) 177.35(5) 
Rh(1)-I(2) 2.6640(13) N(1) - Rh(1) - O(2) 95.0(4) 
Rh(1)-N(1) 2.010(10) N(2) - Rh(1) - O(2) 175.2(4) 
Rh(1)-N(2) 2.015(10) N(2) - Rh(1) - N(3) 106.7(4) 
Rh(1)-N(3) 2.035(11) N(1) - Rh(1) - N(3) 172.8(5) 
Rh(1)-O(2) 2.067(8)   
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Complex 5.5 packed in herringbone motif along the a-axis, and in diagonal linear 
arrangement along the b-axis, as shown in Figure 5.21. The molecules are held 
together by several interactions of intermolecular hydrogen bonding with the DMF 
molecule. Figure 5.22 shows the intermolecular interactions of three complex 
molecules with one DMF molecule. The interactions involve the NH moiety of the 
first complex molecule with the oxygen atom of the DMF molecule (bond distance 
N(4)-O(3) of 2.756(15) Å), a chlorine substituent on the (N,O)-coordinated ligand of 
the second complex molecule with the DMF molecule (bond distance Cl(2)-C(25) of 
3.348(6) Å), and the CO moiety of the third complex molecule with the methyl group 
of the DMF molecule (bond distance C(26A)-O(1) of 3.175(18) Å). Intramolecular 
interactions can also be seen within the molecule, which are between the oxygen atom 
of the (N,O)-coordinated ligand with the phenyl ring of the same ligand (bond distance 
C(20-O(2) of 2.751(17) Å), and pyridyl ring of the (N,N)-coordinated ligand (bond 
distance C(1)-O(2) of 3.146(7) Å). 
  
(a) (b) 
Figure 5.21 Packing diagram viewed along the (a) a-axis (b) b-axis of complex 5.5. 
Hydrogen atoms are omitted for clarity. 
 
 
(a) (b) 
Figure 5.22 (a) Intermolecular and (b) intramolecular hydrogen bond interactions of 
complex 5.5. Hydrogen atoms are omitted for clarity.
Synthesis of Rhodium Dihalide Complexes                                                      Chapter 5 
117 
5.10 PXRD Powder Diffraction Studies  
The powder diffraction (PXRD) pattern of complex 5.3 was recorded to compare 
between the bulk powder sample of the complex with its single crystal structure in 
order to determine the purity of its structural geometry in the bulk sample. The 
diffractogram simulated from a single cis crystal structure of complex 5.3 is compared 
with the diffractogram recorded from its powder sample, as shown in Figure 5.23. 
 
The PXRD patterns show some similarities on the peaks between their diffractograms, 
with few additional peaks observed as well. There may be a possibility that most of the 
complex molecules from the bulk powder sample matches with the cis-trans-cis crystal 
data, and that the additional peaks are the presence of different isomeric compounds as 
seen from the NMR spectra. There are also peaks from the simulated diffractogram, 
which did not appear in the experimental powder data. However, the data collected are 
insufficient to conclude these observations, and an attempt to repeat the crystallisation 
of the complex would be useful. This is to obtain crystals suitable for x-ray 
crystallography that may have different unit cell and hence, a different structural 
geometry to the cis-trans-cis crystal structure, for comparison of their diffractograms. 
 
 
Figure 5.23 PXRD data of complex 5.3 showing the simulated and experimental 
diffractograms  
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Powder diffraction (PXRD) pattern for bis-picolinamide rhodium diiodide complex 5.5 
was also recorded to determine the stability of its structural geometry in the bulk 
powder sample. The ruthenium diiodide analogues described in Chapter 4 have 
showed the unit cell data matches very well between the single crystal structure of the 
complex and from the data analysis of the powder sample. This indicates that the 
ruthenium diiodide complex has a stable structural geometry in the bulk powder 
sample. The diffractogram simulated from a single trans crystal structure of complex 
5.5 is compared with the powder diffractogram recorded at scan rate of 30secs/scan, as 
shown in Figure 5.24. 
 
The PXRD patterns have showed similarities on the peaks between their 
diffractograms. One aspect that may need to be considered is that the diffractogram 
was collected from a dry powder sample, whereas the crystal structure has a solvent 
molecule present within its crystal structure. Although, the attempt to record the 
diffractogram of the “wet” powder sample, containing the DMF molecule, did not 
show a clear pattern. However, apart from this, both diffractograms have showed 
similar pattern and may contain a stable structural geometry as observed with the 
ruthenium diiodide analogues. 
 
 
Figure 5.24 PXRD data of complex 5.5 showing the simulated and experimental 
diffractograms recorded at scan rate 30 secs/scan 
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CHAPTER 6 
 
Cytotoxicity studies of Bis-functionalised Ruthenium 
Dihalide Complexes 
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6 Cytotoxicity Studies 
 
6.1 Introduction 
The first stage of the preclinical phase for anti-cancer drug discovery and development 
is in vitro cytotoxicity screening.
1
 These assays are widely used to measure the 
effectiveness of drugs towards a variety of human cancer cell lines and to identify 
potential drugs for further analysis. Drug candidates can be classified as inactive, 
moderately active or highly active based on their IC50 values. IC50 is defined as the 
concentration of the drug that is required to inhibit 50% of cell proliferation. The 
screening for cytotoxicity of anti-cancer drugs can be monitored using the SRB
2
 or 
MTT
3
 assays. This chapter discusses these two different types of assays carried out in 
a 96-well plate setup, and the potency of ruthenium dihalide complexes under both 
normoxia and hypoxia conditions. Unfortunately, the rhodium dihalide complexes 
described in Chapter 5 were not evaluated for cytotoxicity. This is due to the limited 
access of the cell culture lab which was performed with the collaborators at the 
Institute of Cancer Therapeutics, Bradford. Therefore, cytotoxicity studies on bis-
picolinamide rhodium dihalide complexes will be added to the future work for studies 
as comparison with its ruthenium analogue. 
 
6.2 SRB Assay 
The sulforhodamine B (SRB) assay is a colorimetric assay that was first developed by 
Skehan et al. in 1990.
2
 This assay uses a bright pink anionic aminoxanthene dye 
containing two sulfonic acid groups that are able to bind electrostatically to basic 
protein components under mildly acidic conditions, and stain the cell cultures that are 
fixed by trichloroacetic acid (TCA). Figure 6.1 shows the structure of SRB dye that is 
used in this assay. The dye can be extracted from the stained cells and dissolved by a 
weak base solution for optical density measurements. 
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Figure 6.1 Structure of Sulforhodamine B (SRB) dye 
 
6.3 MTT Assay 
The MTT assay is a colorimetric assay used to measure cytotoxicity, cell proliferation 
and cell viability. This assay was first described by Mosmann
3
 in 1983 and further 
optimised by Niks
4
 and Sylvester.
5
 It detects living cell cultures that generate signals 
in order to metabolically reduce the yellow water soluble salt, 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazoliumbromide (MTT) to dark blue or purple formazan crystals 
which are insoluble in water, as shown in Figure 6.2.  
 
               Yellow MTT salt Dark blue/Purple Formazan 
Figure 6.2 The reduction of yellow MTT salt to dark blue or purple formazan crystals 
 
The reduction occurs outside the mitochondrial inner membrane via the NADP and 
NADPH-dependant mechanisms involving mitochondrial dehydrogenase enzymes that 
are metabolically active in living cells.
6
 The dark blue or purple formazan crystals 
formed are solubilised and the colour produced can be read using a multiwell scanning 
spectrophotometer (ELISA reader). The amount of formazan formed is directly 
proportional to the number of living cells present during the MTT exposure. This assay 
is also applicable in detecting the number of cells that are not dividing but are still 
metabolically active. Therefore, besides measuring cytotoxicity, this method can also 
be used to differentiate between the measurement of cell proliferation and activation.
7
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6.4 Cytotoxicity of Bis-Picolinamide Ruthenium Dihalide Complexes 
A series of bis-picolinamide ruthenium dihalide complexes described in Chapters 3 
and 4, with the general structure shown in Figure 6.3 were tested against A2780 
human ovarian adenocarcinoma, A2780cis human ovarian cisplatin-resistant 
adenocarcinoma and HT-29 human colon adenocarcinoma. 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 A general structure for complexes 3.1 - 3.15 and 4.1 - 4.15 
 
The 5-day cytotoxicity studies follow the general procedure performed at the Institute 
of Cancer Therapeutics, Bradford. The drugs were incubated for five days in the cell 
suspension, diluted with RPMI-1640 complete media. The drugs were first dissolved 
in DMSO at a concentration of 25 mM, and diluted further in the cell medium to 250 
µM, which was found to be the approximate maximum concentration to obtain ten 
different concentrations, down to a minimum concentration of 0.49 µM. After five 
Complex 
(X = Cl) 
Complex 
(X = I) 
R substituents 
3.1 4.1 H 
3.2 4.2 2’-F 
3.3 4.3 4’-F 
3.4 4.4 2’,4’-F 
3.5 4.5 2’,5’-F 
3.6 4.6 2’-Cl 
3.7 4.7 3’-Cl 
3.8 4.8 4’-Cl 
3.9 4.9 2’,4’-Cl 
3.10 4.10 2’,5’-Cl 
3.11 4.11 2’-Br 
3.12 4.12 3’-Br 
3.13 4.13 4’-Br 
3.14 4.14 2’,4’-Br 
3.15 4.15 2’,5’-Br 
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days of incubation, the cells were exposed to yellow MTT solution and incubated at 
37°C for four hours. The results to determine the cytotoxicity of the drugs were taken 
as IC50 values based on three independent experiments. The standard deviation is taken 
to be valid with a value of within 10%. If the value exceeded the limit of the standard 
deviation, the experiment was repeated again. The log of concentration is plotted 
against the percentage of cell survival, to obtain the drug concentration that gives 50% 
cell survival (IC50). 
 
The graph plotted is as shown in Figure 6.4, which show plots of one of the three 
independent experiments for an active (complex 3.12), moderately active (complex 
3.2) and less active (complex 3.9) anti-cancer drug against A2870 ovarian cancer cell 
line. The IC50 values for complexes 3.1 - 3.15 and 4.1 - 4.15, along with cisplatin as a 
comparison, tested for cytotoxicity against A2780, A2780cis and HT-29 cancer cell 
lines are as shown in Table 6.1. 
 
 
 
Figure 6.4 Plot of percentage cell survival against drug concentration (in logarithmic 
scale) for complexes 3.2, 3.9 and 3.12 against A2780 ovarian cancer cell line after five 
days incubation 
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Table 6.1 The IC50 values (µM) for ruthenium dihalide complexes 3.1 - 3.15, 4.1 - 4.15 
and cisplatin, against A2780, A2780cis and HT-29. Results are expressed as the mean 
IC50 ± S.D for three independent experiments. 
 
R 
Complex A2780 A2780cis HT-29 
X = Cl X = I X = Cl X = I X = Cl X = I X = Cl X = I 
H 3.1 4.1 24 ± 2 5.4 ± 0.5 47 ± 3 5.3 ± 0.2 23 ± 1 5.5 ± 0.4 
2’-F 3.2 4.2 13 ± 1 13 ± 1 21 ± 2 31 ± 2 6.2 ± 0.4 13 ± 1 
4’-F 3.3 4.3 6.9 ± 0.8 3.4 ± 0.1 35 ± 3 12 ± 1 17 ± 1 8.4 ± 0.3 
2’,4’-F 3.4 4.4 22 ± 1 14 ± 1 25 ± 1 13 ± 1 7.3 ± 0.4 8.5 ± 0.7 
2’,5’-F 3.5 4.5 45 ± 2 16 ± 1 93 ± 2 15 ± 1 20 ± 1 14 ± 2 
2’-Cl 3.6 4.6 21 ± 1 7.2 ± 0.1 33 ± 1 22 ± 2 11 ± 1 10 ± 1 
3’-Cl 3.7 4.7 3.6 ± 0.2 2.8 ± 0.3 6.7 ± 0.1 3.2 ± 0.1 3.0 ± 0.1 2.3 ± 0.1 
4’-Cl 3.8 4.8 9.2 ± 0.4 2.5 ± 0.2 4.4 ± 0.4 2.4 ± 0.2 2.8 ± 0.3 0.9 ± 0.1 
2’,4’-Cl 3.9 4.9 41 ± 1 6.6 ± 0.6 55 ± 2 4.3 ± 0.3 9.7 ± 0.3 3.4 ± 0.3 
2’,5’-Cl 3.10 4.10 31 ± 1 10 ± 1 24 ± 2 12 ± 1 11 ± 1 6.5 ± 0.3 
2’-Br 3.11 4.11 18 ± 2 11 ± 1 37 ± 1 40 ± 2 8.3 ± 0.3 24 ± 2 
3’-Br 3.12 4.12 3.3 ± 0.2 2.0 ± 0.2 6.0 ± 0.4 3.3 ± 0.1 3.3 ± 0.2 1.5 ± 0.1 
4’-Br 3.13 4.13 7.5 ± 0.3 2.3 ± 0.2 12 ± 1 2.9 ± 0.2 6.8 ± 0.3 0.8 ± 0.1 
2’,4’-Br 3.14 4.14 18 ± 1 6.7 ± 0.3 26 ± 1 6.6 ± 0.3 7.7 ± 0.3 4.3 ± 0.2 
2’,5’-Br 3.15 4.15 20 ± 2 11 ± 1 22 ± 2 7.6 ± 0.3 10 ± 1 4.9 ± 0.4 
Cisplatin 1.4 ± 0.3 11 ± 1 2.8 ± 0.3 
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6.4.1 Cytotoxicity of bis-picolinamide ruthenium dichloride complexes 
 
Figure 6.5 A summary of IC50 values (inverse log) for functionalised bis-picolinamide 
ruthenium dichloride complexes 3.1 - 3.15 
 
Bis-picolinamide ruthenium dichloride complexes vary in their cytotoxic acitivities 
when halide substituents are incorporated at different positions on the phenyl ring of 
the picolinamide ligands in the ruthenium complex. A chart of IC50 values (inverse 
log) for bis-picolinamide ruthenium dichloride complexes 3.1 - 3.15 is shown in 
Figure 6.5. Complex 3.1 with an unsubstituted picolinamide ligand has an IC50 value 
of 24 µM, found to be moderately active towards A2780 ovarian cancer cell line. 
When halide substituents are added to the phenyl ring of the picolinamide ligands, 
their potency increases especially when the substituents are on the meta or para 
position. This is shown by complexes 3.3, 3.7, 3.8, 3.12 and 3.13 having IC50 values of 
less than 10 µM, which is considered to be highly active as a drug (p < 0.01 relative to 
complex 3.1).
 
The most potent complex in the A2780 cell line is complex 3.12 having 
3’-bromo substituent with an IC50 value of 3.3 µM that is half as potent as cisplatin 
with IC50 value of 1.4 µM (p < 0.01), and complex 3.5 having 2’,5’ difluoro 
substituent is the least potent complex with an IC50 value of 45 µM (p < 0.01 between 
complex 3.12 and 3.5). 
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In the A2780cis cell line, a similar trend of potency as in the A2780 cell line is 
observed for complexes 3.1 - 3.15. An exception of the trend is for complexes with 
fluoride substituents, where the ortho-fluoro (complex 3.2) is more potent than the 
para-fluoro (complex 3.3) with IC50 values of 21 and 35 µM respectively (p < 0.01). 
Complexes 3.7 and 3.12 with IC50 values of 6.7 µM and 6.0 µM respectively, are two 
times more potent than cisplatin, with an IC50 value of 11 µM (p < 0.01 relative to 
cisplatin). The cytotoxic activity of complex 3.8 is increased by 2-fold, with an IC50 
value of 9.2 µM in A2780 to 4.4 µM in A2780cis (p < 0.01), which is three times more 
potent than cisplatin and the most potent complex in A2780cis cell line. These 
complexes have shown that they may be able to overcome the mechanism that has 
become resistant towards cisplatin in the ovarian cancer cells. 
 
Complexes 3.1 - 3.15 are found to be selective towards different cancer cells as their 
anti-cancer activity is seen to differ when comparing their IC50 values between A2780 
and HT-29 cell line. Most of the complexes are more potent in the HT-29 cell line 
apart from complex 3.1 which performs similar cytotoxic activity towards both cell 
lines, and complex 3.3 that has higher anti-cancer activity towards A2780 cells. The 
highest relative increase in IC50 value can be seen from complex 3.9 that has higher 
potency of up to 4 times from 41 to 9.7 µM in A2780 and HT-29 cell line respectively 
(p < 0.01). Also following the trend as observed in A2780 cell line, complex 3.1 with 
unfunctionalised picolinamide ligands has an IC50 value of 23 µM, and is the least 
potent complex in HT-29 cell line.  Their anti-cancer activity is seen to increase when 
there is an addition of a halide substituent, especially on the meta or para position. 
Complex 3.8 is the most potent having a para-chloro substituent with an IC50 value of 
2.8 µM that is similar to the IC50 value obtained for cisplatin.  
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6.4.2 Cytotoxicity of bis-picolinamide ruthenium diiodide complexes 
 
 
Figure 6.6 A summary of IC50 values (inverse log) for functionalised bis-picolinamide 
ruthenium diiodide complexes 4.1 - 4.15 
 
The IC50 values (inverse log) for bis-picolinamide ruthenium diiodide complexes 4.1 - 
4.15, along with cisplatin against A2780, A2780cis and HT-29 cancer cell lines are 
shown in Figure 6.6. Interestingly, complex 4.1 which contains the unsubstituted 
picolinamide ligands is found to be potent in all the three different cancer cell lines. 
IC50 values of complex 4.1 are 5.4 µM, 5.3 µM and 5.5 µM in A2780, A2780cis and 
HT-29 cancer cell line respectively. The addition of a halide substituent specifically on 
the meta or para position contributes to a higher increase in the anti-cancer activity of 
the complexes, with their IC50 values within the range of 0.8 - 3 µM against all the 
three different cancer cell lines (p < 0.01, for all respective complexes relative to 
complex 4.1). 
 
In the A2780 ovarian cancer cell line, most of the bis-picolinamide ruthenium diiodide 
complexes are found to be active with IC50 values of less than 10 µM. Complexes 4.3, 
4.7, 4.8, 4.12 and 4.13 are highly active having similar IC50 values of 2-3 µM which 
are comparable to cisplatin (IC50 = 1.4 µM), also suggesting that the different halide 
substituents on the phenyl ring of the picolinamide ligands do not affect the anti-cancer 
activity of the whole complex providing that the halide substituents are on the meta or 
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para position. Nevertheless, the addition of ortho halide substituents are also found to 
be active as anti-cancer complexes, as shown by complexes 4.6, 4.9 and 4.14 with IC50 
values of 7.2 µM, 6.6 µM and 6.7 µM respectively. 
 
Investigating the cytotoxicity of complexes 4.1 - 4.15 against A2780cis gave a better 
insight of their potential as anti-cancer agents towards ovarian cancer cells. Most of 
the complexes are found to be more potent than cisplatin (IC50 = 11 µM) in the 
A2780cis cancer cell line. As mentioned previously, complex 4.1 that has the 
unsubstituted picolinamide ligands, is found to be active in all the three different 
cancer cell lines that includes the A2780cis cell line. It has an IC50 value of 5.3 µM 
being significantly more active than cisplatin (p < 0.01). Complexes that consist of 
chloride and bromide substituents on the phenyl ring of the ligands, with an exception 
of those on ortho position, have IC50 values which are comparable to cisplatin ranging 
from 2.4 to 7.6 µM (p < 0.01). It is also fascinating to see that complexes 4.1, 4.7, 4.8, 
4.12, 4.13 and 4.14 maintained their cytotoxic activity between the A2780 and 
A2780cis cell lines with IC50 values that are comparable to cisplatin. Furthermore, 
complexes 4.9 and 4.15 showed a higher potency when in the A2780cis cell line which 
is an excellent contrast to cisplatin. 
 
Most of the bis-picolinamide ruthenium diiodide complexes 4.1 - 4.15 are seen to be 
highly potent in the HT-29 colon cancer cell line. The different halide substituents do 
not seem to affect the anti-cancer activity of the complexes except for complexes 4.5, 
4.10 and 4.15 having 2’,5’ dihalide substituents, have shown an increase in activity 
with the halide substituents in the order of F < Cl < Br. Complexes 4.2, 4.5, 4.6 and 
4.11 which have ortho halide substituents, in common, on their phenyl rings, are the 
only complexes that have shown to be moderately potent. Whereas, all of the other 
complexes have shown to have IC50 values of less than 10 µM. Complexes 4.7 and 4.9, 
both functionalised by chloride substituents, are as active as cisplatin (IC50 = 2.8 µM) 
in the HT-29 cell line, with the IC50 value of 2.3 and 3.4 µM respectively. Complex 
4.12 is almost twice more active than cisplatin with IC50 value of 1.5 µM (p < 0.01). 
The two most outstanding complexes in the HT-29 cancer cell line are found to be 
more active than cisplatin with up to 3-fold difference. These are complexes 4.8 and 
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4.13 having IC50 value of 0.86 µM and 0.84 µM respectively with both having a halide 
substituent on the para position of their phenyl rings (p < 0.01, for both complex 4.8 
and 4.13 relative to cisplatin). 
 
6.4.3 Cytotoxicity of bis-picolinamide ruthenium dichloride VS diidodide 
complexes 
 
As mentioned previously in Chapter 4, several initial studies have showed platinum 
complexes with cis geometry have higher cytotoxicity in vitro and in vivo when 
compared to complexes having trans geometry.
8, 9
 However, in recent studies, most 
trans-platinum complexes have been shown to be more active than their cis analogues 
when the ammine ligand is replaced with a more bulky ligand.
10, 11
 Sadler et al. has 
reported their studies on [Ru(p-cym)(ImpyNMe2)X]PF6  complexes with contrasting 
activities when changing their X ligands from chloride to iodide, with the latter being 
more cytotoxic.
12, 13
 These results have accumulated in breaking the initial rules of 
structural-activity relationship as anti-cancer drugs. Figure 6.7 - 6.9 shows the 
comparison of IC50 values (inverse log) between bis-picolinamide ruthenium 
dichloride and diiodide complexes against A2780, A2780cis and HT-29 cancer cell 
line respectively. This is to investigate the differences of their cytotoxicity when 
changing the ancillary halide ligand between chloride and iodide, especially with the 
ruthenium dichloride complexes consisting of a mixture of structural isomers and 
ruthenium diiodide complexes having a stable trans geometry, as described in Chapter 
3 and 4. 
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Figure 6.7 The comparison of IC50 values (inverse log) between bis-picolinamide 
ruthenium dichloride and diiodide complexes against A2780 ovarian cancer cell line 
 
 
 
 
Figure 6.8 The comparison of IC50 values (inverse log) between bis-picolinamide 
ruthenium dichloride and diiodide complexes against A2780cis ovarian cisplatin-
resistant cancer cell line 
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Figure 6.9 The comparison of IC50 values (inverse log) between bis-picolinamide 
ruthenium dichloride and diiodide complexes against HT-29 colon cancer cell line 
 
The highest relative increase of cytotoxicity up to 6-fold and 13-fold, is seen when the 
ancillary chloride ligand of complex 3.9 is changed to iodide, complex 4.9, with IC50 
value from 41 and 55 µM to 6.6 and 4.3 µM in the A2780 and A2780cis cell line 
respectively (p < 0.01). In the HT-29 cell line, complex 3.13 with dichloride ligands 
gave the highest increase in cytotoxicity of up to 8-fold when changing the halide 
ligands to iodide, complex 4.13, with IC50 value of 6.8 to 0.84 µM (p < 0.01). These 
dramatic cytotoxicity changes have clearly shown that the halide ligands bonded to 
ruthenium metal centre play a crucial role in their anti-cancer activity. 
 
Surprisingly, complex 3.2 and 4.2 having an ortho-fluoro substituent on the phenyl 
ring of the picolinamide ligands, and complex 3.11 and 4.11 functionalised with an 
ortho-bromo substituent, have shown different structural-activity relationship from the 
rest of the bis-picolinamide ruthenium dihalide complexes. Their anti-cancer activity 
either changes insignificantly or substantially decreases on switching the halide 
ligands from chloride to iodide. This is especially true between ruthenium dichloride 
complex 3.2 and ruthenium diiodide complex 4.2 that have shown a consistent 
cytotoxic activity with IC50 value of 13 µM in the A2780 cell line, and a decrease in 
cytotoxicity by 3-fold in the HT-29 cell line of IC50 value 8.3 to 24 µM. 
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Both ruthenium dichloride and diiodide complexes are the most active in the HT-29 
cell line. Interestingly, complex 3.8 which is the most potent among the dichloride 
analogue in the HT-29 cell line, having a para-chloro substituent on the functionalised 
picolinamide ligands, has increased its potency by 3-fold when substituted to diiodide 
ligands, complex 4.8, and is also the most potent among the diiodide analogue in the 
HT-29 cell line, with IC50 values of 2.8 and 0.86 µM respectively. This may suggest 
that both the leaving halide ligands and para-chloro substituent contribute together 
towards the anti-cancer activity of the whole complex, and mechanistic studies such as 
hydrolysis, hydrophobicity, cell uptake, cell fractionation, DNA binding studies, of 
both complexes may lead to a better understanding of their mechanism of action. 
 
With a few exceptions of the ruthenium dihalide complexes, those with diiodide 
ligands have shown, in general, a remarkably higher potency compared to the 
ruthenium dichloride complexes in all the three different cancer cell lines. Table 6.2 
summarises the important ruthenium anti-cancer agents previously reported in the 
literature. KP1019 and KP1339 are the promising candidates which are currently in 
Phase II clinical trials, and have moderate cytotoxicity in vitro of IC50 values 36.6 and 
34.7 µM against colon cancer cells respectively. Reedijk et al. synthesised α-
Ru(Azpy)Cl2 which has a cis-trans-cis geometry, with an IC50 value of 1.90 µM. 
Organometallic compounds developed by Sadler et al. and McGowan et al. showed 
that when an iodide ligand is attached to the ruthenium metal centre, it increases the 
anti-cancer activity of the whole complex. Despite the different cytotoxicity assays 
used by the different researchers, complexes 4.8 and 4.13 which consist of a stable 
trans geometry and diiodide as their halide ligands, are seen to be more potent than the 
previously reported anti-cancer agents, and also in the series of bis-picolinamide 
ruthenium dihalide complex. These results have extended further the rule-breaking of 
structural-activity relationship for anti-cancer drugs. 
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Table 6.2 Previously reported ruthenium anti-cancer agents and their IC50 values against colon cancer cells
Anti-cancer agents Cancer Cell line 
Cytotoxicity 
Assay 
IC50 (µM) Ref. 
KP1019 
 
HCT-116 colon 
cancer cell line 
MTT assay 
3-day incubation 
36.6 ± 17.0 
 
Keppler et al.
14
 
KP1339 
 
34.7 ± 3.6 
α-Ru(Azpy)Cl2 
 
WiDR colon 
cancer cell line 
SRB assay 
5-day incubation 
1.90 ± 0.01 
 
Reedijk et al.
15
 
[Ru(η6-p-cym)(p-
AzpyNMe2)I]PF6 
 
HCT-116 colon 
cancer cell line 
SRB assay 
24 hr incubation 
1.37 ± 0.04 Sadler et al.
13
 
RuCl(η6-p-cym(2,5-
Cl-picolinamide) 
 
HT-29 colon 
cancer cell line 
MTT assay 
5-day incubation 
5.9 ± 0.8 McGowan et al.
16
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6.5 Hypoxia 
Cancer cells are characterised by a low concentration of oxygen level that leads to a 
more reducing environment when compared to normal tissues. This unique reducing 
microenvironment is a result of poor formation of new blood vessels to supply enough 
oxygen during its rapid cell growth.
17
 These cells which are distant from the blood 
vessels only allow limited amount of oxygen to diffuse through, giving the cells 
progressively gradual regions of oxygen concentration from having sufficient oxygen 
on the thin outer layer of the cells to less oxygen towards the inside of the cells.
18
 The 
distance between the blood vessels and the hypoxic regions depends on the rate of 
oxygen consumed by the cells, and typical cells tend to receive insufficient oxygen 
when the distance of the cells is more than 70 µm from the blood vessels.
19
 
 
Hypoxic cells are well recognised in their resistance towards chemotherapy and 
radiotherapy treatments, offering a great challenge in cancer therapeutics. The 
unsuccessful treatments against the hypoxic cells are related to their distance from the 
blood vessels, for which the anti-cancer drugs are not able to reach.
20
 For any 
treatments that destroy the cancer cells with sufficient oxygen may cause the hypoxic 
cells to reoxygenate and grow, hence repopulating the cancer cells in the body.
21
 The 
cells can also create tolerance within the hypoxic atmosphere,
22
 causing it to 
upregulate the genes in drug resistance, and promote cancer cell growth.
23
 Since 
hypoxic cells differ from normal healthy cells, this brings excellent opportunities on 
selective therapeutics to target cancerous cells. 
 
Recent evidence has suggested that protein complex HIF-1 plays a key factor in 
carcinogenesis. Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric transcription 
factor that comprises of an O2-regulated HIF-1α subunit and a constitutively expressed 
HIF-1β subunit.24 Figure 6.10 shows the signalling pathway of HIF-1 in the 
expression of its target genes.
25
 The HIF-α subunit is normally synthesised in the 
cytosol and is continuously degraded under normoxic conditions.
26
 However, under an 
environment of low oxygen concentration, this subunit starts to rapidly accumulate.
26
 
HIF-α is then transported into the nucleus and is reduced by thioredoxin reductase 
enzyme (Trx) that is regulated with an intermediate protein, Ref-1.
27
 A transcriptional 
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co-activator, CBP/p300 is recruited by the redox reaction of Trx/Ref-1, and binds with 
the reduced state of HIF-1α,28 where it dimerises with HIF-1β to form the HIF-1 
complex.
29
 Then, in order to activate the gene expression, HIF-1 complex binds to the 
hypoxia responsive element (HRE) in the promoters of the target genes.
29
 
 
 
Figure 6.10 HIF-1 signalling pathway and target genes expression, adapted from 
“The Interaction Between Redox and Hypoxic Signalling Pathways in the Dynamic 
Oxygen Environment of Cancer Cells, Carcinogenesis” 25 
 
HIF-1 upregulates hundreds of genes to alter expression in the hypoxic cells and code 
for proteins which are involved in pathways close related to cancer, facilitating 
adaptation and cell survival in the low oxygen environment.
30-33
 Figure 6.11 shows the 
role of HIF-1 activation in carcinogenesis. The overexpression of HIF-1 has been 
associated with several cancer types that includes lung, breast, prostate and colon 
cancer cells,
34
 producing the resistance of apoptosis, cell invasion and angiogenesis.
35
 
Furthermore, HIF-1 activates glycolysis that generates energy as ATP, maintaining the 
cell survival and so favours cell invasion, angiogenesis and proliferation.
36
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Figure 6.11 The role of HIF-1 activation in carcinogenesis.
37
 
 
An excellent approach to overcome the resistance of hypoxic cells to chemotherapy 
and radiotherapy treatment is to develop selective bioreductive drugs that become 
activated when they reach the hypoxic cells with reducing environment. Metal 
complexes have the advantages to this approach as they have the ability to vary their 
coordination number, geometry and redox states making them accessible in the 
reducing biological surrounding. They can serve as inert prodrugs, being transported 
into the targeted environment, and become reduced metabolically into its active form. 
The use of transition metal complexes for hypoxia-selective metabolism has been 
focused on the possibility of a one-electron reduction when in the cell reducing 
environment.
38
 
 
6.5.1 Hypoxia-activated metal-based anti-cancer drugs 
Cobalt. The mechanism of action of hypoxia-selective cobalt (III) anti-cancer drugs is 
known to consist of a cytotoxic ligand that is released in the low oxygen 
environment.
39
 Co(III) provides an inert framework that serves to protect the cytotoxic 
ligand prior to reaching the cancer cells. This complex is transported to its target and 
the cytotoxic ligand is then released into the hypoxic environment, after Co(III) is 
reduced to Co(II). Figure 6.12a shows a Co(III) complex that is associated with a 
tetradentate tris(2-methylpyridiyl)-amine (tpa) ligand acting as a carrier ligand, and a 
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matrix metalloproteinases (MMP) inhibitor, marimastat as the cytotoxic ligand.
40
 
Marimastat was in the Phase III clinical trials as an anti-cancer drug, but it was 
discontinued as it did not produce sufficient therapeutic benefits in patients.
41
 When 
incorporating marimastat to the Co(III) metal centre, studies have shown that there is 
an increase in cytotoxicity when compared to the free cytotoxic ligand.
40, 42
 Denny et 
al. studied several different series of Co(III) complexes containing bidentate nitrogen 
mustard ligands, as shown in Figure 6.12b, and for this complex, the bidentate 
nitrogen mustard ligand is the cytotoxic ligand released for its anti-cancer activity.
39, 43
 
  
(a) (b) 
Figure 6.12 Hypoxia-selective Co(III) anti-cancer complex with  (a) tetradentate tpa 
and bidentate marimastat ligands; (b) bidentate acac and bisalkylating nitrogen 
mustard ligands 
 
Iron. Hypoxia-selective Fe complexes as anti-cancer drugs are able to interconvert 
between +3 and +2 oxidation states. They are known to be cytotoxic by generating 
radicals to form reactive oxygen species (ROS) that can induce DNA damage in the 
cells.
44
 This is shown by the ferrocene analogue of tamoxifen, in which the third 
phenyl ring of tamoxifen is substituted by ferrocene (Figure 6.13a).
45
 An Fe analogue 
of Co(III) marimastat complex is as shown in  Figure 6.13b consisting of a 
tetradentate (N,N-bis(salicylidene)ethane-1,2-diimine (salen) ligand instead of a tpa 
ligand.
46
 This complex was found to be more potent than its Co(III) analogue, and may 
undergo a similar mechanism of action. 
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(a) (b) 
Figure 6.13 Hypoxia-activated Fe(III/II) anti-cancer complexes containing (a) 
ferrocene analogue of tamoxifen; (b) tetradentate salen and bidentate marimastat 
ligands 
 
Copper. Cu-based complexes offer an attractive chemistry in developing hypoxia-
selective drugs. It has two oxidation states with accessible reduction potential within 
the physiological potential range in cells.
47
 A Cu(II) complex containing a macrocylic 
cyclen ligand has shown a high increase in cytotoxicity when under hypoxic 
conditions compared to normoxic conditions, indicating it is hypoxia-selective.
48
 The 
complex acts as a prodrug, with Cu(II) undergoing a reduction to Cu(I) when in the 
hypoxic environment, releasing the cytotoxic cyclen ligand to its target cell, as shown 
in Scheme 6.1. 
 
 
Scheme 6.1 Mechanism of inert Cu(II) prodrug in releasing its cytotoxic cyclen ligand 
 
Platinum. Several platinum (IV) complexes have been shown to have advantages over 
cisplatin.
49, 50
 Pt(IV) may act as an inert prodrug that is reduced to its active Pt(II) 
complex in the hypoxic cells, believed to interact with few biological reducing agents 
including glutathione, L-methionine, L-cysteine, ascorbate, metallothionein and 
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albumin.
51
 Scheme 6.2 shows the reduction of Pt(IV) prodrug that yields a Pt(II) 
species when in the reducing environment. The Pt(IV) complex consists of two 
ammine ligands, two chloride ligands and two axial ligands that are lost upon 
reduction, to give the active cisplatin drug. The reduction rate of a Pt(IV) prodrug is 
highly dependant on the nature of the axial ligands, and the non-leaving ammine 
ligands, though the latter is less likely to affect the rate.
52
 Pt(IV) prodrug is easily 
reduced when the axial ligands are the chloro ligands, followed by acetato ligands, 
then those with the hydroxyl groups.
53
 
 
Scheme 6.2 Reduction of inert prodrug Pt(IV) to the active Pt(II) cisplatin 
 
6.5.2 MTT Assay under Hypoxic conditions 
Cytotoxicity studies under hypoxic conditions were determined using the MTT assay, 
which has been described previously in this chapter. HT-29 colon cancer cell line was 
selected for this assay as the ruthenium dihalide complexes were found to be more 
potent in this cell line compared to A2780 ovarian cancer cell line. Hypoxic studies 
were performed in a Whitley H35 Hypoxystation, with the oxygen level set at 0.1%, 
which is a physiologically relevant hypoxia level that leads to the drug resistance in 
radiotherapy and chemotherapy, and the activation of HIF-1 complex.
54
 The media 
used for this study was conditioned for at least 24 hours under the hypoxic atmosphere 
before starting the experiment. HT-29 colon cancer cells were cultured in a 96-well 
plate and incubated overnight in hypoxic conditions of 0.1% oxygen level at 37°C with 
5.0% CO2 atmosphere. The cells were then exposed to different concentrations of the 
drugs to be tested, with a range from 250 µM to 0.49 µM, and incubated for five days 
under hypoxic conditions. Then which, the cell survival analysis is done to determine 
the IC50 values of the drugs against the HT-29 cancer cells. 
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Tirapazamine (TPZ) was used to act as a positive control and to validate the hypoxic 
condition in the study. TPZ is a known hypoxia-selective drug, found to be more 
cytotoxic of up to 200-fold when in low oxygen environment compared to when it is in 
normoxic condition.
55
 TPZ undergoes a one-electron reduction metabolically in 
hypoxic atmosphere to give a free DNA-damaging TPZ radical that spontaneously 
gives oxidising hydroxyl and benzotriazinyl radicals (Scheme 6.3).
56, 57
 TPZ has 
finished Phase III clinical trials, however the results of the outcome are still pending.
58
 
 
Scheme 6.3 One-electron reduction of TPZ to generate a free radical 
 
Four bis-picolinamide ruthenium dihalide complexes, as shown in Figure 6.14, have 
been selected for cytotoxicity studies under hypoxic conditions of 0.1% oxygen level. 
These complexes have been selected due to being the most potent in their respective 
series of analogue. The cytotoxicity study under hypoxia condition is to determine the 
hypoxia-selevtive characteristic of the ruthenium dihalide complexes.  
 
 
 
 
 
 
 
 
Figure 6.14 Selected bis-picolinamide ruthenium dihalide complexes tested for 
cytotoxicity under hypoxic conditions 
Complex X R 
3.7 Cl 3’-Cl 
3.12 Cl 3’-Br 
4.8 I 4’-Cl 
4.13 I 4’-Br 
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Table 6.3 The IC50 values (µM) for TPZ, cisplatin and RuX2(L-R)2 complexes 3.7, 
3.12, 4.8 and 4.13 against HT-29 cell line under normoxic and hypoxic conditions. 
Results are expressed as the mean IC50 ± S.D for three independent experiments. 
Complex Normoxia 21% oxygen Hypoxia 0.1% oxygen 
Tirapazamine (TPZ) 33 ± 2 2.8 ± 0.2 
Cisplatin 2.8 ± 0.1 2.3 ± 0.2 
3.7 3.0 ± 0.1 2.6 ± 0.3 
3.12 3.3 ± 0.2 3.9 ± 0.2 
4.8 0.86 ± 0.1 1.2 ± 0.2 
4.13 0.84 ± 0.1 1.3 ± 0.1 
 
Table 6.3 shows the IC50 values obtained for TPZ, cisplatin and complexes 3.7, 3.12, 
4.8 and 4.13 both in normoxic and hypoxic conditions. In general, some of the 
ruthenium dihalide complexes have displayed a significant difference in their IC50 
values when comparing between the two different conditions. The potency of complex 
3.12 increased when under hypoxic conditions (p < 0.05). Complexes 3.7 and 4.8 have 
shown an insignificant decrease in potency from normoxic to hypoxic (p > 0.05). 
Complex 4.13 significantly lowered its cytotoxicity with differences of almost 2-fold 
between their IC50 values in the respective conditions (p < 0.01). 
 
Nevertheless, the bis-picolinamide ruthenium dihalide complexes 3.7, 3.12, 4.8 and 
4.13 are potent both under normoxic and hypoxic conditions. They have shown equal 
cytotoxicity in the HT-29 cell line suggesting that their anti-cancer mechanisms are 
independent of the oxygen concentration in the atmosphere. The IC50 values for all 
complexes are also seen to be comparable to the cytotoxic activity of cisplatin and 
TPZ when in the hypoxic condition, with the exception for complex 3.12 that has an 
IC50 value of 3.9 µM, about 2-fold less potent than cisplatin and TPZ (p < 0.01). 
Complex 3.7 has an IC50 value similar to cisplatin and TPZ of 2.6, 2.3 and 2.8 µM 
respectively. As for the bis-picolinamide ruthenium diiodide complexes 4.8 and 4.13, 
both complexes have shown to be twice more potent than cisplatin and TPZ, making 
them the two most promising candidates for further studies in vitro and in vivo as anti-
cancer agents. 
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CHAPTER 7 
 
Structural-Activity Relationship Studies of Bis-
Picolinamide Ruthenium Dihalide Complexes 
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7 Structural-Activity Relationship Studies 
7.1 Introduction 
By understanding the relationship between the molecular structure of a drug and its 
biological activity, modifications and improvements can be ensured to offer a 
pharmaceutical drug with high potency and very much less toxicity. Few of the many 
important structural-activity relationship (SAR) studies were conducted for bis-
picolinamide ruthenium dihalide complexes. This chapter includes the results and 
discussion for hydrolysis and hydrophobicity tests on selected ruthenium dihalide 
complexes. 
 
7.2 Hydrolysis 
An important mechanism of action known for anti-cancer drugs is the activation by 
hydrolysis mechanism that has been shown by cisplatin,
1-4
 NAMI-A
5
 and KP-1019.
6
 
These complexes are initially inert when administered intravenously into the blood 
plasma, which is due to the high chloride concentration, hence suppressing the ligand 
substitution reaction. Once these complexes have entered cancer cells that have low 
chloride concentration, they then undergo hydrolysis and became activated. Generally, 
ruthenium complexes with dichloride ligands are hydrolysed to form cationic 
monoaqua or diaqua intermediates under physiological conditions.
7, 8
 
 
Bis-picolinamide ruthenium dihalide complexes are assumed to undergo a hydrolysis 
reaction, following Scheme 7.1, which is a similar mechanism to that of cisplatin, 
NAMI-A and KP1019. In this reaction, the neutral ruthenium dihalide complexes 
undergo a halide substitution with an aqua ligand to form a charged monoaqua 
intermediate, which then undergoes its second substitution with an aqua ligand to give 
a 2+ charged diaqua complex. Following previous reported studies of known anti-
cancer drugs, the aqua complex is the active analogue that is able to bind with DNA 
base molecules by cross-linking thus damaging the DNA structure.
1-8
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Scheme 7.1 Hydrolysis mechanism for bis-picolinamide ruthenium dihalide complexes 
 
A range of complexes from the least to most cytotoxic was selected for hydrolysis 
study. The samples were prepared following the conditions used in hydrolysis studies 
previously reported in the literature.
9-12
 The samples for ruthenium dichloride 
complexes 3.3, 3.5, 3.7, 3.10, 3.12 and 3.14 were prepared in 10% MeOH/90% H2O, 
and ruthenium diiodide complexes 4.7, 4.10, 4.11 and 4.12 in 10% DMF/90% H2O to 
give a final concentration of 50 µM. These solutions were scanned using uv-vis 
spectrophotometry every 24 hours at 293 K over a period of 5 days, to correlate with 
the 5-day drug incubation in cytotoxicity tests, and after 5 days, the uv-vis samples 
were analysed by ESI-MS. Figure 7.1 shows the uv-vis spectra obtained from 
hydrolysis studies for ruthenium dichloride complexes 3.3, 3.5, 3.7, 3.10, 3.12 and 
3.14 and four ruthenium diiodide complexes 4.7, 4.10, 4.11 and 4.12 taken every 24 
hours for 5 days at 293 K. The arrows on the graphs indicate the intensities of the 
peaks that change from Day 0 to Day 5. At Day 0, each complex shows an intense 
absorption in the ultraviolet region (200 – 350 nm), except for complex 3.3 that shows 
two peaks with intense absorption. A few relatively weak peaks are seen in the visible 
light range (350 – 700 nm) for all complexes. The changes of the absorption bands 
indicate that there are ligand substitution reactions occurring when the complexes are 
in aqueous solution.
 7
 For most of the ruthenium dichloride complexes, the highest 
energy absorption band at Day 1 has increased in intensity at Day 5, whereas the 
intensity for the bands at lower energy wavelength decreases, followed by the 
disappearance of the absorption band at the lowest energy wavelength. As for the 
ruthenium diiodide complexes, they have shown a decrease in intensity on all the 
absorption bands, with an appearance of a band at the lower energy at Day 5 seen in 
complex 4.7 and 4.12. Table 7.1 lists the wavelength where the maxima of each 
absorption bands are seen in the respective complexes at Day 0 and Day 5. 
 
 
Structural-Activity Relationship Studies    Chapter 7 
148 
Figure 7.1 Time-evolution UV-Vis spectra for hydrolysis of Ru complexes (50 µM) at 293 K 
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Table 7.1 Wavelength of absorption bands (λmax ) for Ru complexes  
RuX2(L-R)2 R 
λmax / nm 
Day 0 Day 5 
3.3 4-F 258, 310, 488 223, 258, 310, 403, 627 
3.5 2,5-F 258, 393, 480 258, 364 
3.7 3-Cl 258, 314, 488 258, 394 
3.10 2,5-Cl 258, 393, 475 258, 368 
3.12 3-Br 309, 393, 480 258, 368 
3.14 2,5-Br 258, 335, 475 242, 347 
4.7 3-Cl 315, 432, 525, 591 315, 613 
4.10 2,5-Cl 292, 414, 547 370 
4.11 2-Br 310, 432, 587 360 
4.12 3-Br 315, 432, 525, 591 315, 613 
 
All ruthenium dichloride complexes show the disappearance of peaks with maxima at 
475 – 488 nm at Day 5. Complex 3.3, unlike all the other RuCl2 complexes, has the 
appearance of additional absorption bands at 223, 403 and 627 nm. Interestingly, an 
intense colour change was observed in the aqueous solution of complex 3.3 after Day 
5, from a red-brown to a bluish-green solution, which was not shown by the other 
RuCl2 complexes. 
 
Mercer and Dumas reported the preparation and characterisation of blue ruthenium 
chloride dimer complexes involving the reduction of hydrated ruthenium trichloride by 
heating with strong reducing agents.
13
 Quite recently, Pushkar et al. have revealed the 
catalytic process of blue ruthenium dimer in water oxidation cycle.
14
 Figure 7.2 shows 
the structure of the dimer, BD[3,3]
4+
, cis,cis-
[(bpy)2(H2O)Ru(III)ORu(III)(OH2)(bpy)2]
4+
, having two ruthenium complexes with 
each consisting of two bipyridine ligands and a water molecule, bound together by an 
oxygen atom between the two ruthenium metal centres. 
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Figure 7.2 Structure of blue ruthenium dimer
14, 15
 
 
There is a possibility that complex 3.3 may have formed a dimer with an oxygen atom 
bridging with the two ruthenium metal centres, which could explain the appearance of 
more absorption bands at Day 5. Figure 7.3 shows the possible structure of a blue bis-
picolinamide ruthenium aqua dimer complex. ES-MS analysis on this complex has 
shown an m/z ratio of 1221.9 [M Na
+
] which satisfies with the mass of the complex 
3.3 having their chloride ligands substituted with a water molecule, making a dimer by 
two ruthenium metal centres bridging with an oxygen atom. Attempts to isolate the 
product from the blue ruthenium aqua solution, however, was unsuccessful, and so this 
will be added to the list of future work, as it will be interesting to study the blue 
ruthenium bis-picolinamide dimer complex as an anti-cancer agent. 
 
 
Figure 7.3 Possible structure of blue bis-picolinamide ruthenium aqua dimer complex 
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A calibration curve for each complex was used to determine the final concentration of 
the aqua complex formed in solution by taking the wavelength with maximum 
absorbance, and using the formula below to obtain the percentage of the hydrolysed 
complex after Day 5. 
 
 
The IC50 values against A2780 and HT-29 cell line, and percentage of hydrolysed 
complexes 3.3, 3.5, 3.7, 3.10, 3.12 and 3.14 are shown in Table 7.2, and their plot 
against time, fitted to a kinetic curve are as shown in Figure 7.4. Ruthenium chloride 
complexes 3.7 and 3.12 have been shown to undergone the fastest hydrolysis rate 
forming the highest percentage of hydrolysed complex from Day 1 to Day 5, in 
comparison to complex 3.3, 3.5, 3.10 and 3.14. Complexes 3.7 and 3.12, being the two 
most cytotoxic among the ruthenium dichloride complexes, hydrolyses up to 90% after 
five days, with complex 3.7 showing a faster hydrolysis rate. Complex 3.3 is more 
cytotoxic than complex 3.14 against A2780 ovarian cancer cell line, but is less 
cytotoxic than complex 3.14 towards HT-29 colon cancer cell line, their hydrolysis 
reaction undergoes a similar rate nevertheless, whereas for complexes 3.10 and 3.5, 
being the two least cytotoxic in the selected hydrolysis series of complexes, form 48% 
and 25% of hydrolysed complex after 5 days. The uv-vis hydrolysis samples were 
analysed by ESI-MS after five days to investigate the ruthenium complexes that are 
formed in the aqueous solution. Ruthenium dichloride complexes 3.3, 3.7 and 3.12, 
which are the active anti-cancer complexes, have formed the di-aqua complexes, in 
which their two chloride ligands have been replaced by water molecules when in 
solution. Complex 3.5, 3.10 and 3.15 are moderately active towards A2780 and HT-29 
cancer cell lines contained the mono-aqua complex, where only one chloride ligand is 
substituted with a water molecule, supporting their rate of reaction of fast and slow 
hydrolysis respectively. The rate of hydrolysis for ruthenium dichloride complexes 
increases in the order from 3.5 < 3.10 < 3.14 ~ 3.3 < 3.7 < 3.12, correlating very well 
with their cytotoxicity against the A2780 and HT-29 cancer cell line indicating that 
hydrolysis may be one of their mechanisms for anti-cancer activities. 
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Table 7.2 IC50 values against A2780 and HT-29 cell line, and percentage of 
hydrolysed bis-picolinamide ruthenium diiodide complexes 
Complexes 
IC50 / µM 
% hydrolysed 
A2780 HT-29 
Ruthenium dichloride complexes (10% MeOH/90% H2O) 
3.3 6.9 ± 0.8 17 ± 1 69.7 
3.5 45 ± 2 20 ± 1 24.7 
3.7 3.6 ± 0.2 3.0 ± 0.1 91.6 
3.10 31 ± 1 11 ± 1 47.9 
3.12 3.3 ± 0.2 3.3 ± 0.2 90.2 
3.14 18 ± 1 7.7 ± 0.3 64.8 
Ruthenium diiodide complexes (10% DMF/90% H2O) 
4.7 2.8 ± 0.3 2.3 ± 0.1 64.6 
4.10 10.0 ± 0.4 6.5 ±0.3 61.0 
4.11 11 ± 1 24 ± 2 72.5 
4.12 2.0 ± 0.2 1.5 ± 0.1 34.6 
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Figure 7.4 Time-dependence formation of (a) hydrolysed ruthenium dichloride 
complexes in 10% MeOH/90% H2O and, (b) hydrolysed ruthenium diiodide complexes 
in 10% DMF/90% H2O  
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The percentage of hydrolysed complexes 4.7, 4.10, 4.11 and 4.12 over five days fitted 
to a kinetic curve are shown in Figure 7.4b. Ruthenium diiodide complex 4.12 is the 
most cytotoxic in the selected series of complexes, forming 26% of hydrolysed 
complex after five days. Complex 4.10 undergoes the slowest hydrolysis within 72 
hours, reaching its maximum from 55% to 61% from Day 3 to Day 5. Complex 4.7 has 
hydrolysed slightly more than complex 4.10 reaching 65% after five days in aqueous 
solution. The least cytotoxic complex in the series is complex 4.11, which has gone the 
fastest hydrolysis, with almost reaching its maximum of 72% hydrolysed after 24 
hours. Their ES-MS analysis has shown that the ruthenium diiodide complexes have 
formed mono-aqua complexes in the aqueous solution after 5 days, which does not 
correlate with their rate of hydrolysis. Complex 4.11 has reached its maximum 
hydrolysis of 72% but has only substituted one chloride ligand with a water molecule. 
 
The increasing rate of hydrolysis for ruthenium diiodide complexes is in the order 
from complex 4.12 > 4.7 ~ 4.10 > 4.11, opposing their order of cytotoxic activity 
against A2780 ovarian cancer cell line and HT-29 colon cancer cell line. These 
observations are in contrast to their dichloride analogues, similarly shown by Sadler et. 
al. on contrasting activity between chlorido and iodo ruthenium arene complexes.
16, 17
 
This could suggest that the ruthenium diiodide complexes do undergo hydrolysis, 
however, it may not be their major anti-cancer mechanism. In addition to complex 
4.12 being the most cytotoxic in the series and is the least hydrolysed, indicates that it 
is more stable than their chloride analogues that could give the benefit in lowering the 
toxic side effects with respect to its high cytotoxic anti-cancer activities. This, again, 
breaks the rule proposed by Rosenberg,
18
 and Cleare and Hoeschele,
19, 20
 specifying 
that the trans geometry complexes could lead to an increase in toxicity as they were 
found to be highly reactive due to kinetic instability. 
 
There have been many unsuccessful attempts to isolate the aqua products from the 
aqueous solution, and also to synthesise the aqua analogue of the ruthenium dihalide 
complexes. Figure 7.5 shows the structure of complex 8.1, an aqua analogue of 
complex 3.12, which has been synthesised with the presence of a silver salt, AgSbF6, 
and characterised by IR, ESI-MS and microanalysis. The IR spectra for complex 8.1, 
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along with the spectra of its dichloride (complex 3.12) and diiodide (complex 4.12) 
analogue, is as shown in Figure 7.6, where most differences are observed in the 
fingerprint region particularly between 950-400 cm
-1
 region. Attempted crystallisation 
was also carried out on complex 8.1 to obtain crystals suitable for x-ray 
crystallography, although has been unsuccessful up to this point.  
 
 
Figure 7.5 Structure of complex 8.1 
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Figure 7.6 IR Spectra of complex 3.12, 4.12 and 8.1 
Complex 3.12 
Complex 4.12 
Complex 8.1 
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7.3 Hydrophobicity 
The decrease in cellular uptake of drugs has become one of the main factors that could 
lead to acquired drug resistance.
21
 Drugs are required to be hydrophobic to enter the 
cells easily by passive diffusion through the cell membrane of hydrophobic layers.
22
 
Increasing the hydrophobicity of the drug will aid the increase of their uptake into 
cells, hence increasing their cytotoxicity. However, hydrophobicity has to fall within 
the optimum range, as the drug may become very insoluble in aqueous media or is 
embedded within the cell membrane leading to decrease in their activities and increase 
in toxicities. 
 
The hydrophobicity of a drug can be determined by shake-flask method of octanol-
water partition coefficient to obtain log P values.
23
 Deionised water containing 300mM 
of NaCl was used to prevent the complexes from undergoing hydrolysis during the 
study. Several bis-picolinamide ruthenium dichloride complexes were selected, and 
dissolved in water-saturated octanol to be shaken with octanol-saturated water for 4 
hours to ensure equilibrium is reached. The organic layer of the samples before and 
after the partition were analysed by uv-vis spectrophotometry to determine the 
concentration of the complex, obtained from a calibration curve of the respective 
complex. The log P values of the complexes are obtained by using the following 
formula, 
 
 
In a shake-flask method, the organic phase serves as a model for the hydrophobic 
layers on the cell membrane. A complex is measured as hydrophobic where its 
concentration is higher in the organic phase than in the aqueous phase, giving a 
positive log P value. Hence, a negative log P value defines the drug being hydrophilic 
with higher concentration in the aqueous phase of the partition coefficient. The log P 
values for the selected bis-picolinamide ruthenium dichloride complexes 3.2, 3.3, 3.5, 
3.7 and 3.10 - 3.14 are as shown in Figure 7.7. All of the complexes are found to be 
hydrophobic as they partition preferentially in the organic layer. Their log P values are 
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within the range 0.67 - 1.39, that applies well within Lipinski’s ‘rule of five’. The rule 
states that poor absorption and distribution of drugs is expected when it has molecular 
weight over 500 Da, Log P value is greater than 5, number of H-bond donors is more 
than 5, and number of H-bond acceptors is more than 10.
24
 Although, transition metal 
anti-cancer drugs have proved exceptions of the Lipinski rule, as many tend to have a 
higher molecular weight than as stated.
25
 Hansch’s principle of minimum 
hydrophobicity in drug design assert that for drugs to avoid related side effects with 
the central nervous system (CNS), such as depressions and hallucinations, their log P 
value must be less than 2.0.
26
 The two most cytotoxic ruthenium dichloride complex 
3.7 and 3.13 have a log P value of 1.37 and 1.39 respectively, which are also the two 
most hydrophobic in the series. Complex 3.5, the least cytotoxic complex of the series 
is also the least hydrophobic. 
 
 
Figure 7.7 Log P values of bis-picolinamide ruthenium dichloride complexes from the 
average of six independent experiments 
 
Platinum complexes have intermediate hydrophobicity and have been shown that their 
increase in hydrophobicity correlates well with the increase in their anti-cancer 
activity.
27
 Figure 7.8 shows the correlation between log P values and cytotoxicity of 
bis-picolinamide ruthenium dichloride complexes against A2780 and HT-29 cancer 
cell lines. Only very few correlations are seen with respect to the complexes that have 
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fallen within the linear relationship. However, most complexes are outliers from the 
correlation and have showed an irregularity of log P values in the order of their 
cytotoxic activity. 
 
 
Figure 7.8 Correlation between log P values and cytotoxicity of bis-picolinamide 
ruthenium dichloride complexes against A2780 and HT-29 cancer cell lines 
 
From the observations, these may suggest that with the complexes being hydrophobic, 
they may easily enter the cells by passive diffusion. However, with only very few 
correlations seen between their cytotoxicity and log P values, their cell uptake 
mechanism may not be related to their anti-cancer activity within the cells. Studies 
have also shown that cisplatin have the ability to enter the cells via copper 
transporters,
28, 29
 and cell uptake of KP-1019 via overexpressed protein transferrin 
receptor within the cancer cell membrane.
30, 31
 Bis-picolinamide ruthenium dichloride 
complexes may also have this binding potential to a specific transporter as their cell 
uptake mechanism with relation to their anti-cancer activity. Cell uptake studies on 
ruthenium dichloride complexes may provide further evidence to understand their anti-
cancer mechanism. 
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8 Catalytic Transfer Hydrogenation 
8.1 Introduction  
Transfer hydrogenation is a catalytic process for either the oxidation of a substrate 
through the removal of hydrogen from using a hydrogen acceptor, or the reduction 
of a substrate through the addition of hydrogen using a hydrogen donor. The 
substrate for oxidation is generally an alcohol or amine, and for reduction is an 
unsaturated compound such as aldehyde/ketone, imine or alkene. A metal catalyst 
is required to mediate the transfer of hydrogen in the reaction, by removing the 
hydrogen from a hydrogen donor with itself forming a metal hydride species, and 
then adding this hydrogen to a hydrogen acceptor. Scheme 8.1 shows the general 
scheme for a transfer hydrogenation reaction. 
 
Scheme 8.1 General reaction scheme for transfer hydrogenation processes, where 
[DH2] = hydrogen donor 
 
This reaction offers a mild and safer method for practical use on both laboratory 
and industrial scales compared to conventional hydrogenation reactions that 
involve hazardous hydrogen gas at high pressure. A number of cheap and readily 
available alcohols can be used as a reagent for hydrogen donor in transfer 
hydrogenation reactions, which generally proceed through an intermediate metal 
hydride species. The research on this catalytic reaction is targeted towards metal 
catalysts that favour high activity under mild operating conditions, preferably while 
also being selective and recyclable.
1
 In addition, metal catalysts that can provide 
extra stability is also of importance to prevent it from degrading easily during the 
reaction, hence possible for it to catalyse reactions as many as possible.
2, 3
 
Recyclable systems serve the purpose of the catalyst being able to be separated 
from the product after the reaction.  In order to develop newly improved 
procedures for efficient transfer hydrogenation reactions, the catalytic reactivity 
and selectivity can be finely tuned by modifying the chirality and, steric and 
electronic properties of the different ligands that are coordinated to the metal 
centre. 
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The first part of this chapter will focus on a number of reported ruthenium catalysts 
that have been used in the reduction of ketones and aldehydes in iso-propanol. This 
reaction is important to provide a wide range of alcohols, which are used as 
building blocks for the synthesis of pharmaceuticals, agrochemicals, materials, 
flavours, fragrances and fine chemicals.
4-8
 The second part of this chapter will 
review the possible catalytic mechanisms that have been proposed using different 
metal catalysts in transfer hydrogenation reactions. Finally, this chapter will 
describe the catalytic activities of a selection of bis-picolinamide metal dihalide 
complexes. 
 
8.2 The IPA system 
The most common hydrogen donor system is the use of iso-propanol, which is 
cheap, relatively safe and easily available. It is used as the reaction solvent in 
reduction reactions, as shown in Scheme 8.2, whereby it is oxidised to produce 
acetone.
9
 In the IPA system, the reaction is reversible between the substrate and the 
product, and is initially controlled by kinetics. As the product concentration 
increases, the reaction becomes thermodynamically controlled, as the reverse rate 
of reaction also increases.
9
 This causes limited conversions in the reaction, 
affecting the yield and the enantiomeric purity of the product over time. In order to 
prevent this drawback, a large excess of iso-propanol is used in the reaction, hence 
as the solvent, to shift the equilibirium to the favoured product. 
 
Scheme 8.2 Reductive IPA system of catalytic transfer hydrogenation reaction 
 
Iso-butanol may also be used as a hydrogen donor, however, is generally less active 
when compared to iso-propanol.
9
 Primary alcohols tend to form aldehyde as by-
product, which may interfere within the catalytic reactions.
9
 Alcohols containing 
glucose or ascorbic acid may be used at a lower concentration as the reaction 
solvent in transfer hydrogenation.
9
 Acetone is used as a hydrogen acceptor in 
dehydrogenations, where it is reduced to iso-propanol.
10
 In most cases, a base is 
also required in order to activate the pre-catalyst within the system. The base 
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generates the intermediate metal hydride species which is the active species for the 
transfer of hydrogen.
11-13
 
 
8.3 Ruthenium-Catalysed Transfer Hydrogenation of 
Aldehydes/Ketones 
Noyori et al. have developed a series of highly efficient Ru-arene complexes as 
catalysts for the asymmetric transfer hydrogenation (ATH) of ketones and imines 
in the presence of a base.
14
 The first generation of Ru complexes consisted of an 
arene ring, a chloride ligand and chiral N-substituted-1,2-diphenylethylamine 
(DPEN) ligand, as shown in Figure 8.1. 
 
R = 2,4,6-CH3 
       C6H6 
 
X = SO2C6H4-p-CH3 (Ts) 
       COC6H5 
       SO2C6H5 
       SO2CF3 
Figure 8.1 First generation of Noyori Ru-arene ATH catalysts 
 
The best catalytic reaction from the initial series of Noyori Ru-arene chiral 
complexes was for the transfer hydrogenation of acetophenone, as shown in 
Scheme 8.3. The Ru catalyst was prepared in situ from the reaction of 
[RuCl2(mesitylene)]2 and (S,S)-TsDPEN, in IPA with KOH at room temperature. 
The reaction gave a 95% conversion of acetophenone to (S)-1-phenylethanol with 
97% ee in 15 hours. 
 
Scheme 8.3 ATH of acetophenone using [RuCl2(mesitylene)]2 and (S,S)-TsDPEN 
 
The catalytic screening of the Ru-arene complexes revealed that the rate and 
enantioselectivity of the reaction depends on the N-substituted based ligand of the 
complex.
14
 The reactivity decreases with increasing electron-withdrawing N-
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substituents for Ru(η6-benzene) complexes, in the order of COC6H5 > SO2C6H4-p-
CH3 > SO2C6H5 > SO2CF3, where the complexes with the sulfonyl substituents 
gave higher enantioselectivity. The same reaction as in Scheme 8.3 was also 
performed without the presence of (S,S)-TsDPEN ligand, which gave a conversion 
of <8% from acetophenone to (S)-1-phenylethanol in 15 hours. 
 
The second generation of Noyori catalysts for ATH of acetophenones consist of an 
arene ring, a chloride ligand and an amino-alcohol ligand, as shown in Figure 
8.2.
15
 The Ru catalyst was generated in situ from the reaction of Ru-arene dimer 
and N-substituted amino-alcohol in IPA with KOH. 
  
Figure 8.2 Second generation of Noyori Ru-arene ATH catalysts 
 
Replacing the (N,N) DPEN ligands with (N,O) amino-alcohol ligands significantly 
increased the catalytic activity when the appropriate arene and amino-alcohol were 
combined. Scheme 8.4 shows the combination of [(RuCl2(hexamethylbenzene)2] 
and (S,S)-2-methylamino-1,2-diphenylethanol which gave a 94% yield and 92% e.e 
after 1 h.
15
 The catalytic screening of the Ru-arene amino-alcohol complexes have 
shown that the presence of NH proximity in the ligand increases the catalytic 
activity, whereas an increase in steric bulk of the arene ring tends to decrease the 
reactivity of the whole catalyst.  
 
Scheme 8.4 ATH of acetophenone using [(RuCl2(hexamethylbenzene)2] and (S,S)-
2-methylamino-1,2-diphenylethanol 
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Noyori catalysts have also been studied for ATH on deuteurated benzylaldehyde 
following the reaction schemes as shown in Scheme 8.5.
16
  The most active 
catalyst in the series was RuCl(p-cymene)(R,R)-TsDPEN which gave 100% yield 
of deuteurated benzylalcohol with 98% ee in 30 mins. When increasing the reaction 
time to 48 mins, the catalytic activity still maintained with 100% product yield, 
however the enantiomeric purity of the product decreases to 96%. This suggests 
that unnecessary prolonged standing of the reaction after reaching 100% 
conversion should be avoided as to maintain a high degree of kinetic 
enantioselectivity. 
 
 
Scheme 8.5 ATH of benzaldehyde using RuCl(p-cymene)(R,R)-TsDPEN catalyst in 
IPA 
 
Following Noyori’s work, many researchers have explored and extended the work 
in order to optimise the catalytic system for transfer hydrogenation reactions, as 
well as to design and create novel ligands and catalysts. Table 8.1 illustrates three 
of the active ruthenium catalysts that were studied for transfer hydrogenation of 
acetophenone in the IPA/base system (Scheme 8.6) under different reaction 
conditions. Catalyst 1 has shown that their catalytic activity using the optimised 
conditions, is strongly influenced by the substituents on the pyrimidine ring, 
whereby their activity increases as the electron donation from the substituent 
increases.
17
 The high conversion rate when using catalyst 2 for the reaction of 
acetophenone is thought due to the presence of the bulky substituent adjacent to the 
O or N donor atom of the ligand, in which in this case is the ortho-methoxy phenyl 
group attached to the N donor atom.
18
 Baratta et al. have developed an arene-free 
Ru catalyst 3, consisting of the combination of 2-amido-6-methylpyridine (ampy) 
and an N-heterocyclic carbene (NHC) as the ligands.
19
 Its high catalytic 
performance in reducing acetophenone to 1-phenyl-ethanol within 5 mins is 
believed to be due to the presence of the RuH/NH2 motif,
20, 21
 and with the addition 
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of a carbene that adds stability to the Ru centre, preventing degradation; favouring 
long-lived catalytic species. 
 
Scheme 8.6 Reduction of acetophenone in IPA/base system 
 
Ru Catalyst 
Reaction 
Conditions 
% conversion 
Ref 
1 
 
0.0125 mmol Ru 
catalyst 
0.125 mmol KOH 
82°C 
98% in 6h 
Taghizadeh 
Goochany et 
al.
17 
2 
  
0.05 mmol Ru 
catalyst 
0.125 mmol KOH 
Reflux, N2 atm. 
98% in 6h Rath et al.18 
3 
 
0.05 mol% Ru 
catalyst 
2 mol% NaOH 
Reflux, Ar atm. 
99% in 5 mins 
Baratta et 
al.
19 
Table 8.1 Highly active Ru catalysts for ATH of acetophenone in IPA/base system 
 
There has been much work using Ru catalyst for the reduction of benzaldehyde to 
benzylalcohol in the IPA/base system. A series of Ru-p-cymene complexes 
containing diphosphine ligands,
22
 and Ir-Cp* picolinamide complexes
23
 were 
synthesised within the McGowan group, for a study on ATH of benzaldehyde. The 
work involved preparing the Ru catalysts with a series of diphosphine ligands in 
situ, and monitoring their catalytic reactions, as well as the comparison of 
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reactivities when the ligands are coordinating either (N,N) or (N,O) to the metal 
centre for Ir-Cp* picolinamide complexes. 
A series of control experiments were performed by Dr. Andrea Rodríguez-Bárzano 
in order to optimise the catalytic reactions of benzaldehyde reduction using 
[RuCl2(p-cymene)]2  and dppf ligand (Figure 8.3).
22
 The catalysts were prepared in 
situ with the presence of dppf ligand and/or base, Et3N, in IPA at 85°C. The results 
showed a 100% conversion after 24 hours when both dppf and Et3N is present in 
the reaction (Table 8.2). Dr. Stephanie Lucas focused on Ir-Cp* picolinamide 
catalysts (Figure 8.3) for benzaldehyde reductions with 0.08 mmol KO
t
Bu in IPA 
at 60°C.
23
 Her work has shown that a higher catalytic activity was seen when the 
picolinamide ligand coordinates (N,O) to the Ir metal centre with 97% conversion 
compared to the (N,N)-coordinated ligand with 26% after 24 hours. 
 
 
[RuCl2(p-cymene)]2 dppf ligand 
 
 
IrCp*(N,N)-picolinamide IrCp*(N,O)-picolinamide 
Figure 8.3 Structure of Ru and Ir catalysts studied for benzaldehyde reductions 
 
Table 8.2 Summary of conversions in IPA at 85°C for benzaldehyde reduction 
Entry Ru species 
Ligand (5 
mol%) 
Base (8 mol%) 
% conversion 
3h 9h 24h 
1 [RuCl2(p-cymene)]2   dppf Et3N 100 100 100 
2 [RuCl2(p-cymene)]2   dppf - 14.3 60.9 88.8 
3 [RuCl2(p-cymene)]2   - Et3N 38.5 50.6 56.3 
4 [RuCl2(p-cymene)]2   - - 4.2 11.8 22.2 
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8.4 Catalytic Mechanisms 
 
Brandt et al. have reviewed recent catalytic mechanistic studies in transfer 
hydrogenation reactions of ketones/aldehydes.
24
 Two different mechanistic 
pathways have been proposed, which are the “direct hydrogen transfer”, 25-27 and 
the “hydridic route”, with the latter can be further classified into “monohydride 
route” or “dihydride route”. 
 
8.4.1 Hydridic Route 
Transfer hydrogenation reactions using transition metal complexes as catalysts 
generally involve the formation of metal hydride intermediates. This mechanism is 
known as the “hydridic route”. It has been reported that the presence of base 
activates the pre-catalyst in the reaction, promoting the formation of highly active 
metal hydride intermediates, hence increasing the rate of reaction.
13, 28
 Scheme 8.7 
shows the general monohydride and dihydride route for catalytic transfer 
hydrogenation reactions. 
 
  
(a) Monohydride Route (b) Dihydride Route 
 
Scheme 8.7 Catalytic transfer hydrogenation via (a) Monohydride route (b) 
Dihydride route
13, 28
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In the monohydride mechanism, the chloride from the catalyst precursor is 
substituted by the hydrogen donor to generate an alkoxide, and then forming a 
metal hydride complex via β-elimination. The CO from ketonic substrate inserts 
into the metal-hydride bond to give the alcohol product. In the dihydride 
mechanism, metal dihydride intermediates are formed through alkoxide formation 
and β-elimination. Insertion of the ketonic substrate, followed by reductive 
elimination produces the product. The metal dihydride complex is regenerated via 
oxidative addition on the hydrogen donor followed by β-elimination. These two 
mechanisms can be differentiated experimentally by using optically active 
deuteurated alcohol for racemisation.
29, 30
 
 
The monohydride route occurs in the inner sphere mechanism, whereby the 
substrate coordinates to the metal centre of the catalyst precursor during the 
reaction. Another pathway that has been suggested for metal catalysts that operate 
through the monohydride route is the outer sphere mechanism, in which the 
substrate does not coordinate to the metal centre. The outer sphere mechanism can 
either proceed in a concerted manner, or in stepwise mechanism. 
 
Noyori et al. have proposed the concerted outer sphere mechanism for the 
ruthenium complex, Ru
II
-TsDPEN, as catalyst for asymmetric transfer 
hydrogenation of ketones (Scheme 8.8).
14, 31
 The base present in the reaction 
eliminates HCl from the Ru catalyst precursor, generating the 16-electron active 
species. The hydride and a proton from the hydrogen donor are transferred in a 
concerted manner to the ligand and metal of Ru intermediate respectively, giving 
an 18-electron Ru hydride species. The Ru hydride species then transfer the proton 
and hydride to the substrate forming a cyclic six-membered transition state to give 
the alcohol product. 
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Scheme 8.8 The concerted outer sphere mechanism for Noyori’s Ru catalyst14, 31 
 
The function of the amine group in the ligand of the Ru catalyst plays a very 
important role to deliver the hydroxyl proton from the hydrogen donor to the 
substrate. This type of catalyst is termed “metal-ligand bifunctional catalysts”, in 
which one of the sites of the ligands acts as a basic centre and forms a hydrogen 
bond interaction with the substrate to facilitate the transfer of hydrogen in the 
reaction.
32
 
 
8.5 Catalytic Studies of bis-Picolinamide Metal Dihalide Complexes 
Several bis-picolinamide metal dihalide complexes (MX2(L-R2)) with the general 
structure as shown in Figure 8.4 were selected to study for their application as 
catalysts for the reduction of benzaldehyde. These complexes are interesting as the 
ligands can be easily functionalised giving advantages towards investigating 
structural-activity relationships. Their catalytic activities were studied based on the 
complexes having different metal centres (M = Ru or Rh), different halides (X = Cl 
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or I), and different R substituents attached at different positions on the phenyl ring 
of the picolinamide ligands. Previous studies have shown that the presence of 
leaving groups, hydrogen donor atoms, and having NH functionality in the ligand 
close to the metal centre can improve the catalytic activity of the whole complex. 
16-19
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.4 Bis-picolinamide metal dihalide complexes as catalysts  
 
The reaction procedure for the reduction of benzaldehyde is as shown in Scheme 
8.9. This catalytic experiment is used as the first step towards exploring the 
relationship between structure and catalytic activities of bis-picolinamide metal 
dihalide complexes. Isopropanol acts as the hydrogen donor, and was used in 
excess as to avoid the reverse reaction. The conditions used were based on previous 
studies on Ru and Ir catalysts carried out  within the McGowan group.
22, 23
  
 
Scheme 8.9 Catalytic benzaldehyde reduction 
 
Complex M X R 
3.4 Ru Cl 2’,4’-F 
3.9 Ru Cl 2’,4’-Cl 
4.1 Ru I H 
4.4 Ru I 2’,4’-F 
4.7 Ru I 3’-Cl 
4.9 Ru I 2’,4’-Cl 
4.12 Ru I 3’-Br 
5.2 Rh Cl 3’-Cl 
5.3 Rh Cl 3’-Br 
5.5 Rh I 3’-Cl 
5.6 Rh I 3’-Br 
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8.5.1 Catalytic Activities of RuX2(L-R)2 Complexes 
 
Ru complexes 3.4, 3.9, 4.4 and 4.9 were tested for their catalytic activity in the 
reduction of benzaldehyde using the conditions as shown in Scheme 8.9. The 
results are as shown in Figure 8.5, with RuCl3.3H2O as a comparison. 
 
Figure 8.5 Catalytic activities of RuX2(L-R2) complexes in benzaldehyde reduction 
 
RuCl3.3H2O is the starting material used in synthesising the catalysts, as described 
previously in Chapters 3 and 4. When comparing between the RuCl3.3H2O and 
RuX2(L-R2) complexes, the starting material showed the least activity within the 
series, with only 3% conversion after 24 h, suggesting that the picolinamide ligands 
play very important role in catalytic activity when coordinated to the Ru metal 
centre. The activity increases especially when the picolinamide ligands are 
functionalised with a chloride substituent on the ortho and para position on the 
phenyl ring of the picolinamide ligands, as shown by catalysts 3.9 and 4.9, with 
conversions of 72% and 100% respectively. The high catalytic performance of 
catalyst 4.9 with 100% conversion, showing zero presence of the substrate from 
GC and NMR analysis after 24 h, also resulted from having an iodide substituent 
attached to the Ru metal centre. This shows that the choice of X ligand is essential 
in the reduction of benzaldehyde. 
 
Moreover, with respect to a contrast in structural isomers, for which Ru diiodide 
complexes have shown a trans geometry, whereas Ru dichloride complexes 
showed a cis geometry with a mixture of few other structural isomers in solution. 
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These could indicate that a Ru complex with diiodide ligands, in addition of it 
being trans and that there is no mixture of isomers, is of importance in increasing 
the catalytic activities of the complex. 
 
Figure 8.6 shows a different view to illustrate the catalytic effects of the Ru 
complexes with different combinations of X ligand and R substituent. It can be 
seen that there is a significant increase when the substituents are changed from 
2’,4’-difluoro to 2’,4’-dichloro, as in comparison to the difference of reactivities 
based on their X ligands. This could specify that the functionalised picolinamide 
ligands play a large effect in the catalytic activity of the complex. Furthermore, 
when in combination with an iodide as the X ligand, the catalytic reactivity can be 
improved. 
 
Figure 8.6 The catalytic effects of Ru complex with different combinations of X 
ligand and R substituent in benzaldehyde reduction 
 
8.5.2 Catalytic Activity of RuI2(L-R)2 Complexes 
The structural-catalytic activities of RuI2L2 complexes 4.1, 4.4, 4.7, 4.9 and 4.12 
were studied for catalytic transfer hydrogenation of benzaldehyde reduction in IPA 
following Scheme 8.9. The Ru complexes only differ through the 
functionalisations on the picolinamide ligands, specifically on the phenyl ring. 
Figure 8.7 shows the catalytic activities of the selected RuI2L2 complexes. The 
results for catalysts 4.4 and 4.9 have been discussed in the previous section, but are 
also included in the figure for additional comparison within the series. 
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Figure 8.7 Catalytic activities of RuI2L2 complexes in benzaldehyde reduction 
 
With the exception of catalyst 4.9, all of the other complexes showed poor catalytic 
activity in reducing benzaldehyde within 24 hours. Catalyst 4.1, with 
unfunctionalised picolinamide ligand, is the least active in the series with only 2% 
conversion. When an electron-withdrawing substituent is attached on the phenyl 
ring of the picolinamide ligands, their catalytic activities slightly increase. Catalyst 
4.7 functionalised by meta-chloride, and catalyst 4.12 with meta-bromide gave a 
31% and 22% benzaldehyde reduction, respectively. Catalyst 4.9 is the most active 
within the series with 100% conversion, giving the same result in repeated 
reactions. This could agree that the functionalised picolinamide ligands specifically 
on the ortho and para position may highly affect the catalytic activities for transfer 
hydrogenation in the reduction of benzaldehyde. 
 
Catalysts 4.1, 4.7 and 4.12 were also monitored for their catalytic reactions in 
benzaldehyde reduction, with their samples taken at 1h, 3h, 5h, 7h, 9h and 24h. 
Their results are as shown inFigure 8.8. Catalyst 4.7 starts up its catalytic activity 
after 3 hours in the reaction, from 7% conversion and slowly increases after every 2 
hours until it reaches a 31% conversion at 24 h. The reactivity of catalyst 4.12 is 
slower and only starts to reduce benzaldehyde after 5 hours with 6% conversion 
and giving 22% conversion at 24 h, whereas catalyst 4.1, with unsubstituted 
picolinamide ligands is the most inactive, with only 0 - 2 % conversion after 9 
hours. These results have also been previously observed from within the McGowan 
group, of using Ir/Rh catalysts consisting of a picolinamide ligand with halide 
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substituents on the meta position of the phenyl ring.
23
 The catalysts showed low 
activity, but have slightly improved with the meta-halide substituents on the 
picolinamide ligands, when compared to the unsubstituted catalyst.  
 
 
 
Figure 8.8 Catalytic activities of RuI2L2 complexes in benzaldehyde reduction 
 
8.5.3 Catalytic Activities of RhX2(L-R)2 Complexes 
A series of RhX2(L-R)2 complexes with different X ligand and functionalisation of 
the picolinamide ligands were investigated as catalysts in the reduction of 
benzaldehyde via transfer hydrogenation reactions using the reaction procedure as 
in Scheme 8.9. The catalytic activities of the few selected RhX2(L-R)2 complexes 
are as shown in Figure 8.9, along with RhCl3.3H2O as comparison, which was 
used as the starting material to prepare a series of the Rh complexes, described 
previously in Chapter 5. 
 
Figure 8.9 Catalytic activities of RhX2(L-R)2 complexes in benzaldehyde reduction 
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RhCl3.3H2O has the lowest catalytic activity giving only 3% benzaldehyde 
conversion according to the GC and NMR analysis of the samples after 24 hours. 
Their activities are slightly improved when picolinamide ligands are coordinated to 
the Rh metal centre. In general, the bis-picolinamide rhodium dihalide complexes 
have shown moderate catalytic activities with the overall range between 15-50%. 
Interestingly, a trend can be seen as both the X ligand and the R substituents on the 
functionalised picolinamide ligands increase in electron withdrawing. Their 
catalytic activity increases following the X/R substituents in the order of 5.2 (Cl/3’-
Cl) < 5.3 (Cl/3’Br) < 5.5 (I/3’-Cl) < 5.6 (I/3’-Br). Figure 8.10 shows the effects of 
the Rh complexes as catalysts in reduction of benzaldehyde, when combining the 
different X ligands and R substituents. When the X ligands are changed from 
chloride to iodide, their catalytic performance increases from 15% to 42% for 
RhX2(L-3’Cl)2 catalysts, and 28% to 50% for RhX2(L-3’Br)2 catalysts. These 
results could indicate that the X ligands may be the most important factor in their 
catalytic reactivities.  Also, in addition to Rh diiodide complexes having only one 
geometry showing a trans, increases the catalytic activity, with contrast to Rh 
dichloride complexes consisting of cis structure as the major isomer and a mixture 
of few structural isomers in solution. 
 
Figure 8.10 The catalytic effects of Rh complex with different combinations of X 
ligand and R substituent in benzaldehyde reduction 
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8.5.4 Catalytic Activities of MI2(L-R)2 Complexes 
In order to gain structural-activity relationship for catalytic activities of bis-
picolinamide metal dihalide complexes, four selected complexes were used to test 
for catalytic transfer hydrogenation in the reduction of benzaldehyde. These 
complexes vary in their metal centre (M = Ru or Rh) and the R substituents of the 
picolinamide ligands (R = 3’-Cl or 3’-Br) for comparison on their reactivities. 
Figure 8.11 shows the results of complexes 4.7, 4.12, 5.5 and 5.6 from the catalytic 
reactions of benzaldehyde reduction. 
 
 
Figure 8.11 Catalytic activities of MI2(L-R)2 complexes in benzaldehyde reduction 
 
Rh catalysts 5.5 and 5.6 can be seen to have a higher catalytic activity than the Ru 
catalysts 4.7 and 4.12. The percentage conversion for Rh catalysts 5.5 and 5.6 is 
42% and 50% respectively, and for Ru catalysts 4.7 and 4.12 is 31% and 22% 
respectively. Interestingly, there is a contrasting catalytic activity between the two 
groups of metal catalyst, when comparing it along with the different functionalised 
picolinamide ligands. For Ru catalysts, there is a decrease in catalytic activity when 
changing the R substituent from 3’-Cl (catalyst 4.7) to 3’-Br (catalyst 4.12), 
whereas for Rh catalysts, the activity increases from 3’Cl (catalyst 5.5) to 3’-Br 
(catalyst 5.6). These observations have showed that the choices of metals and 
functionalised picolinamide ligands can be used to finely tune the reactivity of bis-
picolinamide metal dihalide catalysts in benzaldehyde reduction. 
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9 Experimental Details 
9.1 General Experimental Procedures 
All ligands and complexes are air stable, and all reactions were carried out in air. All 
chemicals were obtained from Sigma-Aldrich Chemical Co, Acros Organics, Alfa 
Aesar and Strem Chemical Co. and were all used as supplied. Deuterated NMR 
solvents were purchased from Sigma-Aldrich Chemical Co. or Acros Organics. 
 
9.2 Instrumentation 
All NMR spectra were recorded either by the author on a Bruker DPX 300 or DRX 
500 spectrometer, or by Mr. Simon Barrett on a Bruker DRX 500 spectrometer.  
Elemental analyses were acquired by Mr. Ian Blakeley or Ms. Tanya Marinko-Covell 
at the University of Leeds Microanalytical Service. Mass Spectra were recorded either 
by the author on a Bruker maXis impact mass spectrometer or by Ms. Tanya Marinko-
Covell on a Micromass ZMD spectrometer with electrospray ionisation and 
photoiodide array analyser at the University of Leeds Mass Spectrometry Service. 
Infrared spectra were obtained using a Platinum ATR Spectrometer on a crystal plate 
with samples analysed using OPUS software.
1
 Magnetic susceptibilities were 
measured using a Sherwood Scientific Susceptibility at room temperature. UV-Vis 
absorption spectra were recorded on a Cary Series UV-Vis Spectrophotometer using 1 
cm path length quartz cuvettes and a Cary temperature controller. The spectra were 
processed using Cary WinUV software
2
 for Windows 7. Gas chromatography analyses 
were obtained by the author on a Bruker 430-GC System using a Bruker GC capillary 
column with a length of 30 m, a diameter of 0.25 mm and a film thickness of 0.25 µm. 
 
9.3 X-Ray Crystallography 
Single crystal X-ray diffraction data were collected either by the author, Mr. Felix 
Janeway, Dr. Andrea Rodríguez-Bárzano, Dr. Stephanie Lucas or Dr. Helena 
Shepherd. A suitable single crystal was selected and immersed in an inert oil. The 
crystal was then mounted on a glass capillary and attached to a goniometer head on a 
Bruker X8 Apex diffractometer or Agilent SuperNova X-ray diffractometer fitted with 
an Atlas area detector and a kappa-geometry 4-circle goniometer, using graphite 
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monochromated Mo-Kα radiation (λ = 0.71073 Å) using 1.0° ϕ-rotation frames. The 
crystal was cooled to 100-120 K by an Oxford cryostream low temperature device.
3
 
The full data set was recorded and the images processed using DENZO and 
SCALEPACK programs on the Bruker diffractometer, and CrysAlis on the 
SuperNova.
4
 The structures were solved either by the author, Mr. Felix Janeway, Dr. 
Marc Little, Dr. Christopher Pask, or Dr. Helena Shepherd. 
 
Structure solution by direct method was achieved through the use of SHELXS86,
5
 
SIR92
6
 or SIR97
7
 programs and the structural model defined by full matrix least 
squares on F
2
 using SHELX97.
8
 Molecular graphics were plotted using POV-Ray
9
 via 
the XSeed
9
 program. Editing of CIFs and construction of tables and bond lengths and 
angles was achieved using WC
10
 and PLATON,
11
 or Olex2 program.
12
 Unless 
otherwise stated, hydrogen atoms were placed using idealised geometric positions 
(with free rotation for methyl groups), allowed to move in a “riding model” along with 
the atoms to which they are attached, and refined isotropically. SQUEEZE
13
 routine 
was used to remove disordered solvent molecules present in complex 3.7 and 3.12. 
 
9.4 X-Ray Powder Diffraction 
X-Ray powder diffraction data were collected and processed by the author and Dr. 
Christopher Pask, on a Bruker AXS D2Phaser Diffractometer. Powdered samples were 
mounted on a silicon wafer by evenly distributing the powder over the wafer. All 
samples were rotated during data collection to ensure more homogeneous (i.e. 
isotropic) diffraction patterns. Data collection was carried out at room temperature, 
using Cu Kα radiation (λ = 1.54184 Å). Diffraction patterns were recorded in step-scan 
mode with a step size of (2θ) 0.7°, from (2θ) 5° to 50° (5 or 30 secs per step) using a 
0.1 or 0.6mm divergent slit. Samples showed no signiﬁcant evidence of degradation 
within the X-ray beam. The software packages Diffrac.Suite Eva
14
 and Chekcell
15
 
were used to process the experimental powder X-ray diffraction data collected, and 
Mercury
16
 was used to simulate the powder diffraction pattern of the single crystal 
structures. 
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9.5 Preparation of Arene Functionalised Picolinamide Ligands 
The ligands used for complexes 3.1 - 3.10, 3.16 and 4.1 - 4.10 have been previously 
reported,
17, 18
 and were prepared using the same synthetic route, being a modification 
of the published procedure by Bhattacharya et al.
17
 The yields varied in the range 37 - 
69%, and characterisation data of new ligands used for complexes 3.11 - 3.15 and 4.11 
- 4.15 are given in detail. 
 
9.5.1 Pyridine-2-carboxylic acid (2-bromo-phenyl)-amide, C12H9N2OBr 
(2.11) 
2-Bromoaniline (2.74 ml, 25 mmol) was added to a solution of pyridine-2-carboxylic 
acid (3.08 g, 25 mmol) in pyridine (15 ml) and warmed to 50°C for 15 minutes. To this 
mixture, triphenylphosphite (6.60 ml, 25 mmol) was added and heated to 110°C for 18 
hours yielding an orange solution. Addition of water (100 ml) yielded a white paste. 
Dichloromethane (40 ml) was added to the solution and the organic layer separated 
from the aqueous layer. The product in the organic layer was extracted with 1:1 (v/v) 
aqueous HCl (3 x 100 ml). To neutralise the extract, sodium bicarbonate was added 
until pH 7 was reached. A brown solid was isolated by filtration then washed with 
distilled water. After recrystallisation of the product from methanol, washing with 
water and drying in vacuo, pale brown needle-like crystals were obtained. 
Yield: 3.48 g, 12.6 mmol, 50%. ES+MS (CHCl3, 
m/z): 298.98 [M+Na
+
]. Analysis Calculated: C 
52.0%, H 3.3%, N 10.1%, Br 28.8%. Analysis 
Found: C 52.0%, H 3.2%, N 10.3%, Br 28.9%. IR 
(cm
-1
): 3288 (m), 3105 (m), 1691 (s), 1577 (m), 
1503 (m), 1462 (w), 1429 (w), 1375 (s), 1294 (s), 
1227 (w), 1146 (w), 1119 (m), 1072 (s), 1038 (s), 997 (s), 890 (m), 857 (m), 822 (s), 
748 (s), 682 (s), 621 (m), 540 (s). 
1
H NMR (CDCl3, 300.13 MHz, 300K) δ 10.72 (br. 
s, 1H, NH), 8.70 (d, 1H, 
3
J(H-H) = 4.7 Hz, Ha), 8.66 (dd, 1H, 
3
J(H-H) = 8.3 Hz, 
4
J(H-H) = 
1.4 Hz CH of Hd), 8.32 (d, 1H, 
3
J(H-H) = 7.8 Hz, CH of Hh), 7.94 (td, 1H, 
3
J(H-H) = 7.7 
Hz, 
4
J(H-H) = 1.7, Hc), 7.62 (dd, 1H, 
3
J(H-H) = 8 Hz, 
4
J(H-H) = 1.3 Hz, He), 7.53 (ddd, 1H, 
3
J(H-H) = 7.5 Hz, 
4
J(H-H) = 4.8 Hz, 
5
J(H-H) = 1.6 Hz, Hb), 7.40 (m, 1H, CH of Hg/f), 7.04 
(td, 1H, 
3
J(H-H) = 7.7 Hz, 
4
J(H-H) = 1.5 Hz, Hg/f). 
13
C{
1
H} NMR (CDCl3, 75.47 MHz, 
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300 K)  δ 162.28 (C=O), 149.78 (Ci), 148.33 (Ca), 137.64 (Cc), 135.94 (Ck), 132.49 
(Ce), 128.37 (Cg), 126.62 (Cb), 125.13 (Cf), 122.43 (Ch), 121.41 (Cd), 113.90 (C-Br).  
 
9.5.2 Pyridine-2-carboxylic acid (3-bromo-phenyl)-amide, C12H9N2OBr 
(2.12) 
3-Bromoaniline (2.72 ml, 25 mmol) was added to a solution of pyridine-2-carboxylic 
acid (3.08 g, 25 mmol) in pyridine (15 ml) and warmed to 50°C for 15 minutes. To this 
mixture, triphenylphosphite (6.60 ml, 25 mmol) was added and heated to 110°C for 18 
hours yielding an orange solution. Addition of water (100 ml) yielded a white paste. 
Dichloromethane (40 ml) was added to the solution and the organic layer separated 
from the aqueous layer. The product in the organic layer was extracted with 1:1 (v/v) 
aqueous HCl (3 x 100 ml). To neutralise the extract, sodium bicarbonate was added 
until pH 7 was reached. A brown solid was isolated by filtration then washed with 
distilled water. After recrystallisation of the product from methanol, washing with 
water and drying in vacuo, white needle-like crystals were obtained. 
Yield: 3.90 g, 14.1 mmol, 56%. ES+MS 
(CHCl3, m/z): 298.98 [M+Na
+
]. Analysis 
Calculated: C 52.0%, H 3.3%, N 10.1%, Br 
28.8%. Analysis Found: C 52.1%, H 3.2%, N 
10.3%, Br 28.5%. IR (cm
-1
): 3335 (s), 3058 
(m), 1698 (s), 1590 (m), 1537 (m), 1483 (m), 
1402 (m), 1314 (s), 1234 (s), 1160 (w), 1125 (m), 1092 (m), 1038 (m), 997 (s), 897 
(m), 850 (s), 810 (m), 769 (s), 661 (s), 587 (s). 
1
H NMR (CDCl3, 300.13 MHz, 300K) 
δ 10.06 (br. s, 1H, NH), 8.61 (d, 1H, 3J(H-H) = 3.6 Hz, Ha), 8.29 (d, 1H, 
3
J(H-H) = 7.8 Hz, 
Hd), 8.05 (s, 1H, He), 7.92 (t, 1H, 
3
J(H-H) = 7.6 Hz, Hc), 7.69 (d, 1H, 
3
J(H-H) = 7.7 Hz, 
Hf), 7.5 (dd, 1H, 
3
J(H-H) = 7.0 Hz, 
4
J(H-H) = 4.8 Hz, Hb), 7.25 (m, 2H, Hg/h). 
13
C{
1
H} 
NMR (CDCl3, 75.47 MHz, 300 K) δ 161.96 (C=O), 149.37 (Ci), 147.93 (Ca), 139.04 
(Ck), 137.88 (Cc), 130.36 (Cg), 127.30 (Ch), 126.70 (Cb), 122.76 (C-Br), 122.61 (Cd/e), 
118.15 (Cf).  
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9.5.3 Pyridine-2-carboxylic acid (4-bromo-phenyl)-amide, C12H9N2OBr 
(2.13) 
4-Bromoaniline (4.30 g, 25 mmol) was added to a solution of pyridine-2-carboxylic 
acid (3.08 g, 25 mmol) in pyridine (15 ml) and warmed to 50°C for 15 minutes. To this 
mixture, triphenylphosphite (6.60 ml, 25 mmol) was added and heated to 110°C for 18 
hours yielding an orange solution. Addition of water (100 ml) yielded a white paste. 
Dichloromethane (40 ml) was added to the solution and the organic layer separated 
from the aqueous layer. The product in the organic layer was extracted with 1:1 (v/v) 
aqueous HCl (3 x 100 ml). To neutralise the extract, sodium bicarbonate was added 
until pH 7 was reached. A brown solid was isolated by filtration then washed with 
distilled water. After recrystallisation of the product from methanol, washing with 
water and drying in vacuo, white crystals were obtained. 
Yield: 4.78 g, 17.2 mmol, 69%. ES+MS 
(CHCl3, m/z): 298.98 [M+Na
+
]. Analysis 
Calculated: C 52.0%, H 3.3%, N 10.1%, Br 
28.8%. Analysis Found: C 51.8%, H 3.2%, N 
10.4%, Br 28.9%. IR (cm
-1
): 3335 (s), 3058 
(m), 1691 (w), 1590 (w), 1490 (w), 1227 (m), 
1186 (w), 1099 (w), 1038 (w), 997 (m), 816 (m), 688 (m), 614 (s), 506 (s), 486 (m) 
1
H 
NMR (CDCl3, 300.13 MHz, 300K) δ 10.06 (br. s, 1H, NH), 8.63 (d, 1H, 
3
J(H-H) = 4.7 
Hz, Ha), 8.31 (d, 1H, 
3
J(H-H) = 7.8 Hz, Hd), 7.94 (td, 1H, 
3
J(H-H) = 7.7 Hz, 
4
J(H-H) = 1.7 
Hz, Hc), 7.71 (d, 2H, 
3
J(H-H) = 8.8 Hz, He,h), 7.52 (m, 3H, Hb,g,f). 
13
C{
1
H} NMR 
(CDCl3, 75.47 MHz, 300 K)  δ 161.99 (C=O), 149.51 (Ci), 147.98 (Ca), 137.79 (Cc), 
136.85 (Ck), 132.06 (Cb/g/f), 126.63 (Cb/g/f), 122.47 (Cd), 121.21 (Ce,h) 116.87 (C-Br) 
 
9.5.4 Pyridine-2-carboxylic acid (2,4-dibromo-phenyl)-amide, 
C12H9N2OBr2 (2.14) 
2,4-dibromoaniline (6.27 g, 25 mmol) was added to a solution of pyridine-2-carboxylic 
acid (3.08 g, 25 mmol) in pyridine (15 ml) and warmed to 50°C for 15 minutes. To this 
mixture, triphenylphosphite (6.60 ml, 25 mmol) was added and heated to 110°C for 18 
hours yielding an orange solution. Addition of water (100 ml) yielded a white paste. 
Dichloromethane (40 ml) was added to the solution and the organic layer separated 
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from the aqueous layer. The product in the organic layer was extracted with 1:1 (v/v) 
aqueous HCl (3 x 100 ml). To neutralise the extract, sodium bicarbonate was added 
until pH 7 was reached. A brown solid was isolated by filtration then washed with 
distilled water. After recrystallisation of the product from methanol, washing with 
water and drying in vacuo, white needle-like crystals were obtained. 
Yield: 3.83 g, 10.8 mmol, 43%. ES+MS 
(CHCl3, m/z): 378.9 [M+Na
+
]. Analysis 
Calculated: C 40.5%, H 2.3%, N 7.9%, Br 
44.9%. Analysis Found: C 40.6%, H 2.2%, N 
7.7%, Br 44.7%. IR (cm
-1
): 3288 (m), 3112 
(m), 1691 (s), 1563 (m), 1509 (m), 1456 (w), 
1381 (m), 1301 (s), 1234 (w), 1113 (m), 1078 (m), 1038 (s), 997 (m), 890 (m), 863 
(m), 810 (s), 742 (m), 669 (s), 621 (m), 540 (m). 
1
H NMR (CDCl3, 300.13 MHz, 
300K) δ 10.63 (br. s, 1H, NH), 8.60 (d, 1H, 3J(H-H) = 4.7 Hz, Ha), 8.50 (d, 1H, 
3
J(H-H) = 
8.9 Hz, Hd), 8.22 (d, 1H, 
3
J(H-H) = 7.8 Hz, Hg), 7.86 (td, 1H, 
3
J(H-H) = 7.7 Hz, 
4
J(H-H) = 
1.7, Hc), 7.68 (d, 1H, 
3
J(H-H) = 2.3 Hz, He), 7.44 (m, CH of Hb,f). 
13
C{
1
H} NMR 
(CDCl3, 75.47 MHz, 300 K)  δ 162.31 (C=O), 149.50 (Ch), 148.39 (Ca), 137.76 (Cc), 
135.24 (Cj), 134.68 (Ce), 131.43 (Cf),  126.83 (Cb), 122.56 (Cg), 122.27 (Cd), 116.65 
(C-Br), 114.28 (C-Br) 
 
9.5.5 Pyridine-2-carboxylic acid (2,5-dibromo-phenyl)-amide, 
C12H9N2OBr2 (2.15) 
2,5-dibromoaniline (6.27 g, 25 mmol) was added to a solution of pyridine-2-carboxylic 
acid (3.08 g, 25 mmol) in pyridine (15 ml) and warmed to 50°C for 15 minutes. To this 
mixture, triphenylphosphite (6.60 ml, 25 mmol) was added and heated to 110°C for 18 
hours yielding an orange solution. Addition of water (100 ml) yielded a white paste. 
Dichloromethane (40 ml) was added to the solution and the organic layer separated 
from the aqueous layer. The product in the organic layer was extracted with 1:1 (v/v) 
aqueous HCl (3 x 100 ml). To neutralise the extract, sodium bicarbonate was added 
until pH 7 was reached. A brown solid was isolated by filtration then washed with 
distilled water. After recrystallisation of the product from methanol, washing with 
water and drying in vacuo, white needle-like crystals were obtained. 
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Yield: 3.26 g, 9.17 mmol, 37%. ES+MS (CHCl3, 
m/z): 356.90 [M+H
+
]. Analysis Calculated: C 
40.5%, H 2.3%, N 7.9%, Br 44.9%. Analysis 
Found: C 40.6%, H 2.3%, N 7.7%, Br 44.8%. IR 
(cm
-1
): 3301 (s), 3112 (s), 1698 (m), 1570 (m), 
1516 (m), 1288 (m), 1227 (m), 1112 (m), 1018 
(s), 870 (s), 803 (s), 742 (s), 675 (s), 580 (m), 500 (m). 
1
H NMR (CDCl3, 300.13 
MHz, 300K) δ 10.65 (br. s, 1H, NH), 8.82 (d, 1H, 3J(H-H) = 2.4 Hz, Hg), 8.61 (d, 1H, 
3
J(H-H) = 4.7 Hz, Ha), 8.22 (d, 1H, 
3
J(H-H) = 7.8 Hz, Hd), 7.86 (td, 1H, 
3
J(H-H) = 7.7 Hz, 
4
J(H-H) = 1.7, Hc), 7.45 (ddd, 1H, 
3
J(H-H) = 7.6 Hz, 
4
J(H-H) = 4.7 Hz, 
5
J(H-H) = 1.2 Hz, Hb), 
7.38 (d, 1H, 
3
J(H-H) = 8.6 Hz, He), 7.08 (dd, 
3
J(H-H) = 8.5 Hz, 
4
J(H-H) = 2.4 Hz, 1H, Hf). 
13
C{
1
H} NMR (CDCl3, 75.47 MHz, 300 K)  δ 162.31 (C=O), 149.38 (Ch), 148.38 
(Ca), 137.76 (Cc), 137.05 (Cj), 133.36 (Ce), 128.00 (Cf), 126.87 (Cb), 124.01 (Cg), 
122.58 (Cd), 121.25 (C-Br), 112.21 (C-Br). 
 
9.6 Preparation of Bis-Picolinamide Ruthenium Dichloride Complexes 
9.6.1 Bis(N-Ph-picolinamide) ruthenium dichloride, RuC24H19Cl2N4O2 
(3.1) 
Ligand 2.1 (0.336 g, 1.70 mmol) was added to a solution of RuCl3.3H2O (0.215 g, 0.82 
mmol) in ethanol (30 mL), followed by triethylamine (0.086 g, 0.85 mmol). The 
solution was heated under reflux for 2 hours giving a dark red-brown solution. On 
adding pentane, the complex precipitated as brick red-orange solid which was then 
filtered, washed with pentane and dried in vacuo and recrystallised via vapour 
diffusion in methanol-hexane giving red crystals. 
Yield: 0.347 g, 0.60 mmol, 73%. µeff = 1.97 ± 0.12 µβ. ES+MS (CH3OH, m/z): 568.0 
[M+H
+
]. Analysis Calculated: C 46.4; H 4.1; N 9.0%. Analysis found (with 0.75 
molecules of H2O): C 46.9; H 3.60; N 8.9 %. IR (cm
-1
): 3482 (b), 3260 (w), 3200 (m), 
3058 (s), 1617 (b), 1570 (s), 1490 (b), 1449 (b), 1355 (s), 1294 (s), 1146 (s), 1025 (s), 
997 (w), 971 (s), 897 (s), 836 (w), 803 (s), 748 (s), 688 (s), 587 (s), 506 (s) 
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9.6.2 Bis(N-2’-fluoro-Ph-picolinamide) ruthenium dichloride, 
RuC24H17Cl2N4O2F2 (3.2) 
Ligand 2.2 (0.184 g, 0.85 mmol) was added to a solution of RuCl3.3H2O (0.106 g, 0.40 
mmol) in ethanol (30 mL), followed by triethylamine (0.046 g, 0.45 mmol). The 
solution was heated under reflux for 2 hours giving a red-brown solution. On adding 
pentane, the complex precipitated as orange solid which was then filtered, washed with 
pentane, dried in vacuo and recrystallised via vapour diffusion in methanol-pentane 
giving red-orange microcrystals. 
Yield: 0.121 g, 0.20 mmol, 50%. µeff = 1.97 ± 0.12 µβ. ES+MS (CH3OH, m/z): 604.0 
[M+H
+
]. Analysis Calculated: C 45.1; H 3.3; N 8.8%. Analysis found (with 0.67 
molecules of H2O): C 45.1; H 3.3; N 8.6%. IR (cm
-1
): 3489 (b), 3200 (w), 3065 (m), 
1617 (b), 1577 (s), 1496 (s), 1449 (w), 1355 (s), 1301 (s), 1267 (s), 1206 (s), 1153 (s), 
1099 (s), 1031 (s), 964 (s), 917 (s), 863 (s), 755 (s), 682 (s), 601 (s), 547 (w), 519 (w), 
473 (s) 
 
9.6.3 Bis(N-4’-fluoro-Ph-picolinamide) ruthenium dichloride, 
RuC24H17Cl2N4O2F2 (3.3) 
Ligand 2.3 (0.178 g, 0.82 mmol) was added to a solution of RuCl3.3H2O (0.106 g, 0.41 
mmol) in ethanol (30 mL), followed by triethylamine (0.038 g, 0.38 mmol). The 
solution was heated under reflux for 2 hours giving a dark red-brown solution. On 
adding pentane, the complex precipitated as brick orange solid which was then filtered, 
washed with pentane, dried in vacuo and recrystallised via vapour diffusion in 
methanol-pentane giving red crystals. 
Yield: 0.126 g, 0.21 mmol, 51%. µeff = 1.83 ± 0.03 µβ. ES+MS (CH3OH, m/z): 604.0 
[M+H
+
]. Analysis Calculated: C 43.9; H 3.3; N 8.8%. Analysis found (with 0.75 
molecules of H2O): C 44.4; H 3.1; N 8.4%. IR (cm
-1
): 3510 (b), 3254 (w), 3220 (w), 
3058 (m), 1624 (b), 1469 (w), 1409 (s), 1348 (s), 1294 (w), 1234 (s), 1153 (s), 1092 
(w), 1058 (w), 1018 (w), 971 (w), 904 (s), 829 (s), 762 (w), 688 (s), 547 (w), 507 (w), 
493 (w) 
 
Experimental Details  Chapter 9 
187 
9.6.4 Bis(N-2’,4’-difluoro-Ph-picolinamide) ruthenium dichloride, 
RuC24H15Cl2N4O2F4 (3.4) 
Ligand 2.4 (0.187 g, 0.80 mmol) was added to a solution of RuCl3.3H2O (0.102 g, 0.39 
mmol) in ethanol (30 mL), followed by triethylamine (0.040 g, 0.40 mmol). The 
solution was heated under reflux for 2 hours giving a red solution. On adding pentane, 
the complex precipitated as orange solid which was then filtered, washed with pentane, 
dried in vacuo and recrystallised via vapour diffusion in methanol-pentane giving red 
microcrystals. 
Yield: 0.181 g, 0.28 mmol, 72%. µeff = 1.87 ± 0.07 µβ. ES+MS (CH3OH, m/z): 640.0 
[M+H
+
]. Analysis Calculated: C 42.7; H 2.6; N 8.5%. Analysis found (with 0.67 
molecules of H2O): C 43.1; H 2.8; N 8.0%. IR (cm
-1
): 3470 (b), 3220 (w), 3058 (m), 
1611 (b), 1503 (w), 1469 (w), 1429 (w), 1355 (s), 1301 (w), 1260 (w), 1220 (m), 1139 
(s), 1092 (s), 1052 (m), 1031 (m), 964 (s), 924 (m), 850 (m), 803 (m), 755 (m), 735 
(w), 694 (s), 607 (m), 540 (m), 459 (m) 
 
9.6.5 Bis(N-2’,5’-difluoro-Ph-picolinamide) ruthenium dichloride, 
RuC24H15Cl2N4O2F4 (3.5) 
Ligand 2.5 (0.184 g, 0.79 mmol) was added to a solution of RuCl3.3H2O (0.102 g, 0.39 
mmol) in ethanol (30 mL), followed by triethylamine (0.038 g, 0.38 mmol). The 
solution was heated under reflux for 2 hours giving a red-orange solution. On adding 
pentane, the complex precipitated as orange solid which was then filtered, washed with 
pentane, dried in vacuo and recrystallised via vapour diffusion in methanol-pentane 
giving red crystals. 
Yield: 0.070 g, 0.11 mmol, 28%. µeff = 1.96 ± 0.16 µβ. ES+MS (CH3OH, m/z): 641.96 
[M
+
]. Analysis Calculated: C 42.7; H 2.8; N 8.3%. Analysis found (with 0.67 
molecules of H2O): C 43.1; H 3.1; N 8.2%. IR (cm
-1
): 3482 (b), 3207 (w), 3065 (m), 
1584 (b), 1496 (w), 1341 (m), 1241 (m), 1206 (w), 1173 (s), 1099 (s), 1058 (w), 978 
(s), 924 (w), 870 (m), 762 (s), 688 (s), 587 (w), 506 (w), 473 (s). 
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9.6.6 Bis(N-2’-chloro-Ph-picolinamide) ruthenium dichloride, 
RuC24H17Cl4N4O2 (3.6) 
Ligand 2.6 (0.179 g, 0.77 mmol) was added to a solution of RuCl3.3H2O (0.103 g, 0.39 
mmol) in ethanol (30 mL), followed by triethylamine (0.040 g, 0.39 mmol). The 
solution was heated under reflux for 2 hours giving a dark red solution. On adding 
pentane, the complex precipitated as red-orange solid which was then filtered, washed 
with pentane, dried in vacuo and recrystallised via vapour diffusion in methanol-
pentane giving red crystals. 
Yield: 0.146 g, 0.23 mmol, 59%. µeff = 2.21 ± 0.07 µβ. ES+MS (CH3OH, m/z): 637.9 
[M+H
+
]. Analysis Calculated: C 42.9; H 2.9; N 8.6; Cl 21.7%. Analysis found (with 
0.67 molecules of H2O): C 43.4; H 3.1; N 8.1; Cl 22.1%. IR (cm
-1
): 3476 (b), 3220 
(w), 3065 (w), 2856 (w), 1590 (b), 1469 (w), 1442 (w), 1341 (m), 1301 (w), 1260 (w), 
1146 (s), 1052 (s), 1031 (m), 964 (m), 924 (s), 850 (w), 803 (m), 755 (s), 688 (s), 601 
(m), 500 (m), 452 (w) 
 
9.6.7 Bis(N-3’-chloro-Ph-picolinamide) ruthenium dichloride, 
RuC24H17Cl4N4O2 (3.7) 
Ligand 2.7 (0.200 g, 0.86 mmol) was added to a solution of RuCl3.3H2O (0.111 g, 0.42 
mmol) in ethanol (30 mL), followed by triethylamine (0.043 g, 0.42 mmol). The 
solution was heated under reflux for 2 hours giving a dark red-brown solution. On 
adding pentane, the complex precipitated as orange solid which was then filtered, 
washed with pentane, dried in vacuo and recrystallised via vapour diffusion in 
methanol-hexane giving red crystals. 
Yield: 0.149 g, 0.23 mmol, 55%. µeff = 2.40 ± 0.04 µβ. ES+MS (CH3OH, m/z): 637.9 
[M+H
+
]. Analysis Calculated: C 44.1; H 2.9; N 8.6; Cl 21.7%. Analysis found (with 
0.5 molecules of H2O): C 44.0; H 3.2; N 8.3; Cl 21.5%. IR (cm
-1
): 3442 (b), 3254 (w), 
3193 (w), 3065 (m), 1597 (b), 1476 (m), 1435 (w), 1391 (s), 1307 (m), 1260 (m), 1146 
(m), 1065 (w), 965 (m), 883 (m), 762 (s), 675 (s), 594 (w), 513 (w) 
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9.6.8 Bis(N-4’-chloro-Ph-picolinamide) ruthenium dichloride, 
RuC24H17Cl4N4O2 (3.8) 
Ligand 2.8 (0.191 g, 0.82 mmol) was added to a solution of RuCl3.3H2O (0.103 g, 0.39 
mmol) in ethanol (30 mL), followed by triethylamine (0.041 g, 0.41 mmol). The 
solution was heated under reflux for 2 hours giving a red-brown solution. On adding 
pentane, the complex precipitated as brick-orange solid which was then filtered, 
washed with pentane, dried in vacuo and recrystallised via vapour diffusion in 
methanol-pentane giving red microcrystals. 
Yield: 0.070 g, 0.11 mmol, 28%. µeff = 2.08 ± 0.03 µβ. ES+MS (CH3OH, m/z): 637.9 
[M+H
+
]
.
 Analysis Calculated: C 42.9; H 2.9; N 8.6; Cl 21.7%. Analysis found (with 
0.67 molecules of H2O): C 43.2; H 3.0; N 8.1, Cl 21.8%. IR (cm
-1
): 3496 (b), 3247 
(w), 3058 (m), 1584 (b), 1490 (m), 1409 (m), 1355 (m), 1294 (m), 1260 (w), 1241 (w), 
1146 (m), 1085 (s), 1052 (w), 1018 (s), 971 (m), 910 (m), 822 (s), 755 (s), 722 (m), 
688 (s), 506 (s), 466 (w) 
 
9.6.9 Bis(N-2’,4’-dichloro-Ph-picolinamide) ruthenium dichloride, 
RuC24H15Cl6N4O2 (3.9) 
Ligand 2.9 (0.217 g, 0.81 mmol) was added to a solution of RuCl3.3H2O (0.104 g, 0.40 
mmol) in ethanol (30 mL), followed by triethylamine (0.044 g, 0.43 mmol). The 
solution was heated under reflux for 2 hours giving a red-orange solution. On adding 
pentane, the complex precipitated as orange solid which was then filtered, washed with 
pentane, dried in vacuo and recrystallised via vapour diffusion in methanol-pentane 
giving red crystals.  
Yield: 0.120 g, 0.17 mmol, 43%. µeff = 1.99 ± 0.06 µβ. ES+MS (CH3OH, m/z): 705.8 
[M+H
+
]. Analysis Calculated: C 39.9; H 2.4; N 7.8; Cl 29.4%. Analysis found (with 
0.5 molecules of H2O): C 39.7; H 2.5; N 7.6, Cl 29.5%. IR (cm
-1
): 3510 (b), 3207 (w), 
3058 (m), 1590 (b), 1469 (m), 1341 (m), 1301 (w), 1260 (w), 1146 (m), 1099 (s), 1052 
(s), 1025 (w), 964 (w), 917 (m), 857 (m), 803 (m), 762 (s), 688 (m), 560 (w), 526 (m) 
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9.6.10 Bis(N-2’,5’-dichloro-Ph-picolinamide) ruthenium dichloride, 
RuC24H15Cl6N4O2 (3.10) 
Ligand 2.10 (0.218 g, 0.82 mmol) was added to a solution of RuCl3.3H2O (0.104 g, 
0.40 mmol) in ethanol (30 mL), followed by triethylamine (0.044 g, 0.43 mmol). The 
solution was heated under reflux for 2 hours giving an orange solution. On adding 
pentane, the complex precipitated as red-orange solid which was then filtered, washed 
with pentane, dried in vacuo and recrystallised via vapour diffusion in methanol-
pentane giving red microcrystals. 
Yield: 0.113 g, 0.16 mmol, 40%. µeff = 2.53 ± 0.02 µβ. ES+MS (CH3OH, m/z): 705.8 
[M+H
+
]. Analysis Calculated: C 39.9; H 2.4; N 7.9; Cl 30.2%. Analysis found (with 
0.5 molecules of H2O): C 40.6; H 2.9; N 7.5, Cl 30.0%. IR (cm
-1
): 3496 (b), 3200 (w), 
3065 (w), 1577 (b), 1469 (m), 1388 (m), 1334 (m), 1301 (w), 1260 (w), 1139 (m), 
1092 (m), 1052 (m), 964 (m), 931 (m), 890 (w), 863 (w), 803 (s), 762 (s), 688 (s), 594 
(m), 566 (m), 519 (w), 459 (w) 
 
9.6.11 Bis(N-2’-bromo-Ph-picolinamide) ruthenium dichloride, 
RuC24H17Cl2Br2N4O2 (3.11) 
Ligand 2.11 (0.217 g, 0.78 mmol) was added to a solution of RuCl3.3H2O (0.102 g, 
0.39 mmol) in ethanol (30 mL), followed by triethylamine (0.040 g, 0.39 mmol). The 
solution was heated under reflux for 2 hours giving a red-orange solution. On adding 
pentane, the complex precipitated as orange solid which was then filtered, washed with 
pentane, dried in vacuo and recrystallised via vapour diffusion in methanol-pentane 
giving red crystals. 
Yield: 0.131 g, 0.18 mmol, 46%. µeff = 2.02 ± 0.06 µβ. ES+MS (CH3OH, m/z): 725.8 
[M+H
+
]. Analysis Calculated: C 37.9; H 2.8; N 7.4%. Analysis found (with 0.67 
molecules of H2O): C 37.6; H 2.6; N 7.1%. IR (cm
-1
): 3496 (b), 3214 (m), 3065 (m), 
1584 (s), 1476 (s), 1442 (w), 1348 (s), 1307 (s), 1260 (m), 1146 (m), 1052 (s), 971 
(w), 924 (s), 843 (w), 810 (m), 748 (s), 688 (m), 594 (w), 533 (w), 493 (w) 
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9.6.12 Bis(N-3’-bromo-Ph-picolinamide) ruthenium dichloride, 
RuC24H17Cl2Br2N4O2 (3.12) 
Ligand 2.12 (0.229 g, 0.83 mmol) was added to a solution of RuCl3.3H2O (0.106 g, 
0.41 mmol) in ethanol (30 mL), followed by triethylamine (0.042 g, 0.41 mmol). The 
solution was heated under reflux for 2 hours giving a dark red-brown solution. On 
adding pentane, the complex precipitated as brick-orange solid which was then 
filtered, washed with pentane, dried in vacuo and recrystallised via vapour diffusion in 
methanol-pentane giving red crystals. 
Yield: 0.186 g, 0.25 mmol, 61%. µeff = 2.05 ± 0.10 µβ. ES+MS (CH3OH, m/z): 725.8 
[M+H
+
]. Analysis Calculated: C 38.8; H 2.6; N 7.5%. Analysis found (with 0.5 
molecules of H2O): C 38.9; H 2.8; N 7.4%. IR (cm
-1
): 3489 (b), 3254 (w), 3072 (m), 
1570 (b), 1476 (s), 1429 (w), 1348 (s), 1294 (m), 1260 (m), 1146 (m), 1065 (w), 997 
(w), 971 (m), 857 (m), 762 (s), 722 (w), 675 (s), 601 (w), 560 (w), 500 (w) 
 
9.6.13 Bis(N-4’-bromo-Ph-picolinamide) ruthenium dichloride, 
RuC24H17Cl2Br2N4O2 (3.13) 
Ligand 2.13 (0.228 g, 0.82 mmol) was added to a solution of RuCl3.3H2O (0.106 g, 
0.40 mmol) in ethanol (30 mL), followed by triethylamine (0.042 g, 0.41 mmol). The 
solution was heated under reflux for 2 hours giving a dark red solution. On adding 
pentane, the complex precipitated as brick-orange solid which was then filtered, 
washed with pentane, dried in vacuo and recrystallised via vapour diffusion in 
methanol-pentane giving red crystals. 
Yield: 0.126 g, 0.17 mmol, 43%. µeff = 2.04 ± 0.16 µβ. ES+MS (CH3OH, m/z): 725.8 
[M+H
+
]. Analysis Calculated: C 38.8; H 2.6; N 7.5%. Analysis found (with 0.5 
molecules of H2O): C 38.9; H 2.8; N 7.4%. IR (cm
-1
): 3482 (b), 3247 (w), 3072 (m), 
1570 (b), 1490 (m), 1402 (w), 1348 (m), 1288 (m), 1260 (w), 1146 (m), 1065 (m), 
1025 (w), 1004 (s), 964 (w), 910 (w), 822 (s) 755 (s), 688 (s), 513 (s) 
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9.6.14 Bis(N-2’,4’-dibromo-Ph-picolinamide) ruthenium dichloride, 
RuC24H15Cl2Br4N4O2 (3.14) 
Ligand 2.14 (0.291 g, 0.82 mmol) was added to a solution of RuCl3.3H2O (0.106 g, 
0.41 mmol) in ethanol (30 mL), followed by triethylamine (0.041 g, 0.41 mmol). The 
solution was heated under reflux for 2 hours giving a dark red-brown solution. On 
adding pentane, the complex precipitated as bright orange solid which was then 
filtered, washed with pentane, dried in vacuo and recrystallised via vapour diffusion in 
methanol-pentane giving red crystals. 
Yield: 0.186 g, 0.21 mmol, 51%. µeff = 2.10 ± 0.14 µβ. ES+MS (CH3OH, m/z): 882.6 
[M
+
]. Analysis Calculated: C 32.0; H 1.9; N 6.2%. Analysis found (with 0.5 
molecules of H2O): C 31.8; H 2.1; N 5.9%. IR (cm
-1
): 3496 (b), 3200 (w), 3065 (m), 
1584 (b), 1462 (m), 1341 (m), 1301 (m), 1260 (m), 1146 (s), 1072 (s), 1045 (s), 964 
(w), 917 (s), 850 (w), 816 (w), 748 (m), 682 (m), 547 (w), 506 (m) 
 
9.6.15 Bis(N-2’,5’-dibromo-Ph-picolinamide) ruthenium dichloride, 
RuC24H15Cl2Br4N4O2 (3.15) 
Ligand 2.15 (0.281 g, 0.79 mmol) was added to a solution of RuCl3.3H2O (0.103 g, 
0.39 mmol) in ethanol (30 mL), followed by triethylamine (0.040 g, 0.39 mmol). The 
solution was heated under reflux for 2 hours giving a red solution. On adding pentane, 
the complex precipitated as orange solid which was then filtered, washed with pentane, 
dried in vacuo and recrystallised via vapour diffusion in methanol-pentane giving red 
microcrystals. 
Yield: 0.192 g, 0.21 mmol, 54%. µeff = 2.03 ± 0.02 µβ. ES+MS (CH3OH, m/z): 882.6 
[M
+
]. Analysis Calculated: C 32.0; H 1.9; N 6.2%. Analysis found (with 0.5 
molecules of H2O): C 31.8; H 2.2; N 5.9%. IR (cm
-1
): 3510 (b), 3186 (w), 3065 (m), 
1584 (b), 1469 (m), 1388 (m), 1334 (m), 1301 (w), 1267 (w), 1146 (s), 1085 (s), 1031 
(s), 971 (m), 931 (m), 870 (m), 810 (m), 755 (s), 694 (s), 601 (w), 566 (w), 506 (m) 
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9.6.16 Bis(N-2’-iodo-Ph-picolinamide) ruthenium dichloride, 
RuC24H17Cl2I2N4O2 (3.16) 
Ligand 2.16 (0.224 g, 0.81 mmol) was added to a solution of RuCl3.3H2O (0.101 g, 
0.38 mmol) in ethanol (30 mL), followed by triethylamine (0.040 g, 0.40 mmol). The 
solution was heated under reflux for 2 hours giving a dark red solution. On adding 
pentane, the complex precipitated as brick yellow solid which was then filtered, 
washed with pentane, dried in vacuo and recrystallised via vapour diffusion in 
methanol-pentane giving a mixture of red and orange crystals. 
Yield: 0.091 g, 0.13 mmol, 34%. µeff = 2.01 ± 0.01 µβ. ES+MS (CH3OH, m/z): 819.79 
[M
+
]. Analysis Calculated: C 33.7; H 2.5; N 6.6%. Analysis found (with 0.67 
molecules of H2O): C 33.3; H 2.2; N 6.2%. IR (cm
-1
): 3476 (b), 3200 (w), 3051 (m), 
1590 (s), 1556 (s), 1469 (s), 1435 (w), 1341 (m), 1301 (m), 1146 (m), 1018 (m), 917 
(m), 803 (w), 748 (s), 722 (w), 682 (m), 647 (m), 594 (m), 526 (w), 500(m) 
 
9.7 Preparation of Bis-picolinamide Ruthenium Diiodide Complexes 
 
9.7.1 Bis(N-Ph-picolinamide) ruthenium diiodide, RuC24H19I2N4O2 (4.1) 
Ligand 2.1 (0.241 g, 1.21 mmol) was added to a solution of RuCl3.3H2O (0.156 g, 0.60 
mmol) in ethanol (30 mL), followed by triethylamine (0.061 g, 0.60 mmol). The 
solution was heated under reflux for 2 hours giving a dark red-brown solution. An 
excess of potassium iodide (1.014 g, 6.11 mmol) was then added and heated under 
reflux for another 18 hours. The precipitate was filtered, washed with ethanol and 
water, dried in vacuo and recrystallised via vapour diffusion in dimethylformamide-
diethyl ether giving dark coloured microcrystals. 
Yield: 0.260 g, 0.35 mmol, 58%. µeff = 1.68 ± 0.07 µβ. ES+MS (DMF, m/z): 751.9 
[M+H
+
]. Analysis Calculated: C 39.2; H 3.2; N 7.0%. Analysis found (with 0.5 
molecules of C2H6O): C 39.8; H 2.7; N 7.3%. IR (cm
-1
): 3032 (b), 2937 (w), 2836 (b), 
1556 (s), 1544 (s), 1490 (m), 1381 (m), 1355 (m), 1301 (m), 1260 (m), 1173 (w), 1146 
(m), 1018 (w), 964 (w), 931 (m), 903 (m), 843 (w), 803 (w), 755 (s), 688 (s), 594 (m), 
513 (m), 486 (s), 459 (m) 
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9.7.2 Bis(N-2’-fluoro-Ph-picolinamide) ruthenium diiodide, 
RuC24H17I2F2N4O2 (4.2) 
Ligand 2.2 (0.275 g, 1.27 mmol) was added to a solution of RuCl3.3H2O (0.164 g, 0.63 
mmol) in ethanol (30 mL), followed by triethylamine (0.061 g, 0.60 mmol). The 
solution was heated under reflux for 2 hours giving a red-brown solution. An excess of 
potassium iodide (1.058 g, 6.37 mmol) was added to the solution and heated again 
under reflux for 18 hours. The solid was filtered, washed with ethanol and water, dried 
in vacuo and recrystallised via vapour diffusion in dimethylformamide-diethyl ether 
giving dark coloured crystals. 
Yield: 0.289 g, 0.37 mmol, 58%. µeff = 1.71 ± 0.07 µβ. ES+MS (DMF, m/z): 787.9 
[M+H
+
]. Analysis Calculated: C 36.7; H 2.2; N 7.1%. Analysis found: C 36.7; H 2.2; 
N 7.1%. IR (cm
-1
): 3025 (b), 2943 (w), 2854 (b), 1604 (m), 1557 (s), 1488 (s), 1454 
(m), 1358 (m), 1304 (w), 1256 (m), 1215 (w), 1146 (w), 1099 (m), 1023 (w), 969 (w), 
914 (s), 853 (m), 792 (m), 751 (s), 689 (m), 669 (m), 593 (w), 553 (w), 512 (m), 464 
(m), 430 (w) 
 
9.7.3 Bis(N-4’-fluoro-Ph-picolinamide) ruthenium diiodide, 
RuC24H17I2F2N4O2 (4.3) 
Ligand 2.3 (0.261 g, 1.21 mmol) was added to a solution of RuCl3.3H2O (0.158 g, 0.60 
mmol) in ethanol (30 mL), followed by triethylamine (0.061 g, 0.60 mmol). The 
solution was heated under reflux for 2 hours giving a dark red-brown solution. An 
excess of potassium iodide (1.014 g, 6.11 mmol)) was added to the solution and heated 
again under reflux for 18 hours. The solid was filtered, washed with ethanol and water, 
dried in vacuo and recrystallised via vapour diffusion in dimethylformamide-diethyl 
ether giving dark coloured crystals. 
Yield: 0.276 g, 0.35 mmol, 58%. µeff = 1.70 ± 0.09 µβ. ES+MS (DMF, m/z): 787.8 
[M+H
+
]. Analysis Calculated: C 36.7; H 2.2; N 7.1%. Analysis found: C 37.0; H 2.2; 
N 7.0%. IR (cm
-1
): 3038 (b), 2854 (b), 1563 (s), 1502 (s), 1413 (w), 1372 (w), 1345 
(w), 1208 (s), 1146 (m), 1079 (w), 1004 (w), 969 (w), 914 (m), 832 (m), 792 (w), 765 
(s), 689 (m), 609 (m), 539 (m), 491 (m), 402 (w) 
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9.7.4 Bis(N-2’,4’-difluoro-Ph-picolinamide) ruthenium diiodide, 
RuC24H15I2F4N4O2 (4.4) 
Ligand 2.4 (0.276 g, 1.18 mmol) was added to a solution of RuCl3.3H2O (0.151 g, 0.58 
mmol) in ethanol (30 mL), followed by triethylamine (0.061 g, 0.60 mmol). The 
solution was heated under reflux for 2 hours giving a red solution. An excess of 
potassium iodide (0.959 g, 5.78 mmol) was added to the solution and heated again 
under reflux for 18 hours. The solid was filtered, washed with ethanol and water, dried 
in vacuo and recrystallised via vapour diffusion in dimethylformamide-diethyl ether 
giving dark coloured microcrystals. 
Yield: 0.174 g, 0.21 mmol, 36%. µeff = 1.83 ± 0.05 µβ. ES+MS (DMF, m/z): 823.8 
[M+H
+
]. Analysis Calculated: C 35.1; H 1.8; N 6.8%. Analysis found: C 35.1; H 1.8; 
N 6.6%. IR (cm
-1
): 3196 (w), 3052 (w), 2868 (w), 1557 (s), 1495 (s), 1427 (m), 1365 
(m), 1297 (w), 1256 (m), 1140 (s), 1099 (s), 955 (s), 907 (m), 853 (m), 805 (m), 765 
(s), 689 (m), 669 (m), 600 (m), 573 (w), 539 (s), 498 (m), 464 (m), 437 (w) 
 
9.7.5 Bis(N-2’,5’-difluoro-Ph-picolinamide) ruthenium diiodide, 
RuC24H15I2F4N4O2 (4.5) 
Ligand 2.5 (0.38 g, 1.62 mmol) was added to a solution of RuCl3.3H2O (0.20 g, 0.76 
mmol) in ethanol (30 mL), followed by triethylamine (0.076 g, 0.75 mmol). The 
solution was heated under reflux for 2 hours giving a red-orange solution. An excess of 
potassium iodide (1.277 g, 7.70 mmol) was added to the solution and heated again 
under reflux for 18 hours. The solid was filtered, washed with ethanol and water, dried 
in vacuo and recrystallised via vapour diffusion in dimethylformamide-diethyl ether 
giving dark coloured microcrystals. 
Yield: 0.194 g, 0.24 mmol, 32%. µeff = 1.79 ± 0.04 µβ. ES+MS (DMF, m/z): 823.8 
[M+H
+
]. Analysis Calculated: C 35.1; H 1.8; N 6.8%. Analysis found: C 36.0; H 1.8; 
N 6.8%. IR (cm
-1
): 3196 (w), 3045 (w), 2868 (b), 1618 (m), 1577 (s), 1543 (s), 1488 
(s), 1467 (w), 1351 (m), 1304 (w), 1242 (s), 1174 (s), 1133 (m), 1085 (w), 969 (m), 
914 (m), 874 (m), 798 (m), 765 (s), 669 (m), 586 (w), 532 (w), 505 (m), 470 (m), 437 
(m) 
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9.7.6 Bis(N-2’-chloro-Ph-picolinamide) ruthenium diiodide, 
RuC24H17I2Cl2N4O2 (4.6) 
Ligand 2.6 (0.485 g, 2.09 mmol) was added to a solution of RuCl3.3H2O (0.272 g, 1.04 
mmol) in ethanol (30 mL), followed by triethylamine (0.106 g, 1.04 mmol). The 
solution was heated under reflux for 2 hours giving a dark red solution. An excess of 
potassium iodide (1.730 g, 10.42 mmol) was added to the solution and heated again 
under reflux for 18 hours. The solid was filtered, washed with ethanol and water, dried 
in vacuo and recrystallised via vapour diffusion in dimethylformamide-diethyl ether 
giving dark coloured microcrystals. 
Yield: 0.292 g, 0.36 mmol, 34%. µeff = 1.77 ± 0.03 µβ. ES+MS (DMF, m/z): 819.8 
[M
+
]. Analysis Calculated: C 36.1; H 2.7; N 6.5%. Analysis found (with 0.5 
molecules of C2H6O): C 37.1; H 2.2; N 7.1%. IR (cm
-1
): 3215 (w), 3018 (w), 2861 
(w), 1557 (s), 1467 (m), 1441 (m), 1358 (m), 1304 (w), 1256 (w), 1146 (w), 1051 (w), 
962 (w), 914 (s), 798 (w), 689 (m), 593 (w), 532 (w), 498 (m), 457 (m) 
 
9.7.7 Bis(N-3’-chloro-Ph-picolinamide) ruthenium diiodide, 
RuC24H17I2Cl2N4O2 (4.7) 
Ligand 2.7 (0.293 g, 1.26 mmol) was added to a solution of RuCl3.3H2O (0.161 g, 0.62 
mmol) in ethanol (30 mL), followed by triethylamine (0.061 g, 0.61 mmol). The 
solution was heated under reflux for 2 hours giving a dark red-brown solution. An 
excess of potassium iodide (1.029 g, 6.20 mmol) was added to the solution and heated 
again under reflux for 18 hours. The solid was filtered, washed with ethanol and water, 
dried in vacuo and recrystallised via vapour diffusion in dimethylformamide-diethyl 
ether giving dark coloured microcrystals. 
Yield: 0.313 g, 0.38 mmol, 62%. µeff = 1.60 ± 0.09 µβ. ES+MS (DMF, m/z): 841.8 
[M+Na
+
]. Analysis Calculated: C 35.2; H 2.1; N 6.8%. Analysis found: C 34.8; H 
2.1; N 6.7%. IR (cm
-1
): 3038 (b), 2908 (w), 2847 (w), 1563 (s), 1467 (m), 1420 (w), 
1365 (m), 1331 (m), 1297 (w), 1256 (m), 1146 (m), 1072 (m), 983 (w), 935 (w), 874 
(m), 758 (s), 676 (s), 586 (w), 560 (w), 491 (m), 444 (m), 416 (w) 
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9.7.8 Bis(N-4’-chloro-Ph-picolinamide) ruthenium diiodide, 
RuC24H17I2Cl2N4O2 (4.8) 
Ligand 2.8 (0.261 g, 1.21 mmol) was added to a solution of RuCl3.3H2O (0.157 g, 0.60 
mmol) in ethanol (30 mL), followed by triethylamine (0.061 g, 0.60 mmol). The 
solution was heated under reflux for 2 hours giving a red-brown solution. An excess of 
potassium iodide (1.002 g, 6.03 mmol) was added to the solution and heated again 
under reflux for 18 hours. The solid was filtered, washed with ethanol and water, dried 
in vacuo and recrystallised via vapour diffusion in dimethylformamide-diethyl ether 
giving dark coloured microcrystals. 
Yield: 0.293 g, 0.36 mmol, 60%. µeff = 1.77 ± 0.02 µβ. ES+MS (DMF, m/z): 819.8 
[M
+
]. Analysis Calculated: C 35.2; H 2.1; N 6.8%. Analysis found: C 36.0; H 2.1; N 
7.1%. IR (cm
-1
): 3120 (w), 3052 (w), 1563 (s), 1536 (s), 1481 (m), 1406 (w), 1358 
(m), 1290 (w), 1256 (w), 1229 (w), 1140 (w), 1085 (m), 1010 (m), 969 (w), 921 (w), 
819 (s), 765 (s), 723 (m), 689 (m), 505 (s), 470 (m), 437 (m), 416 (m) 
 
9.7.9 Bis(N-2’4’-dichloro-Ph-picolinamide) ruthenium diiodide, 
RuC24H15I2Cl4N4O2 (4.9) 
Ligand 2.9 (0.328 g, 1.23 mmol) was added to a solution of RuCl3.3H2O (0.154 g, 0.59 
mmol) in ethanol (30 mL), followed by triethylamine (0.061 g, 0.60 mmol). The 
solution was heated under reflux for 2 hours giving a red-orange solution. An excess of 
potassium iodide (0.984 g, 5.93 mmol) was added to the solution and heated again 
under reflux for 18 hours. The solid was filtered, washed with ethanol and water, dried 
in vacuo and recrystallised via vapour diffusion in dimethylformamide-diethyl ether 
giving dark coloured microcrystals. 
Yield: 0.231 g, 0.26 mmol, 44%. µeff = 1.67 ± 0.08 µβ. ES+MS (DMF, m/z): 889.7 
[M+H
+
]. Analysis Calculated: C 32.5; H 1.7; N 6.3%. Analysis found: C 32.8; H 1.7; 
N 6.2%. IR (cm
-1
): 3229 (w), 3073 (w), 1597 (s), 1550 (m), 1460 (m), 1379 (w), 1345 
(m), 1249 (w), 1140 (m), 1099 (m), 1051 (m), 969 (w), 914 (w), 888 (w), 853 (s), 819 
(m), 798 (m), 765 (s), 669 (m), 546 (m), 505 (s), 444 (s) 
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9.7.10 Bis(N-2’5’-dichloro-Ph-picolinamide) ruthenium diiodide, 
RuC24H15I2Cl4N4O2 (4.10) 
Ligand 2.10 (0.444 g, 1.66 mmol) was added to a solution of RuCl3.3H2O (0.216 g, 
0.82 mmol) in ethanol (30 mL), followed by triethylamine (0.084 g, 0.83 mmol). The 
solution was heated under reflux for 2 hours giving an orange solution. An excess of 
potassium iodide (1.370 g, 8.26 mmol) was added to the solution and heated again 
under reflux for 18 hours. The solid was filtered, washed with ethanol and water, dried 
in vacuo and recrystallised via vapour diffusion in dimethylformamide-diethyl ether 
giving dark coloured microcrystals. 
Yield: 0.323 g, 0.36 mmol, 44%. µeff = 1.76 ± 0.14 µβ. ES+MS (DMF, m/z): 887.7 
[M
+
]. Analysis Calculated: C 32.5; H 1.7; N 6.3%. Analysis found: C 33.6; H 1.8; N 
6.3%. IR (cm
-1
): 3209 (b), 3052 (w), 2922 (w), 2861 (w), 1583 (s), 1543 (m), 1460 
(m), 1393 (m), 1351 (m), 1311 (w), 1256 (w), 1146 (m), 1099 (m), 1051 (m), 962 (m), 
935 (m), 881 (m), 805 (m), 751 (s), 682 (m), 593 (m), 560 (m), 512 (m), 451 (m) 
 
9.7.11 Bis(N-2’-bromo-Ph-picolinamide) ruthenium diiodide, 
RuC24H15I2Br4N4O2 (4.11) 
Ligand 2.11 (0.358 g, 1.30 mmol) was added to a solution of RuCl3.3H2O (0.167 g, 
0.64 mmol) in ethanol (30 mL), followed by triethylamine (0.068 g, 0.68 mmol). The 
solution was heated under reflux for 2 hours giving a red-orange solution. An excess of 
potassium iodide (1.078 g, 6.49 mmol) was added to the solution and heated again 
under reflux for 18 hours. The solid was filtered, washed with ethanol and water, dried 
in vacuo and recrystallised via vapour diffusion in dimethylformamide-diethyl ether 
giving dark coloured microcrystals. 
Yield: 0.304 g, 0.33 mmol, 52%. µeff = 1.65 ± 0.09 µβ. ES+MS (DMF, m/z): 909.7 
[M+H
+
]. Analysis Calculated: C 31.7; H 1.9; N 6.2%. Analysis found: C 31.9; H 2.1; 
N 6.0%. IR (cm
-1
): 3175 (w), 3045 (w), 1590 (s), 1557 (s), 1467 (m), 1441 (m), 1345 
(m), 1297 (m), 1256 (w), 1140 (w), 1051 (m), 1023 (m), 962 (w), 914 (m), 839 (w), 
798 (w), 751 (s), 716 (w), 682 (m), 593 (w), 525 (m), 484 (m), 444 (m) 
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9.7.12 Bis(N-3’-bromo-Ph-picolinamide) ruthenium diiodide, 
RuC24H15I2Br4N4O2 (4.12) 
Ligand 2.12 (0.357 g, 1.29 mmol) was added to a solution of RuCl3.3H2O (0.167 g, 
0.64 mmol) in ethanol (30 mL), followed by triethylamine (0.068 g, 0.68 mmol). The 
solution was heated under reflux for 2 hours giving a dark red-brown solution. An 
excess of potassium iodide (1.075 g, 6.48 mmol) was added to the solution and heated 
again under reflux for 18 hours. The solid was filtered, washed with ethanol and water, 
dried in vacuo and recrystallised via vapour diffusion in dimethylformamide-diethyl 
ether giving dark coloured crystals. 
Yield: 0.322 g, 0.35 mmol, 55%. µeff = 1.81 ± 0.06 µβ. ES+MS (DMF, m/z): 931.7 
[M+Na
+
]. Analysis Calculated: C 31.7; H 1.9; N 6.2%. Analysis found: C 31.8; H 
1.9; N 6.1%. IR (cm
-1
): 3011 (b), 2854 (w), 1557 (s), 1529 (m), 1467 (m), 1413 (w), 
1365 (m), 1331 (m), 1297 (w), 1256 (m), 1140 (m), 1065 (m), 969 (w), 928 (w), 867 
(m), 758 (s), 669 (s), 586 (w), 546 (w), 491 (m), 437 (m) 
 
9.7.13 Bis(N-4’-bromo-Ph-picolinamide) ruthenium diiodide, 
RuC24H15I2Br4N4O2 (4.13) 
Ligand 2.13 (0.326 g, 1.17 mmol) was added to a solution of RuCl3.3H2O (0.153 g, 
0.59 mmol) in ethanol (30 mL), followed by triethylamine (0.061 g, 0.60 mmol). The 
solution was heated under reflux for 2 hours giving a dark red solution. An excess of 
potassium iodide (1.060 g, 6.39 mmol) was added to the solution and heated again 
under reflux for 18 hours. The solid was filtered, washed with ethanol and water, dried 
in vacuo and recrystallised via vapour diffusion in dimethylformamide-diethyl ether 
giving dark coloured crystals. 
Yield: 0.295 g, 0.32 mmol, 55%. µeff = 1.92 ± 0.05 µβ. ES+MS (DMF, m/z): 909.7 
[M+H
+
]. Analysis Calculated: C 31.7; H 1.9; N 6.2%. Analysis found: C 31.8; H 1.9; 
N 5.9%. IR (cm
-1
): 3236 (w), 3059 (w), 2936 (w), 1550 (s), 1488 (m), 1399 (m), 1358 
(m), 1260 (w), 1297 (w), 1256 (w), 1133 (m), 1055 (m), 1010 (m), 962 (w), 914 (w), 
819 (m), 758 (s), 716 (w), 676 (m), 498 (s), 409 (w) 
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9.7.14 Bis(N-2’,4’-dibromo-Ph-picolinamide) ruthenium diiodide, 
RuC24H15I2Br4N4O2 (4.14) 
Ligand 2.14 (0.436 g, 1.22 mmol) was added to a solution of RuCl3.3H2O (0.156 g, 
0.60 mmol) in ethanol (30 mL), followed by triethylamine (0.061 g, 0.60 mmol). The 
solution was heated under reflux for 2 hours giving a dark red-brown solution. An 
excess of potassium iodide (1.011 g, 6.08 mmol) was added to the solution and heated 
again under reflux for 18 hours. The solid was filtered, washed with ethanol and water, 
dried in vacuo and recrystallised via vapour diffusion in dimethylformamide-diethyl 
ether giving dark coloured microcrystals. 
Yield: 0.472 g, 0.44 mmol, 74%. µeff = 1.68 ± 0.05 µβ. ES+MS (DMF, m/z): 1090.5 
[M+Na
+
+H
+
]. Analysis Calculated: C 27.0; H 1.4; N 5.3%. Analysis found: C 28.2; 
H 1.5; N 5.5%. IR (cm
-1
): 3366 (w), 3209 (w), 3059 (w), 2915 (w), 1583 (s), 1557 
(m), 1460 (m), 1345 (m), 1263 (w), 1133 (w), 1079 (w), 1037 (m), 969 (w), 907 (w), 
846 (w), 805 (m), 765 (m), 669 (m), 546 (w), 498 (m), 444 (m) 
 
9.7.15 Bis(N-2’,5’-dibromo-Ph-picolinamide) ruthenium diiodide, 
RuC24H15I2Br4N4O2 (4.15) 
Ligand 2.15 (0.561 g, 1.58 mmol) was added to a solution of RuCl3.3H2O (0.202 g, 
0.77 mmol) in ethanol (30 mL), followed by triethylamine (0.076 g, 0.75 mmol). The 
solution was heated under reflux for 2 hours giving a red solution. An excess of 
potassium iodide (1.286 g, 7.75 mmol) was added to the solution and heated again 
under reflux for 18 hours. The solid was filtered, washed with ethanol and water, dried 
in vacuo and recrystallised via vapour diffusion in dimethylformamide-diethyl ether 
giving dark coloured microcrystals. 
Yield: 0.269 g, 0.25 mmol, 33%. µeff = 1.85 ± 0.10 µβ. ES+MS (DMF, m/z): 1067.5 
[M+H
+
]. Analysis Calculated: C 27.0; H 1.4; N 5.3%. Analysis found: C 27.6; H 1.4; 
N 5.4%. IR (cm
-1
): 3196 (w), 3052 (w), 2840 (b), 1583 (s), 1543 (m), 1454 (m), 1386 
(m), 1351 (m), 1297 (w), 1146 (m), 1079 (m), 1023 (s), 962 (m), 928 (m), 867 (m), 
798 (s), 758 (s), 682 (s), 600 (m), 505 (s), 451 (s), 409 (w) 
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9.8 Preparation of Bis-picolinamide Rhodium Dihalide Complexes 
 
9.8.1 Bis(N-3’-fluoro-picolinamide) rhodium dichloride, 
RuC24H17Cl2F2N4O2 (5.1) 
3’-fluoro-picolinamide ligand (0.218 g, 1.00 mmol) was added to a solution of RhCl3 
(0.111 g, 0.47 mmol) in ethanol (30 mL), followed by triethylamine (0.07 g, 0.50 
mmol). The solution was heated under reflux for 2 hours giving an orange solution. On 
adding pentane, the complex precipitated as yellow solid which was then filtered, 
washed with pentane, dried in vacuo and recrystallised via vapour diffusion in 
methanol-pentane giving orange crystals. 
Yield: 0.183 g, 0.23 mmol, 49%. ES+MS 
(CH3OH, m/z): 605.0 [M
+
]. Analysis 
Calculated: C 47.6; H 2.8; N 9.3, Cl 11.7%. 
Analysis found: C 47.3; H 3.0; N 8.9; Cl 
11.4%. 
IR (cm
-1
): 3330 (b), 3079 (w), 1563 (s), 1486 
(m), 1475 (m), 1401 (m), 1349 (w), 1305 (w), 
1264 (m), 1189 (w), 1120 (w), 1030 (w), 971 
(w), 907 (w), 865 (m), 761 (s), 706 (m), 676 (s), 593 (w), 518 (m), 457 (m), 448 (w) 
Major isomer: 
1
H NMR (d4-MeOD, 300.13 MHz, 300K) δ 9.81 (d, 1H, 
3
J(H-H) = 5.9 
Hz, Ha), 9.38 (d, 1H, 
3
J(H-H) = 5.5 Hz, Ha’), 8.35 (d, 1H, 
3
J(H-H) = 7.2 Hz, Hd), 8.30 (dd, 
1H, 
3
J(H-H) = 7.7 Hz, 
4
J(H-H) = 1.5 Hz, Hd’), 8.19 (m, 2H, Hc,c’), 7.90 (ddd, 
3
J(H-H) = 7.6 
Hz, 
3
J(H-H) = 5.8 Hz, 
4
J(H-H) = 1.6 Hz, Hb), 7.81 (t, 
3
J(H-H) = 6.5(x2) Hz, Hb’), 7.36 (m, 
3H, He,f,g), 7.03 (m, 2H, Hh,h’), 6.78 (m, 3H, He’,f’,g’) 
13
C{
1
H} NMR (d4-MeOD, 75.47 
MHz, 300 K)  δ 178.4 (C=O of (N,N)-ligand), 174.6 (C=O of (N,O)-ligand), 169.7 
(Ca), 164.4 (Ci), 158.8 (Ci’), 157.3 (Cj), 156.1 (Cj’), 148.9 (Cc), 146.2 (Cc’), 145.0 (Cf), 
132.9 (Cf’), 131.5 (Cb), 128.4 (Cd), 125.2 (Cd’), 119.2 (Cb’), 118.8 (Ce), 118.3 (Cg), 
114.8 (Ca’), 113.8 (Ch), 113.4 (Ce’), 107.2 (C-F of (N,N)-ligand), 106.7 (Cg’), 106.0 (C-
F of (N,O)-ligand), 97.7 (Ch’) Minor isomer: 
1
H NMR (d4-MeOD, 75.47 MHz, 300K) 
δ 9.69 (d, 1H, 3J(H-H) = 5 Hz, Ha), 9.32 (d, 1H, 
3
J(H-H) = 5.2 Hz, Ha’), 8.59 (m, 2H,
 
Hd,d’), 
7.59 (br. m, 9H, Hb/c/e/f/g/b’/c’/e’/f’/g’), 7.19 (d, 2H, 
3
J(H-H) = 6 Hz, Hh,h’), 6.70 (br. m, 1H, 
Hg/g’). 
13
C{
1
H} NMR (d4-MeOD, 75.47 MHz, 300 K)  δ 195.8 (C=O of (N,N)-ligand, 
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190.3 (C=O of (N,O)-ligand), 187.5 (Ci), 180.7 (Ci’), 180.4 (Ca), 177.1 (Cj), 172.4 
(Cj’), 170.8 (Cc), 166.1 (Cc’), 165.3 (Cf), 159.6 (Cf’), 155.8 (Cb), 151.9 (Cd), 146.3 
(Cd’), 141.3 (Cb’), 139.6 (Ce), 129.6 (Cg), 124.2 (Ca’), 117.4 (Ch), 111.9 (C-F of (N,N)-
ligand), 109.2 (C-F of (N,O)-ligand), 105.1 (Ce’), 94.1 (Cg’), 90.9 (Ch’) 
 
9.8.2 Bis(N-3’-chloro-picolinamide) rhodium dichloride, RuC24H17Cl4N4O2 
(5.2) 
Ligand 2.7 (0.221 g, 0.951 mmol) was added to a solution of RhCl3 (0.112 g, 0.47 
mmol) in ethanol (30 mL), followed by triethylamine (0.06 g, 0.48 mmol). The 
solution was heated under reflux for 2 hours giving a yellow solution. On adding 
pentane, the complex precipitated as yellow solid which was then filtered, washed with 
pentane, dried in vacuo and recrystallised via vapour diffusion in methanol-pentane 
giving yellow microcrystals. 
Yield: 0.185 g, 0.29 mmol, 62%. ES+MS (CH3OH, m/z): 636.9 [M+H
+
]. Analysis 
Calculated: C 40.7; H 3.0; N 7.9; Cl 25.1%. Analysis found (0.33 molecules of H2O 
and Cl): C 40.0; H 2.9; N 7.4; Cl 25.5%. 
IR (cm
-1
): 3287 (b), 3086 (w), 1563 (s), 1479 
(m), 1428 (w), 1357 (w), 1305 (w), 1297 (w), 
1189 (w), 1155 (w), 1098 (w), 1059 (w), 974 
(w), 886 (m), 763 (m), 676 (s), 603 (w), 516 
(w), 447 (m). 
Major isomer:
 1
H NMR (d6-MeOD, 300.13 
MHz, 300K) δ 9.69 (d, 1H, 3J(H-H) = 5.7 Hz, 
Ha), 9.29 (d, 1H, 
3
J(H-H) = 5.5 Hz, Ha’), 8.31 
(d, 1H, 
3
J(H-H) = 7.9 Hz, Hd), 8.21 (td, 2H, 
3
J(H-
H) = 7.6 Hz, 
4
J(H-H) = 1.3, Hb’,c’), 8.14 (m, 1H, Hd’), 8.09 (m, 2H, Hb,c), 7.80 (m, 3H, 
He,f,g), 7.50 (s, 1H, Hh), 7.41 (s, 1H, Hh’), 6.80 (m, 3H, He’,f’,g’). 
13
C{
1
H} NMR (d4-
MeOD, 75.47 MHz, 300 K)  δ 195.4 (C=O of (N,N)-ligand), 194.2 (C=O of (N,O)-
ligand), 190.4 (Ci), 185.7 (Cj), 185.5 (Cj’), 179.9 (Ci’), 178.5 (Ca), 173.7 (Cc), 167.5 
(Cf), 157.4 (Cc’), 154.1 (Cf’), 151.3 (Ce), 141.5 (Cb,d), 137.8 (Cg), 135.1 (Cb’,d’), 131.2 
(Ca’), 128.9 (Ch), 128.1 (Ce’), 126.7 (Cg’), 124.1 (Ch’), 119.7 (C-Cl of (N,N)-ligand), 
117.5 (C-Cl of (N,O)-ligand). Minor isomer: 
1
H NMR (d6-MeOD, 300.13 MHz, 
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300K) δ 9.65 (d, 1H, 3J(H-H) = 5.1 Hz, Ha), 9.46 (d, 1H, 
3
J(H-H) = 5.6 Hz, Ha’), 8.66 (d, 
1H, 
3
J(H-H) = 7.6 Hz, Hd), 8.50 (t, 1H, 
3
J(H-H) = 7(x2) Hz, Hc), 8.39 (t, 1H, 
3
J(H-H) = 
8.4(x2) Hz, Hb), 8.01 (d, 1H, 
3
J(H-H) = 7.6 Hz Hd’), 7.93 (m, 2H, Hb’,c’), 7.86 (s, 1H, 
Hh), 7.75 (s, 1H, Hh’), 7.45 (m, 1H, He), 7.30 (br. m, 2H, Hg,f), 7.09 (br. m, 2H, Hg’,f’), 
6.97 (br. m, 1H, He’). 
13
C{
1
H} NMR (d4-MeOD, 75.47 MHz, 300 K) δ 194.7 (C=O of 
(N,N)-ligand), 193.3 (C=O of (N,O)-ligand), 188.9 (Ca), 184.3 (Ci), 181.7 (Cj), 175.1 
(Ci’), 174.1 (Cj’), 168.3 (Cc), 165.5 (Cc’), 163.5 (Cf), 160.0 (Cf’), 154.8 (Ce), 153.2 
(Ca’), 148.2 (Cb), 140.2 (Cd), 133.2 (Cg), 129.7 (Cb’), 125.9 (Cd’), 123.9 (Cg,h), 114.7 
(C-Cl of (N,N)-ligand), 110.7 (C-Cl of (N,O)-ligand), 107.3 (Cg’,h’). 
 
9.8.3 Bis(N-3’-bromo-picolinamide) rhodium dichloride, 
RuC24H17Cl2Br2N4O2 (5.3) 
Ligand 2.12 (0.276 g, 1.00 mmol) was added to a solution of RhCl3 (0.104 g, 0.50 
mmol) in ethanol (30 mL), followed by triethylamine (0.05 g, 0.53 mmol). The 
solution was heated under reflux for 2 hours giving an orange solution. On adding 
pentane, the complex precipitated as yellow solid which was then filtered, washed with 
pentane, dried in vacuo and recrystallised via vapour diffusion in methanol-pentane 
giving a mixture of red and orange crystals, and yellow microcrystals. 
Yield: 0.183 g, 0.25 mmol, 50%. ES+MS (CH3OH, m/z): 726.8 [M+H
+
]. Analysis 
Calculated: C 39.7; H 2.4; N 7.7%. Analysis found: C 39.4; H 2.4; N 7.5%. 
IR (cm
-1
): Red 2997 (w), 2915 (w), 2759 (b), 1543 (s), 1467 (m), 1427 (w), 1338 (m), 
1297 (w), 1256 (m), 1146 (m), 1058 (m), 969 (m), 928 (w), 860 (m), 778 (m), 751 (m), 
682 (s), 593 (w), 567 (w), 512 (m), 484 (m), 437 (m); Orange 3189 (w), 3052 (b), 
2980 (w), 1618 (m), 1590 (m), 1562 (s), 1469 (m), 1420 (w), 1389 (w), 1344 (w), 
1297 (w), 1229 (m), 1153 (w), 1085 (w), 1058 (w), 983 (m), 907 (w), 860 (m), 758 (s), 
672 (s), 600 (w), 553 (w), 512 (m), 470 (w), 430 (w); Yellow 3380 (b), 3209 (b), 3066 
(w), 1618 (s), 1598 (s), 1568 (s), 1466 (m), 1433 (w), 1413 (w), 1390 (w), 1340 (w), 
1311 (w), 1260 (w), 1151 (w), 1062 (w), 1025 (w), 999 (w), 966 (w), 922 (w), 896 
(w), 860 (m), 776 (s), 758 (s), 723 (w), 677 (s), 601 (w), 561 (w), 548 (w), 498 (w), 
475 (m), 435 (m), 415 (w). 
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Major isomer:
 1
H NMR (d6-CH3CO, 300.13 
MHz, 300K) δ 9.85 (d, 1H, 3J(H-H) = 5.6 Hz, 
Ha), 9.39 (d, 1H, 
3
J(H-H) = 5.6 Hz, Ha’), 8.57 (d, 
1H, 
3
J(H-H) = 7.8 Hz, Hd), 8.29 (dtd, 2H, 
3
J(H-H) 
= 10.4 Hz, 
3
J(H-H) = 7.8 Hz, 
4
J(H-H) = 1.5 Hz, 
Hc,c’), 8.14 (m, 1H, Hd’), 7.95 (ddd, 1H, 
3
J(H-H) 
= 7.8 Hz, 
3
J(H-H) = 5.5 Hz, 
4
J(H-H) = 1.2 Hz, Hb), 
7.90 (ddd, 1H, 
3
J(H-H) = 7.6 Hz, 
3
J(H-H) = 5.7 
Hz, 
4
J(H-H) = 1.6 Hz, Hb’), 7.83 (t, 1H, 
3
J(H-H) = 
2(x2) Hz, Hh), 7.64 (ddd, 1H, 
3
J(H-H) = 8.1 Hz, 
3
J(H-H) = 2.1 Hz, 
4
J(H-H) =0.9 Hz, He), 
7.45 (ddd, 1H, 
3
J(H-H) = 8.0 Hz, 
3
J(H-H) = 1.9 Hz, 
4
J(H-H) = 1 Hz, Hg), 7.34 (t, 1H, 
3
J(H-H) = 
8.1(x2) Hz, Hf), 7.18 (t, 1H, 
3
J(H-H) = 1.9(x2) Hz, Hh’), 7.01 (m, 2H, He’,g’), 6.86 (m, 
1H, Hf’). 
13
C{
1
H} NMR (d6-CH3CO, 75.47 MHz, 300 K) δ 199.2 (C=O of (N,N)-
ligand), 197.2 (Ca), 194.1 (C=O of (N,O)-ligand), 188.6 (Ci), 168.7 (Ci’), 153.3 (Ca’), 
152.7 (Cj), 151.7 (Cj’), 139.6 (Cc), 139.4 (Cc’), 130.8 (Cb’), 130.5 (Cf), 130.1 (Ce), 
129.9 (Cb), 129.6 (Cg), 129.2 (Cg’), 126.9 (Ce’), 126.3 (Cf’,h’), 125.5 (Cd), 125.3 (Cd’), 
121.5 (Ch), 121.2 (C-Br of (N,N)-ligand), 120.8 (C-Br of (N,O)-ligand). 
Minor isomer 1: 
1
H NMR (d6-CH3CO, 300.13 MHz, 300K) δ 9.46 (d, 1H, 
3
J(H-H) = 5.6 
Hz, Ha), 8.91 (d, 1H, 
3
J(H-H) = 5.2 Hz, Ha’), 8.04 (dd, 1H, 
3
J(H-H) = 3.0 Hz, 
4
J(H-H) = 1.4 
Hz, Hb), 7.8 (d, 1H, 
3
J(H-H) = 1.9 Hz, Hd), 7.75 (m, 2H, Hc,d’), 7.73 (m, 1H, Hc’), 7.68 
(ddd, 1H, 
3
J(H-H) = 7.5 Hz, 
3
J(H-H) = 5.7 Hz, 
4
J(H-H) = 1.5 Hz , Hb’), 7.14 (t, 2H, 
3
J(H-H) = 
1.9(x2) Hz, Hf,g), 7.12 (m, 1H, He), 7.05 (m, 2H, He’,g’), 6.97 (s, 1H, Hh), 6.93 (s, 1H, 
Hh’), 6.91 (m, 1H, Hf’). 
13
C{
1
H} NMR (d6-CH3CO, 75.47 MHz, 300 K)  δ 209.0 (C=O 
of (N,N)-ligand), 201.1 (C=O of (N,O)-ligand), 195.4 (Ca), 192.2 (Ca’), 161.2 (Cc), 
159.5 (Ci), 156.8 (Ci’), 155.7 (Cc’), 149.7 (Cj), 146.1 (Cj’), 143.6 (Cb), 141.6 (Cf), 138.5 
(Ce), 136.2 (Cb’), 134.0 (Cg), 133.3 (Cg’), 132.7 (Ce), 131.7 (Ch), 127.2 (Cf’), 123.6 
(Cd), 120.7 (C-Br of (N,N)-ligand), 120.3 (Cd’) 118.4 (C-Br of (N,O)-ligand), 115.4 
(Ch’). Minor isomer 2: 
1
H NMR (d6-CH3CO, 300.13 MHz, 300K) δ 9.70 (d, 1H, 
3
J(H-H) 
= 5.4 Hz, Ha), 9.50 (d, 1H, 
3
J(H-H) = 5.8 Hz, Ha’), 8.72 (d, 1H, 
3
J(H-H) = 8.6 Hz, Hd), 8.39 
(m, 1H, Hc), 8.09 (m, 1H, Hb), 8.05 (dd, 1H, 
3
J(H-H) = 3.1 Hz, 
4
J(H-H) = 1.4 Hz, Hb’/c’), 
8.02 (dd, 1H, 
3
J(H-H) = 3.1 Hz, 
4
J(H-H) = 1.4 Hz, Hb’/c’), 7.99 (d, 1H, 
3
J(H-H) = 7.3 Hz, 
Hd’), 7.86 (m, 1H, Hg), 7.78 (d, 1H, 
3
J(H-H) = 1.5 Hz, Hh), 7.55 (m, 1H, He), 7.51 (m, 
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1H, Hf), 7.39 (t, 1H, 
3
J(H-H) = 1.9(x2) Hz, Hh’), 7.37 (t, 1H, 
3
J(H-H) = 2(x2) Hz, Hg’), 7.15 
(m, 1H, Hf’), 7.07 (dd, 1H, 
3
J(H-H) = 1.9 Hz, 
4
J(H-H) = 1.1 Hz, He’). 
13
C{
1
H} NMR (d6-
CH3CO, 75.47 MHz, 300 K)  δ 203.2 (C=O of (N,N)-ligand), 196.5 (C=O of (N,O)-
ligand), 190.4 (Ca), 186.6 (Ca’), 183.6 (Ci), 156.1 (Cj), 154.0 (Cc), 147 (Ci’), 145.7 
(Cc’), 143.3 (Cj’), 137.8 (Cb), 135.8 (Cf), 134.5 (Ce), 131.1 (Cf’), 127.9 (Ce’), 125.0 
(Cb’), 119.3 (Cd), 117.6 (Cg), 116.5 (Cd’), 115.7 (Cg’), 114.3 (C-Br of (N,N)-ligand), 
112.8 (Ch), 110.9 (C-Br of (N,O)-ligand), 109.3 (Ch’) 
 
9.8.4 Bis(N-3’-iodo-picolinamide) rhodium dichloride, RuC24H17Cl2I2N4O2 
(5.4) 
3’-Iodo-picolinamide (0.322 g, 1.00 mmol) was added to a solution of RhCl3 (0.117 g, 
0.49 mmol) in ethanol (30 mL), followed by triethylamine (0.07 g, 0.50 mmol). The 
solution heated under reflux for 2 hours giving a yellow solution. On adding pentane, 
the complex precipitated as yellow solid which was then filtered, washed with pentane, 
dried in vacuo and recrystallised via vapour diffusion in methanol-pentane giving red 
crystals. 
Yield: 0.294 g, 0.36 mmol, 73%. ES+MS 
(CH3OH, m/z): 820.8 [M+H
+
]. Analysis 
Calculated: C 34.4; H 2.3; N 6.7%. Analysis 
found (with 0.5 molecules of H2O): C 34.0; H 
2.2; N 6.3%. 
IR (cm
-1
): 3236 (b), 3091 (w), 1564 (s), 1469 
(m), 1418 (w), 1302 (w), 1270 (w), 1155 (w), 
1063 (w), 1028 (w), 995 (w), 860 (w), 764 (m), 
681 (s), 601 (w), 515 (w), 437 (w) 
Major isomer:
 1
H NMR (d4-MeOD, 300.13 MHz, 300K) δ 9.83 (d, 1H, 
3
J(H-H) = 5.6 
Hz, Ha), 9.42 (d, 1H, 
3
J(H-H) = 5.2 Hz, Ha’), 8.43 (d, 1H, 
3
J(H-H) = 8.7 Hz, Hd), 8.35 (d, 
1H, 
3
J(H-H) = 8.7 Hz, Hd’), 8.28 (td, 1H, 
3
J(H-H) = 8.0(x2) Hz, 
4
J(H-H) = 1 Hz, Hc), 8.01 
(dd, 2H, 
3
J(H-H) = 8.4(x2) Hz, 
3
J(H-H) = 1.5 Hz, Hb,b’), 7.94 (m, 1H, Hc’), 7.79 (m, 1H, 
Hf), 7.71 (m, 2H, He,g), 7.37 (s, 1H, Hh), 7.19 (m, 3H, He’,f’,g’), 6.83 (s, 1H, Hh’). 
13
C{
1
H} NMR (d4-MeOD, 75.47 MHz, 300 K)  δ 192.0 (C=O of (N,N)-ligand), 190.2 
(Ca), 188.50 (C=O of (N,O)-ligand), 173.6 (Ca’), 158.0 (Ci), 155.7 (Cj), 154.7 (Cb,c), 
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141.6 (Ci’), 139.7 (Cj’), 137.6 (Cc’), 137.4 (Cb’), 135.8 (Cf), 135.3 (Ce), 134.7 (Cf’), 
133.1 (Cg), 132.3 (Cg’), 131.6 (Ce’), 130.1 (Cd), 126.4 (Ch), 124.9 (Cd’), 121.4 (C-I of 
(N,N)-ligand), 118.6 (C-I of (N,O)-ligand), 112.9 (Ch’). Minor isomer: 
1
H NMR (d4-
MeOD, 300.13 MHz, 300K) δ 9.16 (d, 1H, 3J(H-H) = 5.3 Hz, Ha), 9.03 (d, 1H, 
3
J(H-H) = 
5.2 Hz, Ha’), 8.29 (dd, 2H, 
3
J(H-H) = 7.8 Hz, 
4
J(H-H) = 1.6 Hz, Hb,b’), 8.08 (d, 1H, 
3
J(H-H) = 
8.3 Hz, Hd), 7.81 (m, 2H, Hc,c’), 7.73 (d, 1H, 
3
J(H-H) = 6.2 Hz, Hd’), 7.69 (br. m, 3H, 
He,f,g), 7.45 (s, 1H, Hh), 7.32 (d, 1H, 
3
J(H-H) = 7.1 Hz, He’), 7.21 (d, 1H, 
3
J(H-H) = 7.7 Hz, 
Hg’), 7.00 (s, 1H, Hh’), 6.95 (br. m, 1H, Hf’). 
13
C{
1
H} NMR (d4-MeOD, 75.47 MHz, 
300 K) δ 178.6 (C=O of (N,N)-ligand), 178.3 (Ca), 177.6 (C=O of (N,O)-ligand), 176.1 
(Ci), 174.6 (Cj), 157.6 (Ca’), 144.3 (Ci), 143.5 (Cj’), 140.4 (Cb), 139.3 (Cc’), 139.0 (Cb’), 
136.2 (Cf), 136.1 (Ce), 135.2 (Cf’), 133.7 (Cg), 132.8 (Cg’), 127.0 (Ce), 126.3 (Cf), 
125.5 (Ch), 122.8 (Cd), 122.0 (Cd’), 117.8 (C-I of (N,N)-ligand), 117.6 (Ch), 116.0 (C-I 
of (N,O)-ligand) 
 
9.8.5 Bis(N-3’-chloro-picolinamide) rhodium diiodide, RuC24H17I2Cl2N4O2 
(5.5) 
Ligand 2.7 (0.213 g, 0.92 mmol) was added to a solution of RhCl3 (0.103 g, 0.43 
mmol) in ethanol (30 mL), followed by triethylamine (0.06 g, 0.46 mmol). The 
solution was heated under reflux for 2 hours giving a yellow solution. An excess of 
potassium iodide (0.721 g, 4.35 mmol) was added to the solution and heated again 
under reflux for 18 hours. The dark brown solid was filtered, washed with ethanol and 
water, dried in vacuo and recrystallised via vapour diffusion in dimethylformamide-
diethyl ether giving red crystals. 
Yield: 0.160 g, 0.19 mmol, 45%. ES+MS 
(DMF, m/z): 820.8 [M+H
+
]. Analysis 
Calculated: C 36.2; H 2.9; N 7.8%. Analysis 
found (with 0.33 molecules of DMF and H2O) : 
C 36.2; H 2.6; N 7.7%. 
IR (cm
-1
): 3054 (b), 2865 (w), 1567 (s), 1471 
(m), 1427 (w), 1343 (m), 1305 (m), 1258 (m), 
1155 (m), 1074 (m), 981 (w), 875 (m), 760 (s), 
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676 (m), 613 (w), 497 (m), 440 (m) 
1
H NMR (d4-MeOD, 300.13 MHz, 300K) δ 9.62 (d, 1H, 
3
J(H-H) = 5.6 Hz, Ha), 8.45 (d, 
1H, 
3
J(H-H) = 4.9 Hz, Ha’), 7.77 (td, 1H, 
3
J(H-H) = 7.8(x2) Hz, Hb), 7.71 (m, 1H, Hc), 7.66 
(m, 1H, Hd), 7.42 (dd, 1H, 
3
J(H-H) = 8.2 Hz, 
3
J(H-H) = 1.4 Hz, Hd’), 7.36 (m, 1H, Hc’), 
7.29 (ddd, 1H 
3
J(H-H) = 7.4 Hz, 
3
J(H-H) = 5.8 Hz, 
4
J(H-H) = 2 Hz, Hb’), 7.00 (s, 1H, Hh), 
6.87 (t, 1H, 
3
J(H-H) = 7.1(x2) Hz, Hf), 6.7 (m, 5H, He,g,e’,f’,g’), 6.6 (s, 1H, Hh’). 
13
C{
1
H} 
NMR (d4-MeOD, 75.47 MHz, 300 K)  δ 194.2 (C=O of (N,N)-ligand), 192.50 (C=O of 
(N,O)-ligand), 191.6 (Ca), 174.2 (Ca’), 172.8 (Ci), 167.9 (Cj), 159.9 (Ci’), 157.6 (Cj’), 
147.6 (Cc), 147.1 (Cc’), 135.7 (Cb), 133.4 (Cf), 132.3 (Ce), 130.5 (Cb’), 129.1 (Cg), 
128.7 (Cg’), 128.1 (Ce), 127.0 (Ch’), 125.3 (Cf’), 122.0 (Cd), 118.8 (C-Cl of (N,N)-
ligand), 117.5 (Cd’), 117.3 (Ch), 116.5 (C-Cl of (N,O)-ligand). 
 
9.8.6 Bis(N-3’-bromo-picolinamide) rhodium diiodide, RuC24H17I2Br2N4O2 
(5.6) 
Ligand 2.12 (0.254 g, 0.91 mmol) was added to a solution of RhCl3 (0.115 g, 0.48 
mmol) in ethanol (30 mL), followed by triethylamine (0.06 g, 0.46 mmol). The 
solution heated under reflux for 2 hours giving an orange solution. An excess of 
potassium iodide (0.819 g, 4.93 mmol) was added to the solution and heated again 
under reflux for 18 hours. The dark brown solid was filtered, washed with ethanol and 
water, dried in vacuo and recrystallised via vapour diffusion in dimethylformamide-
diethyl ether giving dark coloured microcrystals. 
Yield: 0.156 g, 0.17 mmol, 36%. ES+MS 
(DMF, m/z): 908.7 [M+H
+
]. Analysis 
Calculated: C 26.8; H 1.6; N 5.2%. Analysis 
found (0.5 molecules of KI): C 27.2; H 1.7; N 
5.0%. 
IR (cm
-1
): 3044 (b), 2919 (w), 1544 (s), 1468 
(m), 1430 (w), 1343 (m), 1298 (m), 1263 (m), 
1148 (m), 1059 (w), 996 (w), 924 (w), 862 (m), 
783 (m), 778 (m), 678 (s), 600 (w), 562 (w), 516 
(m), 514 (m), 437 (m) 
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1
H NMR (d4-MeOD, 300.13 MHz, 300K) δ 9.96 (d, 1H, 
3
J(H-H) = 5.3 Hz, Ha), 9.62 (d, 
1H, 
3
J(H-H) = 5.0 Hz, Ha’), 8.41 (d, 1H, 
3
J(H-H) = 7.6 Hz, Hd), 8.09 (m, 1H, Hb), 7.92 (d, 
1H, 
3
J(H-H) = 7.9 Hz, Hd’), 7.73 (td, 1H, 
3
J(H-H) = 7.6(x2) Hz, 
4
J(H-H) = 1.8 Hz, Hb’), 7.42 
(m, 2H, Hc,c’), 7.31 (dd, 1H, 
3
J(H-H) = 6.5 Hz, 
4
J(H-H) = 4.8 Hz, Hh), 7.18 (t, 1H, 
3
J(H-H) = 
8.5(x2) Hz, Hf), 7.01 (m, 2H, He,g), 6.91 (d, 1H, 
3
J(H-H) = 8.3 Hz, He’). 6.87 (m, 2H, 
Hf’,g’), 6.76 (s, 1H, Hh’). 
13
C{
1
H} NMR (d4-MeOD, 75.47 MHz, 300 K)  δ 193.7 (C=O 
of (N,N)-ligand), 192.3 (Ca), 192.0 (C=O of (N,O)-ligand), 188.3 (Ci), 179.2 (Ca’), 
173.4 (Cj), 163.0 (Ci’), 147.9 (Cj’), 142.5 (Cb), 138.9 (Cb’,c’), 138.3 (Cc), 136.8 (Cf), 
130.8 (Ce), 130.2 (Cg), 129.8 (Cf’), 128.9 (Cg’), 128.2 (Ce’), 126.7 (Ch), 124.2 (Cd), 
123.4 (Cd’), 122.0 (C-Br of (N,N)-ligand), 117.4 (Ch’), 116.6 (C-Br of (N,O)-ligand) 
 
9.9 Preparation of Bis(N-3’-bromo-Ph-picolinamide) ruthenium diaqua, 
RuC24H21Br2N4O4[2SbF6] (8.1) 
A solution of AgSbF6 (0.110 g, 0.320 mmol) in acetone (1 mL) was added to a solution 
of complex 3.12 (0.102 g, 0.141 mmol) in dichloromethane (25 mL). The suspension 
was stirred overnight in the dark, and the AgCl formed was filtered off. The resulting 
solution was evaporated to dryness to obtain an oily residue which was recrystallised 
by stirring with diethyl ether. 
Yield: 0.098 g, 0.08 mmol, 60%. ES+MS (CH3OH, m/z): 689.8 [M+H
+
]. Analysis 
Calculated: C 24.8; H 1.8; N 4.8%. Analysis found: C 24.6; H 1.9; N 4.2%. IR (cm
-
1
): 3284 (w), 3073 (w), 2950 (w), 1557 (s), 1467 (m), 1427 (w), 1338 (w), 1263 (w), 
1229 (w), 1153 (w), 1120 (w), 1065 (w), 1030 (w), 976 (w), 765 (s), 669 (m), 593 (m), 
430 (m) 
 
9.10 Cell Culture Work 
9.10.1 General Experimental Procedures 
The in vitro tests were performed at the Institute of Cancer Therapeutics, Bradford, on 
A2780 (human ovarian adenocarcinoma), A2780cis (human ovarian cisplatin resistant 
adenocarcinoma) and HT-29 (human colon adenocarcinoma) cell lines. Standard 
sterile techniques were used throughout this work.  Chemicals were purchased through 
Sigma Aldrich and were used as supplied. The stock cultures were grown in T-75 
flasks containing RPMI-1640 complete cell medium (20 mL) and incubated at 37 °C 
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with 5.0 % CO2.  The complete media was prepared from RPMI-1640 Incomplete 
Media (500 mL), sodium pyruvate (5 mL, 0.5 mmol), L-glutamine (5 mL, 1.0 mmol) 
and foetal bovine serum (50 mL).  HANKS Balanced Salt Solution was used to wash 
the cells, and 0.25 % Trypsin-EDTA solution was used to detach the rest of the cells 
from the flask. RPMI-1640 incomplete media, RPMI-1640 complete media, sodium 
pyruvate, MTT and MTT stock solutions were all stored at 4 °C.  L-glutamine, foetal 
bovine serum and 0.25 % trypsin-EDTA solution were all stored at -20 °C.  All 
chemicals except the MTT stock solution were incubated at 37 °C prior to use. 
 
9.10.2 Cell Passaging 
Cells were washed with HANKS Balanced Salt Solution (3 x 10 mL), and were 
carefully removed so no salt solution remained in the flask. 0.25 % Trypsin-EDTA 
solution (5 mL) was added and the T-75 flask was incubated at 37 °C for 5 minutes.  
When the cells were lifted and become detached from the flask wall, cell media (10 
mL) was added.  Two new flasks were prepared with cell suspension (0.5 mL) and cell 
media (20 mL) added to each.  The lids of the flask were cracked and transferred into 
the incubator. 
 
9.10.3 Cell Counting 
After cells were trypsinised, each cell suspension (10 L) was transferred to a 
haemocytometer, onto each side of the glass slide.  Cells were counted under the 
microscope in five squares of the haemocytometer and an average was taken with units 
of 10
4
 cells/mL. 
 
9.10.4 MTT Solution 
The MTT stock solution (5 mg/mL) was prepared by dissolving MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (250 mg) in distilled water 
(50 mL), then passing through a 0.2 m sterile filter. 
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9.10.5 The 5-day Cytotoxic Study (Normoxic Conditions) 
The cell suspension was diluted with RPMI-1640 complete media to give a 
concentration of 2 X 10
4
 cells/mL. A 96-well plate was used and 100 L of cell media 
was added to lane one, to serve as a blank.  100 L of the diluted cell suspension was 
then added to lanes 2 to 12, and were incubated for 24 hours at 37°C in an atmosphere 
of 5.0% CO2 prior to drug exposure. The drugs to be tested were dissolved in 
dimethylsulfoxide and diluted further with media to obtain drug solutions ranging from 
250 to 0.49 μM. The ﬁnal dimethylsulfoxide concentration was 0.1% (v/v) which is 
non-toxic to cells. Drug solutions were applied to cells and incubated for five days at 
37 °C in an atmosphere of 5% CO2. Cell survival was determined using the MTT assay 
and MTT (20 µL of a 5mg/ml stock) was added to each well and incubated for 3 hours 
at 37°C in an atmosphere of 5% CO2. The solutions were then removed and 150 μL of 
dimethylsulfoxide was added to each well to dissolve the purple formazan crystals. 
 
9.10.6 Data Analysis 
A Thermo Scientific Multiskan EX microplate photometer was used to measure the 
absorbance at 540 nm. Lanes containing medium only and cells in medium (no drug) 
were used as blanks and 100% cell survival respectively. Cell survival was determined 
as the absorbance of treated cells divided by the absorbance of controls and expressed 
as a percentage. The IC50 values were determined from plots of % survival against 
drug concentration. Each experiment was repeated three times, to give the mean of 
IC50 values and standard deviations. 
 
9.11 The 5-day Cytotoxic Study (Hypoxic Conditions) 
The hypoxic studies were carried out in a Don Whitley Scientific H35 Hypoxystation, 
with the oxygen level set at 0.1%, on HT-29 (human colon adenocarcinoma) cell lines. 
RPMI-1640 complete media was conditioned for at least 24 hours in 0.1% O2 
atmosphere prior to start of the experiment. HT-29 colon cancer cells were cultured in 
a 96-well plate and incubated overnight at 37 °C with 0.1% O2 atmosphere. The cells 
were then exposed to different concentrations of the drugs to be tested, with a range 
from 250 µM to 0.49 µM, and incubated for five days at 37 °C with 0.1% O2 
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atmosphere. Cell survival was then determined using the MTT assay as described 
previously. 
 
9.12 Mechanistic studies 
9.12.1 Hydrolysis studies 
A calibration curve was prepared for each complex by dissolving in either 10% of 
methanol or DMF, and diluting it further with deionised water. The concentrations 
used were 100, 80, 60, 40 and 20 µM. The maximum absorbance (λmax) was taken to 
plot the calibration curve of concentration against absorbance. Hydrolysis samples 
were prepared by dissolving complexes 3.3, 3.5, 3.7, 3.10, 3.12 and 3.14 in 10% 
methanol for RuCl2L2 complexes, and complexes 4.7, 4.10, 4.11 and 4.12 in 10% 
DMF for RuI2L2 complexes, followed by the addition of 90% deionised water to give a 
final concentration of 50 µM. These aqueous solutions were scanned every 24 hours 
by UV-Visible Spectrophotoscopy over five days at 293 K. The concentration of each 
complex every 24 hours was determined using its individual calibration curve. The 
following formula is used to calculate the percentage of hydrolysed complex, 
 
9.12.2 Hydrophobicity tests 
A calibration curve was prepared for each complex by dissolving the complexes in 
octanol, and diluting it further to obtain the concentrations of 100, 80, 60, 40 and 20 
µM. The maximum absorbance (λmax) was taken to plot the calibration curve of 
concentration against absorbance. Equal amounts of octanol and deionised water 
(containing 300mM NaCl to prevent complexes from undergoing hydrolysis) were 
stirred overnight for saturation and separated to obtain water-saturated octanol and 
octanol-saturated water solutions. Approximately 1 mg of complexes 3.2, 3.3, 3.5, 3.7, 
3.10, 3.11, 3.12, 3.13 and 3.14 were dissolved in 25 ml of water-saturated octanol as 
stock solution, and sonicated for complete dissolution. Six independent samples were 
prepared for each complex by adding 2 ml of octanol-saturated water, followed by 2 
ml of the stock solution containing ruthenium complexes in each labelled 15 ml Falcon 
tubes. The samples were then shaken using the IKA Vibrax VXC basic shaker at 500 
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g/min for 4 hours. Organic (octanol) layer of the stock solution and from the six 
independent samples were taken for analysis on UV-Visible spectrophotometry. The 
concentration of each complex was determined using its individual calibration curve. 
The following formula is used to calculate the partition coefficient of the complexes 
(Log P), 
 
 
 
9.13 Catalytic Benzaldehyde Reduction 
Isopropanol (10 ml) was added to the selected complexes (0.01 mmol Ru/Rh) in a 
carousel tube, followed by the addition of triethylamine (0.01 ml, 0.08 mmol). The 
mixture was stirred at reflux for 30 mins in order to pre-activate the catalyst. 
Benzaldehyde (0.1 ml, 1 mmol) was then added and the reaction was left to stir at 
reflux for 24 hours. Where monitoring of reaction was performed, 250 µl of the 
reaction sample was taken at 1, 3, 5, 7, 9 and 24 hours while maintaining the reflux. A 
stock solution of acetonitrile containing 0.1 mmol external standard, n-decane, was 
prepared. The samples taken from the reaction were dissolved in 1.5 ml of the 
acetonitrile stock solution for gas chromatography analysis.  
 
Prior to GC analysis of the samples, benzaldehyde (0.1 ml, 1 mmol) and benzylalcohol 
(0.1 ml, 1 mmol) in 1.5ml of acetonitrile stock solution were run to obtain the response 
factor using the following formula, 
 
The retention times for benzaldehyde, n-decane and benzylalcohol was 4.13, 4.40 and 
4.71 minutes respectively, and the response factors for benzaldehyde and 
benzylalcohol were 1.91 and 1.10 respectively. The following formula was used for 
the calculation of percentage conversion, 
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9.14 Attempted Techniques for Separation of Pure Isomers 
9.14.1 Column Chromatography 
Recrystallised product of Ru complex was dissolved in methanol and subjected to 
column chromatography containing silica (10g) packed with the respective apolar 
solvent. Orange, dark red, light brown and light red bands were collected separately. 
The extracts were evaporated giving very low yield of coloured precipitates. The 
precipitates were recrystallised in methanol, however, a mixture of different shapes 
and colours of the few crystals were still obtained. The following is a list for the 
combination of apolar and polar solvents used with different ratios, after separation of 
few spots was seen on a TLC plate. 
 
Apolar solvent Polar solvent Ratio (apolar:polar) 
CHCl3 - - 
CHCl3 CH3CN 1:9, 1:4, 3:1 
- CH3CN - 
- EtOAc - 
Hexane EtOAc 1:9, 1:4, 3:1, 2:3, 1:1 
C6H6 CH3CN 1:1 
Diethyl ether - - 
Diethyl ether CHCl3 1:9, 1:4, 3:1, 2:3, 1:1 
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9.14.2 Syntheses following Krause and Krause Procedure 
The attempted syntheses were followed using the same synthetic route of the published 
procedure by Krause and Krause.
19
 
Isomer 1 
Ligand 2.12 (0.346 g, 1.25 mmol) was added to a solution of RuCl3.3H2O (0.160 g, 
0.61 mmol) in ethanol (30 mL), followed by triethylamine (0.08 g, 0.63 mmol). The 
solution was heated under reflux for 2 hours giving a dark red solution. After cooling 
of the mixture, the red-orange precipitate was filtered and washed with ethanol and 
diethyl ether, and dried in vacuo. 0.1 g of the precipitate was finely ground, mixed 
with toluene and heated under reflux (30 mL) for 1 hour. The dark red precipitate was 
filtered hot, washed with diethyl ether, and dried in vacuo. Few spots were observed 
on TLC plate. 
Yield: 0.134 g, 0.19 mmol, 30%. ES+MS (DMSO, m/z): 725.82 [M
+
]. 
IR (cm
-1
): 3067 (b), 2887 (w), 1608 (s), 1472 (m), 1414 (w), 1340 (m), 1298 (w), 1258 
(m), 1134 (m), 1084 (w), 969 (w), 921 (w), 860 (s), 780 (s), 674 (s), 598 (w), 470 (m) 
 
Isomer 2 
Ligand 2.12 (0.189 g, 0.68 mmol) was added to a solution of RuCl2(DMSO)4 (0.164 g, 
0.34 mmol) in acetone (30 mL). The solution was heated under reflux for 18 hours 
giving a dark coloured solution. Upon cooling of the mixture, the orange precipitate 
was filtered, washed with acetone and dried in vacuo. Product expected: RuCl2L2. 
Product obtained: RuCl2L(DMSO)2 
Yield: 0.053 g, 0.09 mmol, 26%. ES+MS (DMSO, m/z): 606.9 [M+H
+
]. Analysis 
Calculated: C 31.7; H 3.5; N 4.6%. Analysis found: C 31.9; H 3.5; N 4.5%. 
IR (cm
-1
): 3016 (b), 2891 (w), 1600 (m), 1575 (m), 1546 (m), 1479 (m), 1430 (m), 
1336 (w), 1302 (w), 1287 (w), 1260 (w), 1236 (w), 1195 (w), 1165 (w), 1135 (w), 
1086 (s), 1057 (w), 1008 (m), 961 (w), 924 (w), 866 (w), 804 (w), 790 (m), 757 (m), 
712 (w), 679 (m), 591 (m), 547 (m), 446 (w), 424 (w). 
1
H NMR (d6-DMSO, 300.13 MHz, 300K) δ 11.95 (br. s, 1H, NH), 10.34 (d, 1H, 
3
J(H-
H) = 5.5 Hz, pyridyl CH ortho to N), 8.73 (d, 1H, 
3
J(H-H) = 8.0 Hz, pyridyl H meta to N, 
ortho to amide), 8.34 (t, 1H, 
3
J(H-H) = 7.2(x2) Hz, pyridyl CH para to N), 7.98 (t, 1H, 
3
J(H-H) = 6.5(x2) Hz, pyridyl CH para to amide), 7.93 (s, 1H, CH ortho to Br and 
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CONH), 7.63 (d, 1H, 
3
J(H-H) = 8.2 Hz, CH ortho to CONH), 7.58 (m, 1H, CH meta to 
CONH),  7.53 (m, 1H, CH para to CONH), 3.37 (s, 6H, 2CH3 of DMSO ligand), 3.31 
(s, 6H, 2CH3 of DMSO ligand) 
 
Isomer 3 
Product obtained from ‘Isomer 2’ (0.0814 g, 0.13 mmol) was mixed with 30 ml of 
xylenes and heated under reflux for 3 hours. When the reaction is cooled, the brown 
precipitate was filtered, washed with diethyl ether and dried in vacuo. 
Product expected: RuCl2L2. Product obtained: RuCl2L(DMSO)2 
Yield: 0.037 g, 0.06 mmol, 47%. ES+MS (DMSO, m/z): 606.9 [M+H
+
]. 
IR (cm
-1
): 3023 (b), 2885 (w), 1592 (w), 1472 (w), 14156 (w), 1369 (w), 1196 (w), 
1134 (w), 1086 (s), 995 (w), 926 (w), 868 (w), 788 (m), 757 (m), 679 (m), 590 (w), 
546 (w), 429 (w). 
1
H NMR (d6-DMSO, 300.13 MHz, 300K) δ 11.94 (br. s, 1H, NH), 10.33 (d, 1H, 
3
J(H-
H) = 5.5 Hz, pyridyl CH ortho to N), 8.72 (d, 1H, 
3
J(H-H) = 8.0 Hz, pyridyl H meta to N, 
ortho to amide), 8.33 (t, 1H, 
3
J(H-H) = 7.2(x2) Hz, pyridyl CH para to N), 7.98 (t, 1H, 
3
J(H-H) = 6.5(x2) Hz, pyridyl CH para to amide), 7.92 (s, 1H, CH ortho to Br and 
CONH), 7.62 (d, 1H, 
3
J(H-H) = 8.2 Hz, CH ortho to CONH), 7.54 (m, 2H, CH meta to 
CONH & CH para to CONH), 3.36 (s, 6H, 2CH3 of DMSO ligand), 3.30 (s, 6H, 2CH3 
of DMSO ligand) 
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9.14.3 Extraction with Solvents 
To several fractions of the Ru product, were washed with a range of solvents to obtain 
coloured filtrates, which were then evaporated to obtain coloured precipitates. The 
products were recrystallised via vapour diffusion in methanol/pentane to obtain 
crystals. The following is the list of solvents used for the attempted technique. 
 
Solvents 
Observation 
(colour of filtrate; precipitate; recystallised product) 
Diethyl ether Colourless filtrate 
Pentane Colourless filtrate 
Petrol Colourless filtrate 
Toluene Slightly yellow filtrate; No precipitate obtained. 
Dichloromethane Orange filtrate; Red-orange precipitate; No product 
obtained after recrystallisation. 
Chloroform Orange filtrate; Red precipitate; Red-orange precipitate 
after recrystallisation; Few spots were observed on TLC 
Ethanol Red-orange filtrate; Red-orange precipitate; Mixture of red 
block and orange microcrystals after recrystallisation 
Ethyl Acetate Light orange filtrate; No precipitate obtained 
THF Light orange filtrate; Dark coloured precipitate; Very low 
yield after recrystallisation 
Acetone Orange filtrate; No precipitate obtained 
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10 Conclusions and Future Work 
 
10.1 Conclusions 
The peptide chemistry of amide ligands is of importance due to their biological role 
that includes protein construction and maintenance. Five novel functionalised 
picolinamide ligands have been synthesised using the general procedure from picolinic 
acid and substituted anilines. These ligands have been fully characterised by IR, NMR, 
mass spectrometry and elemental analysis, and where suitable crystals were obtained, 
analysed for x-ray crystallography, as described in Chapter 2. Their crystal structures 
have shown that these ligands adopt an almost planar configuration with a twist 
between the two planes of pyridyl ring and the aniline ring, giving a degree of 
flexibility to incorporate with metal centres either by N,N- or N,O- coordination. 
 
A library of novel functionalised bis-picolinamide ruthenium (III) dichloride 
complexes have been successfully synthesised and fully characterised using IR, ES-
MS, elemental analysis and single crystal X-Ray diffraction, where suitable crystals 
were obtained, as described in Chapter 3. These complexes were all prepared by using 
the same procedure and recrystallised by vapour diffusion, either from 
methanol/hexane or methanol/pentane. Three different types of structural isomers, 
which are the cis-cis-cis, cis-trans-cis and trans-trans-trans structural isomers were 
obtained, and have shown a distorted octahedral geometry about the ruthenium metal 
centre. Isomerisation studies on complex 3.7 showed insignificant changes over time 
and within a range of temperature. Powder diffraction patterns of complex 3.7 did not 
match between the bulk powder samples and crystal structures. There have been many 
attempts to separate the pure isomers, however has been unsuccessful. Despite the 
different structural isomers obtained, complex 3.1 - 3.16 have been tested against 
various cancer cell lines for an indication as potential anti-cancer agents, reported in 
Chapter 6. Selected Ru dichloride complexes were also tested as catalysts in 
benzaldehyde reduction, described in Chapter 8.  
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There have been few studies in investigating the effects of trans geometry, also when 
changing the leaving group of metal complexes towards biological activities. The 
diiodide analogues of bis-picolinamide ruthenium (III) dichloride complexes have 
been synthesised, by a halide exchange reaction with an excess of solid potassium 
iodide. They were characterised using IR, ES-MS, elemental analysis, and x-ray 
diffraction. Two different types of structural isomers were found for the ruthenium 
diiodide analogue, which are the trans-trans-trans and trans-cis-cis structural isomers. 
Bis-picolinamide Ru diiodide complexes have been studied for isomerisation in DMF 
solution by UV-Vis spectrophotometry, and as powder samples by powder diffraction. 
No changes were observed in their uv-vis spectra over a period of time and also, when 
decreasing temperature from 100°C to 0°C. Comparison between a diffractogram 
simulated from single crystal data of the ruthenium diiodide complex and a 
diffractogram recorded from its powder sample have also shown no differences in their 
peaks, and very well matches the unit cell between both data, showing the evidence of 
stability for trans-ruthenium diiodide complexes both in solution and powder. These 
complexes are tested against A2780 and HT-29 cancer cell lines for cytotoxicity to 
determine their potential as anti-cancer agents (Chapter 6), as well as, their application 
as catalysts in benzaldehyde reduction (Chapter 8). 
 
Novel bis-picolinamide rhodium (III) dihalide complexes with meta-functionalisation 
on the phenyl ring of the picolinamide ligands were also synthesised and characterised 
in Chapter 5. These complexes are the analogues of the bis-picolinamide ruthenium 
dihalide complexes and were prepared to specifically study the possible isomerisation 
of the complex, both in solid state and in solution. The rhodium complexes were 
synthesised following the same procedure as the preparation of the ruthenium 
analogues, and were crystallised either with methanol/pentane or 
dimethylformamide/ether. Two different types of structural isomers were obtained, 
which are the cis-trans-cis for the rhodium dichloride complexes, and trans-trans-
trans for the rhodium diiodide complexes. The 
1
H NMR studies of the rhodium 
dichloride complex 5.3 have shown to have a mixture of isomers with different ratios 
when in solution. The highest ratio obtained is that of the cis-trans-cis complex. These 
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isomers are found to be stable and do not undergo any structural changes over days at 
room temperature. The changes of shifts and signals seen in the NMR temperature-
dependant study were the possible stacking of the complex molecules. The signals 
showed broad peaks when at low temperature and sharpens when the temperature is 
increased, as the molecules became separated from each other. The 
1
H NMR spectrum 
of complex 5.3 is in contrast with the rhodium diiodide complex 5.5 which has only 
shown one possible structure in solution, which is the trans-trans-trans. Powder 
diffraction studies on both complexes 5.3 and 5.5, however, were inconclusive as to 
insufficient data obtained. Although, the diffractograms of complex 5.5 have shown a 
similar pattern and may possibly have only one structural geometry both in the powder 
sample and in solution.  Bis-picolinamide rhodium complexes 5.1 - 5.6 were tested for 
their catalytic applications in benzaldehyde reduction with comparison to the 
ruthenium analogues, and these are reported in Chapter 8. Due to limited access to 
perform cell culture studies at Institute Cancer Therapeutics, Bradford, rhodium 
dihalide complexes were not tested for cytotoxicity in this thesis. 
 
A series of functionalised bis-picolinamide ruthenium dihalide complexes were tested 
for cytotoxicity against three different cancer cell lines, A2780 ovarian, A2780cis 
ovarian cisplatin-resistant and HT-29 colon cancer cell lines. Their cytotoxicity was 
determined following the general procedure used at the cell culture lab, which is a 5-
day drug exposure MTT assay. Shorter incubation times often shows a very low 
potency of the drug, hence 5-day incubation time was used in the assay. This assay 
allowed the IC50 values of the drugs to be calculated. The cytotoxicity of bis-
picolinamide ruthenium dihalide complexes is affected by the halide ligands that are 
bonded to the ruthenium metal centre, as most of the ruthenium diiodide complexes 
are seen to be highly potent than their chloride analogues. The different halide 
substituents attached on the phenyl ring of the picolinamide ligands are dependent on 
their position on the ring. Complexes with meta or para chloro and bromo substituents 
are more cytotoxic when compared with other functionalised complexes in the series. 
The complexes are also seen to be selective in different cancer cell lines. Some of the 
complexes have increased in their anti-cancer activity when in the HT-29 cell line, 
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suggesting that they are specific for targeting cancer cells. From the hypoxic 
cytotoxicity studies, the activities of the complexes are seen to be comparable to 
cisplatin and TPZ. They are also potent under both normoxic and hypoxic conditions, 
suggesting that they are independent towards the hypoxic environment. Complexes 4.8 
and 4.13 are the two most promising anti-cancer complexes in the series of bis-
picolinamide ruthenium dihalide complexes.  
 
Following the cytotoxicity studies on bis-picolinamide ruthenium dihalide complexes 
against A2780 ovarian and HT-29 colon cancer cell lines, selected complexes from 
this series were examined for further structural-activity relationship studies. 
Hydrolysis and hydrophobicity tests have been conducted for the selected complexes 
with interesting results and observations. The UV-Vis hydrolysis study taken over a 
period of five days showed changes of peak intensity and absorbances, indicating that 
substitution reactions have taken place between the monosubstituted halide ligands 
attached on the ruthenium metal centre of the neutral complex and water molecules 
from the aqueous sample solution. The exchange of ligands was confirmed by ESI-MS 
analysis at day 5 which has shown the presence of di-aqua and mono-aqua ruthenium 
complexes. Their fitted kinetic curve between time and percentage of hydrolysed 
complex have shown that the ruthenium dichloride complexes are very well correlated 
with their cytotoxic activity whereby the most cytotoxic complex hydrolyses more and 
undergoes the fastest hydrolysis. This is in contrast with the ruthenium diiodide 
complexes which have shown the opposite correlation, by which the most cytotoxic 
complex undergoes the least hydrolysis after five days. These results suggest that 
hydrolysis may be one of the major mechanisms in anti-cancer activity for ruthenium 
dichloride complexes, but may not be for the diiodide analogues. Ruthenium 
dichloride complexes have shown to have hydrophobic properties with acceptable log 
P values according to Lipinski’s rule of five and Hansch’s principle of minimum 
hydrophobicity, suggesting that these complexes may possibly enter the cells by 
passive diffusion. Although, there are very few correlations observed between the 
cytotoxicity and log P values of the ruthenium dichloride complexes, which are not as 
comparable as the platinum complexes that have shown their cytotoxicity increases 
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with increasing hydrophobicity. This could also suggest that the cell uptake 
mechanism of bis-picolinamide ruthenium dichloride complexes may not relate to their 
cytotoxic anti-cancer activities. The potential for the complexes to bind with specific 
transporters within the cell membrane may contribute to their cell uptake mechanism 
that could also relate to their cytotoxic activity.  
 
Several bis-picolinamide metal dihalide complexes have been studied as catalysts in 
the reduction of benzaldehyde. The reactions were performed in an excess of 
isopropanol in the presence of a base, Et3N, and heated under reflux for 24 hours. The 
complexes that were selected for the studies have several components that can be used 
to investigate their structural-activity relationship in catalytic benzaldehyde reductions. 
Both the starting materials, RuCl3.3H2O and RuCl3.3H2O have showed no activities in 
the reaction. Whereas, when picolinamide ligands are coordinated to the metal centre, 
their catalytic activities increase depending on the halide ligands that are attached to 
the metal centre, and the halide substituents that are attached on the phenyl ring of the 
picolinamide ligands. In general, the diiodide analogues of the catalysts are more 
active than the dichloride analogues. In combination of the dihalide ligands with the 
appropriate functionalised picolinamide ligands can improve their catalytic activities. 
However, having a halide substituent at the meta position on the phenyl ring of the 
picolinamide ligands only showed low to moderate catalytic activities. The highest 
percentage conversion is seen for complex 4.9 that consists of diiodide ligands and bis-
2’,4’dichloro picolinamide ligands coordinated to the Ru metal centre. There is a 
contrasting activity seen between Ru and Rh catalysts, whereby their catalytic 
activities are affected by different components of the catalysts. Ru catalyst may be 
largely affected by the different functionalised picolinamide ligands (Figure 8.6), 
whereas Rh catalysts have showed more difference when changing the X ligands 
(Figure 8.10). 
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10.2 Future Work 
Further analysis for the structural isomers of bis-picolinamide ruthenium dihalide 
complexes will include variable-dependant solution studies by Electron Paramagnetic 
Resonance (EPR) spectroscopy. This is to investigate whether the complexes undergo 
isomerisation when in solution over time and temperature. Further attempts to separate 
the mixtures of isomers are necessary to obtain pure products of each isomer for 
further study in structural characterisation. As for bis-picolinamide rhodium dihalide 
complexes, the attempt to obtain single crystals of different molecular structural 
isomers can give more data in comparison with the collected data for 
1
H NMR 
characterisation and PXRD powder diffraction studies. Cytotoxicity studies on bis-
picolinamide rhodium dihalide complexes will also be added as future work for studies 
as comparison with its ruthenium analogue.  
 
Bis-picolinamide ruthenium dihalide complexes are novel and little is known about 
ruthenium complexes with trans-dihalide ligands that are potent both in normoxic and 
hypoxic conditions. Further studies on bis-picolinamide ruthenium dihalide complexes 
can develop towards a better understanding on their structural-activity relationships as 
potential anti-cancer drugs. The studies may include isolating the ruthenium aqua 
complex, followed by cytotoxicity study, to further prove that hydrolysis is one of its 
anti-cancer mechanisms. Also, time-dependant cell uptake studies in order to measure 
the pharmacokinetics of the drug by measuring the intracellular concentration for 
prolonged incubation time. Temperature-dependant cell uptake studies is also 
important to indicate the transport mechanism of the drug into the cells, either passive 
diffusion or active transport. Another study that will be helpful is cell fractionation 
study, in order to determine the major drug distribution within the cells that could 
relate to its anti-cancer activity: cytoplasm (e.g. mitochondria), cell membrane (e.g. 
protein receptor), nucleus (e.g. DNA binding) and cytoskeleton (e.g. tubulin 
polymerisation). In vivo drug accumulation in an experimental model is also an 
important study to aim for clinical potential anti-cancer drugs, especially for complex 
4.13 which is the most potent in the series of bis-picolinamide ruthenium dihalide 
complexes. 
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Catalytic work on the ruthenium and rhodium dihalide complexes is the initial step of 
bis-picolinamide Ru and Rh complexes towards catalytic applications. In order to 
extend this work further, various studies could include catalytic screening for a larger 
library of bis-picolinamide Ru and Rh catalysts in order to have a better understanding 
in the correlation between the structure and activity. As well as, catalytic study of 
different transfer hydrogenation reactions, for example reductions in acetophenone, or 
redox neutral alkylation of tert-butylamine 
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Crystal data and structure refinement for Ligand 2.13 
 
Formula C12H9BrN2O 
Formula weight 277.12 
Size 0.27 x 0.24 x 0.06 mm 
Crystal morphology Colourless Prism 
Temperature 150(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Triclinic 
Space group P1 
Unit cell dimensions a = 6.3232(10) Å  = 89.585(10)° 
 b = 8.2665(15) Å  = 87.599(9)° 
 c = 11.1055(19) Å  = 78.366(10)° 
Volume 568.07(17) Å
3
 
Z 2 
Density (calculated) 1.62 Mg/m
3
 
Absorption coefficient 3.597 mm
-1
 
F(000) 276 
Data collection range 1.84  30.22° 
Index ranges -8  h 8,  -11  k  11,  -15  l  15 
Reflections collected 19736 
Independent reflections 3323 [R(int) = 0.1295] 
Observed reflections 1653 [I >2(I)] 
Absorption correction none 
Max. and min. transmission 0.8131 and 0.4435 
Refinement method Full 
Data / restraints / parameters 3323 / 0 / 145 
Goodness of fit 1.045 
Final R indices  [I >2(I)] R1 = 0.0953, wR2 = 0.2291 
R indices (all data) R1 = 0.1859, wR2 = 0.287 
Largest diff. peak and hole 2.096 and -1.586e.Å
-3 
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Crystal data and structure refinement for Ligand 2.15 
 
Formula C12H8Br2N2O 
Formula weight 356.02 
Size 0.25 x 0.06 x 0.03 mm 
Crystal morphology Colourless Needle 
Temperature 150(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group P21/c 
Unit cell dimensions a = 4.3255(10) Å  = 90° 
 b = 20.510(6) Å  = 106.851(12)° 
 c = 14.314(4) Å  = 90° 
Volume 1215.4(6) Å
3
 
Z 4 
Density (calculated) 1.946 Mg/m
3
 
Absorption coefficient 6.653 mm
-1
 
F(000) 688 
Data collection range 2.48  18.663° 
Index ranges -5  h 5,  -29  k  29,  -20  l  20 
Reflections collected 13083 
Independent reflections 8192 [R(int) = 0.2137] 
Observed reflections 1402 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.8254 and 0.2871 
Refinement method Full 
Data / restraints / parameters 3125 / 0 / 154 
Goodness of fit 0.959 
Final R indices  [I >2(I)] R1 = 0.0847, wR2 = 0.1825 
R indices (all data) R1 = 0.1974, wR2 = 0.2781 
Largest diff. peak and hole 1.751 and -1.185e.Å
-3 
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Crystal data and structure refinement for Complex 3.1a 
 
Formula C25H23Cl2N4O3Ru 
Formula weight 599.44 
Size 0.3255 x 0.0394 x 0.0296 mm 
Crystal morphology Red needle 
Temperature 100.01(10) K 
Wavelength 0.7107 Å  [Mo -K] 
Crystal system Monoclinic 
Space group P21/c 
Unit cell dimensions a = 15.7095(6) Å  = 90° 
 b = 8.3304(3) Å  = 93.397(3)° 
 c = 18.7473(6) Å  = 90° 
Volume 2449.08(15) Å
3
 
Z 4 
Density (calculated) 1.626 Mg/m
3
 
Absorption coefficient 0.894 mm
-1
 
F(000) 1212 
Data collection range 2.18  29.76° 
Index ranges -20  h 20,  -10  k  11,  -24  l  24 
Reflections collected 28232 
Independent reflections 6313 [R(int) = 0.0706] 
Observed reflections 5118 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.60303 
Refinement method Full 
Data / restraints / parameters 6313 / 0 / 317 
Goodness of fit 1.143 
Final R indices  [I >2(I)] R1 = 0.0681, wR2 = 0.1319 
R indices (all data) R1 = 0.0881, wR2 = 0.1403 
Largest diff. peak and hole 2.021 and -0.865e.Å
-3 
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Crystal data and structure refinement for Complex 3.1b 
 
Formula C25H23Cl2N4O3Ru 
Formula weight 599.44 
Size 0.3255 x 0.0394 x 0.0296 mm 
Crystal morphology Red needle 
Temperature 100.01(10) K 
Wavelength 0.7107 Å  [Mo -K] 
Crystal system Monoclinic 
Space group P21/c 
Unit cell dimensions a = 15.7095(6) Å  = 90° 
 b = 8.3304(3) Å  = 93.397(3)° 
 c = 18.7473(6) Å  = 90° 
Volume 2449.08(15) Å
3
 
Z 4 
Density (calculated) 1.626 Mg/m
3
 
Absorption coefficient 0.894 mm
-1
 
F(000) 1212 
Data collection range 2.18  29.76° 
Index ranges -20  h 20,  -10  k  11,  -24  l  24 
Reflections collected 28232 
Independent reflections 6313 [R(int) = 0.0706] 
Observed reflections 5118 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.60303 
Refinement method Full 
Data / restraints / parameters 6313 / 0 / 317 
Goodness of fit 1.143 
Final R indices  [I >2(I)] R1 = 0.0681, wR2 = 0.1319 
R indices (all data) R1 = 0.0881, wR2 = 0.1403 
Largest diff. peak and hole 2.021 and -0.865e.Å
-3 
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Crystal data and structure refinement for Complex 3.3 
 
Formula C24H17Cl2F2N4O2Ru 
Formula weight 603.39 
Size 0.08 x 0.07 x 0.03 mm 
Crystal morphology Red prism 
Temperature 100.01(10) K 
Wavelength 0.7107 Å  [Mo -K] 
Crystal system Monoclinic 
Space group P21/n 
Unit cell dimensions a = 10.1863(5) Å  = 90° 
 b = 12.7202(6) Å  = 95.399(5)° 
 c = 17.8694(10) Å  = 90° 
Volume 2305.1(2) Å
3
 
Z 4 
Density (calculated) 1.739 Mg/m
3
 
Absorption coefficient 0.959 mm
-1
 
F(000) 1204 
Data collection range 1.97  26.37° 
Index ranges -12  h 9,  -12  k  15,  -22  l  20 
Reflections collected 10765 
Independent reflections 4718 [R(int) = 0.0501] 
Observed reflections 3653 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.79922 
Refinement method Full 
Data / restraints / parameters 4718 / 0 / 316 
Goodness of fit 1.021 
Final R indices  [I >2(I)] R1 = 0.0484, wR2 = 0.0993 
R indices (all data) R1 = 0.0688, wR2 = 0.1116 
Largest diff. peak and hole 0.911 and -0.903e.Å
-3 
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Crystal data and structure refinement for Complex 3.5 
 
Formula C25H19Cl2F4N4O3Ru 
Formula weight 671.41 
Size 0.45 x 0.09 x 0.02 mm 
Crystal morphology Red Plate 
Temperature 150(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Triclinic 
Space group P1 
Unit cell dimensions a = 8.5290(11) Å  = 89.670(5)° 
 b = 8.6964(14) Å  = 78.981(5)° 
 c = 17.728(3) Å  = 89.770(5)° 
Volume 1290.6(3) Å
3
 
Z 2 
Density (calculated) 1.728 Mg/m
3
 
Absorption coefficient 0.88 mm
-1
 
F(000) 670 
Data collection range 2.61  30.42° 
Index ranges -10  h 8,  -12  k  12,  -25  l  24 
Reflections collected 13034 
Independent reflections 6035 [R(int) = 0.0438] 
Observed reflections 4950 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.9826 and 0.909 
Refinement method Full 
Data / restraints / parameters 6035 / 0 / 354 
Goodness of fit 1.101 
Final R indices  [I >2(I)] R1 = 0.0452, wR2 = 0.1261 
R indices (all data) R1 = 0.0611, wR2 = 0.1368 
Largest diff. peak and hole 0.949 and -2.055e.Å
-3 
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Crystal data and structure refinement for Complex 3.6 
 
Formula C49.25H39Cl8N8O5.25Ru2 
Formula weight 1312.62 
Size 0.71 x 0.71 x 0.24 mm 
Crystal morphology Red Fragment 
Temperature 150.15 K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group P21/c 
Unit cell dimensions a = 20.4382(12) Å  = 90° 
 b = 15.1424(8) Å  = 113.339(3)° 
 c = 19.7673(11) Å  = 90° 
Volume 5617.1(5) Å
3
 
Z 4 
Density (calculated) 1.552 Mg/m
3
 
Absorption coefficient 0.97 mm
-1
 
F(000) 2626 
Data collection range 1.75  26.39° 
Index ranges -25  h 25,  -14  k  18,  -24  l  24 
Reflections collected 52269 
Independent reflections 11441 [R(int) = 0.0715] 
Observed reflections 7153 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.8006 and 0.5459 
Refinement method Full 
Data / restraints / parameters 11441 / 14 / 624 
Goodness of fit 1.005 
Final R indices  [I >2(I)] R1 = 0.0535, wR2 = 0.1271 
R indices (all data) R1 = 0.1071, wR2 = 0.1524 
Largest diff. peak and hole 1.389 and -0.997e.Å
-3
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Crystal data and structure refinement for Complex 3.7a 
 
Formula C25H21Cl4N4O3Ru 
Formula weight 668.33 
Size 0.1155 x 0.0697 x 0.0438 mm 
Crystal morphology Red needle 
Temperature 100.00(10) K 
Wavelength 0.7107 Å  [Mo -K] 
Crystal system Triclinic 
Space group P1 
Unit cell dimensions a = 8.5066(5) Å  = 88.281(5)° 
 b = 10.1491(6) Å  = 86.551(5)° 
 c = 15.1443(9) Å  = 83.546(5)° 
Volume 1296.48(13) Å
3
 
Z 2 
Density (calculated) 1.712 Mg/m
3
 
Absorption coefficient 1.053 mm
-1
 
F(000) 670 
Data collection range 2.02  26.37° 
Index ranges -9  h 10,  -12  k  12,  -18  l  13 
Reflections collected 10188 
Independent reflections 5316 [R(int) = 0.0406] 
Observed reflections 4258 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.89396 
Refinement method Full 
Data / restraints / parameters 5316 / 0 / 336 
Goodness of fit 1.038 
Final R indices  [I >2(I)] R1 = 0.0419, wR2 = 0.0718 
R indices (all data) R1 = 0.0573, wR2 = 0.0815 
Largest diff. peak and hole 0.491 and -0.478e.Å
-3
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Crystal data and structure refinement for Complex 3.7b 
 
Formula C24H17Cl4N4O2Ru 
Formula weight 636.29 
Size 0.35 x 0.3 x 0.09 mm 
Crystal morphology Red Prism 
Temperature 150(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group P21/n 
Unit cell dimensions a = 7.9504(11) Å  = 90° 
 b = 16.070(2) Å  = 95.268(7)° 
 c = 24.526(3) Å  = 90° 
Volume 3120.2(7) Å
3
 
Z 4 
Density (calculated) 1.354 Mg/m
3
 
Absorption coefficient 0.869 mm
-1
 
F(000) 1268 
Data collection range 2.09  30.42° 
Index ranges -11  h 11,  0  k  22,  0  l  34 
Reflections collected 9430 
Independent reflections 9430 
Observed reflections 8291 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.9259 and 0.7506 
Refinement method Full 
Data / restraints / parameters 9430 / 0 / 316 
Goodness of fit 1.105 
Final R indices  [I >2(I)] R1 = 0.0315, wR2 = 0.0809 
R indices (all data) R1 = 0.038, wR2 = 0.084 
Largest diff. peak and hole 1.178 and -0.583e.Å
-3
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Crystal data and structure refinement for Complex 3.9 
 
Formula C25H19Cl6N4O3Ru 
Formula weight 737.21 
Size 0.18 x 0.11 x 0.04 mm 
Crystal morphology Red Cuboid 
Temperature 150(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Triclinic 
Space group P1 
Unit cell dimensions a = 9.3548(12) Å  = 104.592(5)° 
 b = 12.7693(15) Å  = 98.755(5)° 
 c = 13.3128(15) Å  = 100.683(5)° 
Volume 1478.8(3) Å
3
 
Z 2 
Density (calculated) 1.656 Mg/m
3
 
Absorption coefficient 1.107 mm
-1
 
F(000) 734 
Data collection range 1.62  37.62° 
Index ranges -15  h 15,  -20  k  21,  -22  l  22 
Reflections collected 49310 
Independent reflections 14172 [R(int) = 0.0361] 
Observed reflections 10930 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.9571 and 0.8257 
Refinement method Full 
Data / restraints / parameters 14172 / 0 / 354 
Goodness of fit 1.029 
Final R indices  [I >2(I)] R1 = 0.0394, wR2 = 0.0944 
R indices (all data) R1 = 0.0603, wR2 = 0.1036 
Largest diff. peak and hole 1.477 and -1.38e.Å
-3 
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Crystal data and structure refinement for Complex 3.11 
 
Formula C25H21Br2Cl2N4O3Ru 
Formula weight 757.25 
Size 0.32 x 0.18 x 0.09 mm 
Crystal morphology Red Fragment 
Temperature 150(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group P21/c 
Unit cell dimensions a = 8.6661(9) Å  = 90° 
 b = 18.3450(17) Å  = 114.132(6)° 
 c = 19.1648(18) Å  = 90° 
Volume 2780.5(5) Å
3
 
Z 4 
Density (calculated) 1.809 Mg/m
3
 
Absorption coefficient 3.664 mm
-1
 
F(000) 1484 
Data collection range 1.61  31.8° 
Index ranges -12  h 12,  -26  k  27,  -28  l  28 
Reflections collected 106652 
Independent reflections 9463 [R(int) = 0.0451] 
Observed reflections 7657 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.7339 and 0.3868 
Refinement method Full 
Data / restraints / parameters 9463 / 0 / 336 
Goodness of fit 1.147 
Final R indices  [I >2(I)] R1 = 0.0427, wR2 = 0.1033 
R indices (all data) R1 = 0.0594, wR2 = 0.111 
Largest diff. peak and hole 1.659 and -1.494e.Å
-3
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Crystal data and structure refinement for Complex 3.12 
 
Formula C24H17Br2Cl2N4O2Ru 
Formula weight 725.21 
Size 0.18 x 0.1 x 0.01 mm 
Crystal morphology Red Cuboid 
Temperature 150(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group P21/n 
Unit cell dimensions a = 8.0068(6) Å  = 90° 
 b = 16.0313(11) Å  = 93.717(4)° 
 c = 24.677(2) Å  = 90° 
Volume 3160.9(4) Å
3
 
Z 4 
Density (calculated) 1.524 Mg/m
3
 
Absorption coefficient 3.218 mm
-1
 
F(000) 1412 
Data collection range 2.09  30.42° 
Index ranges -11  h 11,  -21  k  22,  -35  l  35 
Reflections collected 55509 
Independent reflections 9479 [R(int) = 0.0927] 
Observed reflections 7580 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.9624 and 0.5951 
Refinement method Full 
Data / restraints / parameters 9479 / 0 / 316 
Goodness of fit 1.048 
Final R indices  [I >2(I)] R1 = 0.0399, wR2 = 0.0945 
R indices (all data) R1 = 0.0535, wR2 = 0.1009 
Largest diff. peak and hole 1.343 and -0.997e.Å
-3
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Crystal data and structure refinement for Complex 3.13 
 
Formula C25H20Br2Cl2N4O3Ru 
Formula weight 756.24 
Size 0.1505 x 0.0675 x 0.0396 mm 
Crystal morphology Orange needle 
Temperature 100.01(10) K 
Wavelength 0.7107 Å  [Mo -K] 
Crystal system Triclinic 
Space group P1 
Unit cell dimensions a = 11.1486(11) Å  = 103.937(9)° 
 b = 11.3608(13) Å  = 108.713(9)° 
 c = 12.3471(12) Å  = 103.653(9)° 
Volume 1351.5(2) Å
3
 
Z 2 
Density (calculated) 1.858 Mg/m
3
 
Absorption coefficient 3.769 mm
-1
 
F(000) 740 
Data collection range 1.85  29.83° 
Index ranges -15  h 15,  -14  k  12,  -15  l  17 
Reflections collected 13453 
Independent reflections 6362 [R(int) = 0.0686] 
Observed reflections 4245 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.94213 
Refinement method Full 
Data / restraints / parameters 6362 / 0 / 336 
Goodness of fit 1.01 
Final R indices  [I >2(I)] R1 = 0.0617, wR2 = 0.0819 
R indices (all data) R1 = 0.109, wR2 = 0.0938 
Largest diff. peak and hole 0.828 and -0.886e.Å
-3
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Crystal data and structure refinement for Complex 3.15 
 
Formula C26H23Br4Cl2N4O4Ru 
Formula weight 947.09 
Size 0.18 x 0.14 x 0.09 mm 
Crystal morphology Red Fragment 
Temperature 150(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group P21/c 
Unit cell dimensions a = 14.508(3) Å  = 90° 
 b = 17.366(3) Å  = 116.143(6)° 
 c = 14.786(3) Å  = 90° 
Volume 3344.2(11) Å
3
 
Z 4 
Density (calculated) 1.881 Mg/m
3
 
Absorption coefficient 5.444 mm
-1
 
F(000) 1828 
Data collection range 1.56  29.61° 
Index ranges -20  h 20,  -23  k  24,  -20  l  20 
Reflections collected 55567 
Independent reflections 9366 [R(int) = 0.0621] 
Observed reflections 6995 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.64 and 0.4407 
Refinement method Full 
Data / restraints / parameters 9366 / 0 / 374 
Goodness of fit 1.033 
Final R indices  [I >2(I)] R1 = 0.0392, wR2 = 0.1002 
R indices (all data) R1 = 0.0611, wR2 = 0.1082 
Largest diff. peak and hole 1.306 and -0.957e.Å
-3 
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Crystal data and structure refinement for Complex 3.16a 
 
Formula C25H21Cl2I2N4O3Ru 
Formula weight 851.23 
Size 0.1 x 0.07 x 0.02 mm 
Crystal morphology Red block 
Temperature 100.00(10) K 
Wavelength 1.5418 Å  [Cu -K] 
Crystal system Orthorhombic 
Space group P212121 
Unit cell dimensions a = 8.4296(8) Å  = 90° 
 b = 17.8286(11) Å  = 90° 
 c = 18.1388(11) Å  = 90° 
Volume 2726.1(3) Å
3
 
Z 4 
Density (calculated) 2.074 Mg/m
3
 
Absorption coefficient 24.54 mm
-1
 
F(000) 1628 
Data collection range 3.48  74.15° 
Index ranges -9  h 10,  -20  k  21,  -22  l  15 
Reflections collected 7629 
Independent reflections 4785 [R(int) = 0.0631] 
Observed reflections 4012 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.87282 
Refinement method Full 
Data / restraints / parameters 4785 / 0 / 337 
Goodness of fit 1.036 
Final R indices  [I >2(I)] R1 = 0.0618, wR2 = 0.1391 
R indices (all data) R1 = 0.0766, wR2 = 0.1491 
Largest diff. peak and hole 1.82 and -1.6e.Å
-3
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Crystal data and structure refinement for Complex 3.16b 
 
Formula C24H17Cl2I2N4O2Ru 
Formula weight 819.19 
Size 0.02 x 0.008 x 0.008 mm 
Crystal morphology Orange needle 
Temperature 100.00(10) K 
Wavelength 0.7107 Å  [Mo -K] 
Crystal system Monoclinic 
Space group P21/n 
Unit cell dimensions a = 12.1869(4) Å  = 90° 
 b = 16.5955(5) Å  = 93.836(3)° 
 c = 12.6592(4) Å  = 90° 
Volume 2554.56(14) Å
3
 
Z 4 
Density (calculated) 2.13 Mg/m
3
 
Absorption coefficient 3.27 mm
-1
 
F(000) 1556 
Data collection range 2.03  25.03° 
Index ranges -13  h 14,  -17  k  19,  -14  l  15 
Reflections collected 11805 
Independent reflections 4510 [R(int) = 0.0405] 
Observed reflections 3703 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.75701 
Refinement method Full 
Data / restraints / parameters 4510 / 95 / 326 
Goodness of fit 1.039 
Final R indices  [I >2(I)] R1 = 0.0344, wR2 = 0.0619 
R indices (all data) R1 = 0.0483, wR2 = 0.0679 
Largest diff. peak and hole 0.875 and -0.682e.Å
-3
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Crystal data and structure refinement for Complex 4.2 
 
Formula C24H16F2I2N4O2Ru 
Formula weight 785.28 
Size 0.24 x 0.22 x 0.19 mm 
Crystal morphology Black block 
Temperature 100.01(10) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Orthorhombic 
Space group Pna21 
Unit cell dimensions a = 19.4788(15) Å  = 90° 
 b = 10.3583(11) Å  = 90° 
 c = 12.0324(12) Å  = 90° 
Volume 2427.7(4) Å
3
 
Z 4 
Density (calculated) 2.148 Mg/m
3
 
Absorption coefficient 3.235 mm
-1
 
F(000) 1488 
Data collection range 2.09  25.02° 
Index ranges -18  h 23,  -7  k  12,  -14  l  7 
Reflections collected 6768 
Independent reflections 3133 [R(int) = 0.0471] 
Observed reflections 2441 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.60303 
Refinement method Full 
Data / restraints / parameters 3133 / 1 / 296 
Goodness of fit 1.029 
Final R indices  [I >2(I)] R1 = 0.0624, wR2 = 0.1652 
R indices (all data) R1 = 0.0798, wR2 = 0.1805 
Largest diff. peak and hole 1.525 and -1.171e.Å
-3
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Crystal data and structure refinement for Complex 4.3 
 
Formula C24H17F2I2N4O2Ru 
Formula weight 786.29 
Size 0.14 x 0.13 x 0.02 mm 
Crystal morphology Green irregular 
Temperature 100.01(10) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Orthorhombic 
Space group Pna21 
Unit cell dimensions a = 19.483(2) Å  = 90° 
 b = 10.2433(9) Å  = 90° 
 c = 12.4461(11) Å  = 90° 
Volume 2483.9(4) Å
3
 
Z 4 
Density (calculated) 2.103 Mg/m
3
 
Absorption coefficient 3.162 mm
-1
 
F(000) 1492 
Data collection range 2.09  30.77° 
Index ranges -27  h 27,  -14  k  14,  -16  l  17 
Reflections collected 27470 
Independent reflections 7404 [R(int) = 0.0474] 
Observed reflections 6135 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.60303 
Refinement method Full 
Data / restraints / parameters 7404 / 1 / 311 
Goodness of fit 1.066 
Final R indices  [I >2(I)] R1 = 0.0519, wR2 = 0.141 
R indices (all data) R1 = 0.0673, wR2 = 0.1523 
Largest diff. peak and hole 2.485 and -2.642e.Å
-3
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Crystal data and structure refinement for Complex 4.12 
 
Formula C27H24Br2I2N5O3Ru 
Formula weight 981.2 
Size 0.19 x 0.18 x 0.12 mm 
Crystal morphology Black prism 
Temperature 120(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group Cc 
Unit cell dimensions a = 15.7434(14) Å  = 90° 
 b = 9.3052(9) Å  = 95.791(4)° 
 c = 21.721(2) Å  = 90° 
Volume 3165.7(5) Å
3
 
Z 4 
Density (calculated) 2.059 Mg/m
3
 
Absorption coefficient 5.006 mm
-1
 
F(000) 1860 
Data collection range 1.88  25.03° 
Index ranges -18  h 18,  -10  k  11,  -25  l  25 
Reflections collected 26603 
Independent reflections 5403 [R(int) = 0.0202] 
Observed reflections 5351 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.7461 and 0.5098 
Refinement method Full 
Data / restraints / parameters 5403 / 8 / 363 
Goodness of fit 1.123 
Final R indices  [I >2(I)] R1 = 0.0174, wR2 = 0.0475 
R indices (all data) R1 = 0.0177, wR2 = 0.0476 
Largest diff. peak and hole 0.809 and -0.589e.Å
-3
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Crystal data and structure refinement for Complex 4.13 
 
Formula C27H24Br2I2N5O3Ru 
Formula weight 981.2 
Size 0.08 x 0.02 x 0.02 mm 
Crystal morphology Black plank 
Temperature 100.01(10) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group P21/n 
Unit cell dimensions a = 11.5135(11) Å  = 90° 
 b = 18.5582(18) Å  = 99.770(4)° 
 c = 14.3455(12) Å  = 90° 
Volume 3020.7(5) Å
3
 
Z 4 
Density (calculated) 2.158 Mg/m
3
 
Absorption coefficient 5.247 mm
-1
 
F(000) 1860 
Data collection range 2.1  26.36° 
Index ranges -14  h 13,  -22  k  23,  -10  l  17 
Reflections collected 20606 
Independent reflections 6131 [R(int) = 0.1072] 
Observed reflections 3401 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.60303 
Refinement method Full 
Data / restraints / parameters 6131 / 30 / 363 
Goodness of fit 0.96 
Final R indices  [I >2(I)] R1 = 0.0554, wR2 = 0.0906 
R indices (all data) R1 = 0.133, wR2 = 0.1118 
Largest diff. peak and hole 1.196 and -1.074e.Å
-3
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Crystal data and structure refinement for Complex 5.1 
 
Formula C24H17F2Cl2N4O2Rh 
Formula weight 605.2 
Size 0.48 x 0.20 x 0.13 mm 
Crystal morphology Orange block 
Temperature 100.01(4) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Orthorhombic 
Space group P212121 
Unit cell dimensions a = 10.5456(3) Å  = 90° 
 b = 12.0060(4) Å  = 90° 
 c = 19.5775(7) Å  = 90° 
Volume 2478.72(14) Å
3
 
Z 4 
Density (calculated) 1.622 Mg/m
3
 
Absorption coefficient 0.949 mm
-1
 
F(000) 1208 
Data collection range 6.62  59.08° 
Index ranges -14  h 10,  -15  k  15,  -19  l  27 
Reflections collected 9366 
Independent reflections 5515 [R(int) = 0.0438] 
Observed reflections 4829 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.86114 
Refinement method Full 
Data / restraints / parameters 5515 / 0 / 336 
Goodness of fit 1.047 
Final R indices  [I >2(I)] R1 = 0.0524, wR2 = 0.1084 
R indices (all data) R1 = 0.0636, wR2 = 0.1159 
Largest diff. peak and hole 1.24 and -0.73e.Å
-3
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Crystal data and structure refinement for Complex 5.3 
 
Formula C24H17Cl2Br2N4O2Rh 
Formula weight 727.05 
Size 0.06 x 0.054 x 0.017 mm 
Crystal morphology Red Plate 
Temperature 100.01(10) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group Cc 
Unit cell dimensions a = 9.3722(6) Å  = 90° 
 b = 23.9103(17) Å  = 100.609(7)° 
 c = 11.5081(7) Å  = 90° 
Volume 2534.8(3) Å
3
 
Z 4 
Density (calculated) 1.905 Mg/m
3
 
Absorption coefficient 4.068 mm
-1
 
F(000) 1416 
Data collection range 6.76  62° 
Index ranges -13  h 11,  -33  k  21,  -15  l  19 
Reflections collected 5735 
Independent reflections 4369 [R(int) = 0.0419] 
Observed reflections 4012 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.91409 
Refinement method Full 
Data / restraints / parameters 4369 / 2 / 316 
Goodness of fit 1.011 
Final R indices  [I >2(I)] R1 = 0.0378, wR2 = 0.0811 
R indices (all data) R1 = 0.0434, wR2 = 0.0841 
Largest diff. peak and hole 0.92 and -0.84e.Å
-3
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Crystal data and structure refinement for Complex 5.4 
 
Formula C26H25Cl2I2N4O4Rh 
Formula weight 885.11 
Size 0.41 x 0.37 x 0.32 mm 
Crystal morphology Red Plate 
Temperature 100.2(4) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group P21/c 
Unit cell dimensions a = 17.9801(8) Å  = 90° 
 b = 10.3200(4) Å  = 115.036(6)° 
 c = 17.7408(9) Å  = 90° 
Volume 2982.6(2) Å
3
 
Z 5 
Density (calculated) 2.464 Mg/m
3
 
Absorption coefficient 3.576 mm
-1
 
F(000) 2130 
Data collection range 6.38  59.06° 
Index ranges -24  h 20,  -13  k  14,  -24  l  24 
Reflections collected 19498 
Independent reflections 7240 [R(int) = 0.0499] 
Observed reflections 5836 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.74238 
Refinement method Full 
Data / restraints / parameters 7240 / 0 / 356 
Goodness of fit 1.081 
Final R indices  [I >2(I)] R1 = 0.0499, wR2 = 0.0963 
R indices (all data) R1 = 0.0667, wR2 = 0.1047 
Largest diff. peak and hole 2.73 and -1.95e.Å
-3
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Crystal data and structure refinement for Complex 5.5 
 
Formula C27H23Cl2I2N5O3Rh 
Formula weight 893.11 
Size 0.12 x 0.11 x 0.03 mm 
Crystal morphology Red Plate 
Temperature 100.0(3) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group Cc 
Unit cell dimensions a = 15.4740(11) Å  = 90° 
 b = 9.1361(6) Å  = 95.700(6)° 
 c = 21.4115(13) Å  = 90° 
Volume 3012.0(3) Å
3
 
Z 4 
Density (calculated) 1.970 Mg/m
3
 
Absorption coefficient 2.832 mm
-1
 
F(000) 1716 
Data collection range 6.22  52.74° 
Index ranges -16  h 19,  -11  k  9,  -26  l  21 
Reflections collected 9196 
Independent reflections 4805 [R(int) = 0.0675] 
Observed reflections 3986 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.9973 and 0.7721 
Refinement method Full 
Data / restraints / parameters 4805 / 2 / 361 
Goodness of fit 1.046 
Final R indices  [I >2(I)] R1 = 0.0524, wR2 = 0.1030 
R indices (all data) R1 = 0.0689, wR2 = 0.1149 
Largest diff. peak and hole 1.22 and -0.82e.Å
-3 
  
 
